Protocol  for 
 
Official Title of Study  
A Phase 2, Randomized, Double-blinded, Placebo- controlled, 5 Parallel -group Study of 
BMS -986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe 
Atopic Dermatitis  
 
[STUDY_ID_REMOVED]  
June 30, 2021  
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Protocol Amendment No.: 01
Date: 30-Jun-2021 2This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By [CONTACT_576907], you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS sponsored 
study. Any permitted disclosures will be made only on a confide ntial "need to know" basis 
within your organization or  to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by [CONTACT_20444]. Any supplemental information (eg,  amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document.  Any person who receives 
this document without due authorization from BMS is requested t o return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply to partners to which BMS has transferred obligations, eg, a Contract Research Organization (CRO).
2.0 Approved 930158234 2.0v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 01
Section Number & Title Description of Change Brief Rationale
Section 9.4  Safety Added that an external, 
independent DMC will be empaneled to review safety on 
a prescheduled and ad-hoc 
basis, in addition to contemporaneous safety monitoring by [CONTACT_519292].Added for clarification.
Section 9.4.9  Clinical Safety 
Laboratory AssessmentsAdded PT/INR test to the 
coagulation panel and SARS-
CoV-2:RT-PCR test or Antigen test to â€œOther Analyses.â€.Coagulation tests are to be performed at screening to ensure normal clotting 
function upon study entry.
SARS-CoV-[ADDRESS_756603] positive for COVID-19.
Section 9.8  Biomarkers Clarified that serum collected at baseline and end of study for SARS-CoV-2 (anti-SARS-
CoV-2 IgM and/or IgG and/or 
IgA) measurements are optional.To clarify and align with other sections of the protocol stating the analysis is optional.
Section 10.[ADDRESS_756604] to exposure to 
active drug(s).
APPENDIX 2 STUDY 
GOVERNENCE CONSIDERATIONSUpdated information on the Informed Consent Process and Source documents. 
Added Information on remote 
monitoring that will be included in the monitoring plan. 
Updated â€œReturn of Study 
Treatmentâ€â€™ Section: Added 
information on handling of partially used supplies 
Removed information on the 
process when on-site drug destruction is not allowed.
Added new section â€˜Study and 
Site Start and ClosureTo align with the current BMS processes.
To address the details of remote 
monitoring if it is utilized in the study.
To provide guidance on partially used 
supplies.
The process is not applicable for the sites 
participating in this study.
To provide guidance on study and site 
closure.
Informed consent will be restricted to the 
study participant; consent by [CONTACT_576908].
Protocol Amendment No.: 01
Date: 30-Jun-2021 7
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 01
Section Number & Title Description of Change Brief Rationale
Removed â€œlegally acceptable 
representativeâ€ (LAR) language.
Added new section 
Dissemination of Clinical Study DataBMS will make information about clinical research studies and results available to the public as per regulatory and BMS requirements.
APPENDIX 3 ADVERSE 
EVENTS AND SERIOUS 
ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, FOLLOW UP AND REPORTINGUpdated the Assessment of Intensity table. 
Updated the Serious Adverse 
Event (SAE) contact 
[CONTACT_72080].To clarify expectations and contact [CONTACT_576909].
APPENDIX [ADDRESS_756605] not been summarized.
Protocol Amendment No.: 01
Date: 30-Jun-2021 8
2.0 Approved 930158234 2.0v
Approved
1.0
v
TABLE OF CONTENTS 
  
TITLE PAGE ................................................................................................................  
DOCUMENT HISTORY .............................................. ................................................  
OVERALL RATIONALE FOR PROTOCOL AMENDMENT 01: ............................  
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 01 ................  
TABLE OF CONTENTS ..............................................................................................  
1 SYNOPSIS .................................................... .............................................................  
2 SCHEDULE OF ACTIVITIES..................................................................................  
3 INTRODUCTION ................................................ .....................................................  
3.1 Study Rationale .................................................................................................  
3.1.1 Disease Rationale ....................................................................................  
3.1.2 Rationale for Study Drug Mechanisms ....................................................  
3.1.3 Rationale for Study Population ................................................................  
3.1.4 Rationales for Primary and Secondary Efficacy Endpoints ....................  
3.1.5 Research Hypothesis ................................................................................  
3.2 Background ................................................ .......................................................  
3.2.1 BMS-986166 ............................................................................................  
[IP_ADDRESS] In Vitro Pharmacology ...................................................................  
[IP_ADDRESS] In Vivo Pharmacology ....................................................................  
[IP_ADDRESS] Nonclinical Toxicology ...................................................................  
[IP_ADDRESS] Pharmacokinetic Drug Interaction Summary .................................  
[IP_ADDRESS] Clinical Safety .................................................................................  
3.2.2 Branebrutinib ...........................................................................................  
[IP_ADDRESS] In Vitro Pharmacology ...................................................................  
[IP_ADDRESS] In Vivo Pharmacology ....................................................................  
[IP_ADDRESS] Nonclinical Toxicology ...................................................................  
[IP_ADDRESS] Pharmacokinetic Drug Interaction Summary .................................  
[IP_ADDRESS] Clinical Safety .................................................................................  
3.3 Benefit/Risk Assessment ..................................................................................  
3.3.1 BMS-986166 ............................................................................................  
3.3.2 Branebrutinib ...........................................................................................  
3.3.3 COVID-19-associated Risks ....................................................................  
[IP_ADDRESS] BMS-986166 ...................................................................................  
[IP_ADDRESS] Branebrutinib ..................................................................................  
[IP_ADDRESS] COVID-19-related Mitigations .......................................................  
[IP_ADDRESS] Vaccination Against SARS-CoV-2 ..................................................  
4 OBJECTIVES AND ENDPOINTS .................................... .......................................  
5 STUDY DESIGN.......................................................................................................  
5.1 Overall Design ............................................ ......................................................  
5.1.1 Screening Period Days -35 to -1 ..............................................................  
5.1.2 Treatment Period, Days 1-113 .................................................................  
5.1.3 Follow-up Period, Days 114-169 ............................................................  
5.1.4 Data Monitoring Committee ....................................................................  
5.2 Number of Participants .....................................................................................  
5.3 End of Study Definition ................................... .................................................  



Clinical Protocol
BMS-986166 and BMS-986195IM018005
S1P Receptor Modulator and Branebrutinib
Protocol Amendment No.: 01Date: 30-Jun-2021 9
2.0 Approved 930158234 2.0v
Approved
1.0
v
5.4 Scientific Rationale for Study Design ..............................................................  
5.5 Justification for Dose .................................... ....................................................  
5.5.1 BMS-986166 ............................................................................................  
5.5.2 Branebrutinib ...........................................................................................  
6 STUDY POPULATION ............................................................................................  
6.1 Inclusion Criteria ..............................................................................................  
6.2 Exclusion Criteria ........................................ .....................................................  
6.3 Lifestyle Restrictions ........................................................................................  
6.3.1 Meals and Dietary Restrictions ...............................................................  
6.3.2 Caffeine, Alcohol, and Tobacco ...............................................................  
6.3.3 Activity .....................................................................................................  
6.4 Screen Failures ........................................... .......................................................  
6.4.1 Retesting During Screening or Lead-In Period .......................................  
7 TREATMENT ................................................... ........................................................  
7.1 Treatments Administered ................................... ...............................................  
7.2 Method of Treatment Assignment ....................................................................  
7.3 Blinding.............................................................................................................  
7.4 Dosage Modification ....................................... ..................................................  
7.5 Preparation/Handling/Storage/Accountability ............... ...................................  
7.5.1 Retained Samples for Bioavailability / Bioequivalence / Biocomparability
.....................................................................................................................  
7.6 Treatment Compliance ...................................... ................................................  
7.7 Concomitant Therapy........................................ ................................................  
7.7.1 Prohibited and/or Restricted Treatments.................................................  
7.7.[ADDRESS_756606] to Follow-Up ......................................... ....................................................  
9 STUDY ASSESSMENTS AND PROCEDURES ............................ .........................  
9.1 Efficacy Assessments ........................................................................................  
9.1.1 Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-
AD) ..............................................................................................................  
9.1.2 Eczema Area and Severity Index (EASI) ..................................................  
9.1.3 Body Surface Area (BSA) .........................................................................  
9.1.4 Pruritus and Sleep Quality Numerical Rating Scale (NRS) .....................  
9.1.5 Dermatology Life Quality Index (DLQI) .................................................  
9.1.6 Patient Oriented Eczema Measure (POEM) ............................................  
9.1.7 Patient Global Impression of Change (PGI-C) .......................................  
9.1.8 Patient Global Impression of Severity (PGI-S) .......................................  
9.2 Adverse Events .................................................................................................  
9.2.1 Time Period and Frequency for Collecting AE and SAE Information ....  
9.2.2 Method of Detecting AEs and SAEs .........................................................  






Clinical Protocol
BMS-986166 and BMS-986195IM018005
S1P Receptor Modulator and Branebrutinib
Protocol Amendment No.: 01Date: 30-Jun-[ADDRESS_756607] Result Abnormalities .....................................................  
9.2.7 Potential Drug Induced Liver Injury (DILI) ............................................  
9.2.[ADDRESS_756608] (AEIs) ........  
9.2.[ADDRESS_756609] Engagement Assays ...................................................................  
9.8.2 Additional Exploratory Biomarkers .........................................................  
9.8.3 Additional Research Collection ...............................................................  
9.9 Health Economics OR Medical Resource Utilization and Health  Economics .  
10 STATISTICAL CONSIDERATIONS ................................. ...................................  
10.1 Sample Size Determination ................................ .............................................  
10.2 Populations for Analyses ................................. ...............................................  
10.3 Statistical Analyses .........................................................................................  
10.3.1 Efficacy Analyses ...................................................................................  
[IP_ADDRESS] Primary Endpoint..........................................................................  
[IP_ADDRESS] Secondary Endpoint ......................................................................  
10.3.2 Safety Analyses.......................................................................................  
10.3.3 Other Analyses .......................................................................................  
10.3.4 Interim Analyses .....................................................................................  
11 REFERENCES ................................................. .......................................................  
12 APPENDICES ................................................. ........................................................  
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS ....................... .................  
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS .................... .............  

Clinical Protocol
BMS-986166 and BMS-986195IM018005
S1P Receptor Modulator and Branebrutinib
Protocol Amendment No.: 01Date: 30-Jun-2021 11
2.0 Approved 930158234 2.0v
Approved
1.0
v
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW UP AND REPORTING ....................................... ..................................  
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION ...................................... ...............................  
APPENDIX 5 DIAGNOSTIC CRITERIA FOR ATOPIC DERMATITIS .................  
APPENDIX 6 NEW YORK HEART ASSOCIATION (NYHA) CLASSIFICATION 
OF CARDIOVASCULAR DISABILITY .................................. ............................  
APPENDIX 7 DSM-5 DIAGNOSTIC CRITERIA FOR SUBSTANCE USE 
DISORDER....................................................... ......................................................  
APPENDIX 8 VALIDATED INVESTIGATOR GLOBAL ASSESSMENT SCALE 
FOR ATOPIC DERMATITIS (VIGA-ADTM) .....................................................  
APPENDIX 9 ECZEMA AREA AND SEVERITY INDEX (EASI) ..........................  
APPENDIX 10 BODY SURFAC E AREA ESTIMATE WORKSHEET (SCORAD-A 
METHOD) ..............................................................................................................  
APPENDIX 11 PRURITUS AND SLEEP QUALITY NUMERICAL RATING 
SCALES (NRS) .................................................. ....................................................  
APPENDIX 12 DERMATOLOGY LIFE QUALITY INDEX (DLQI) ............. ..........  
APPENDIX 13 PATIENT ORIENTED ECZEMA MEASURE (POEM) ............ .......  
APPENDIX 14 PATIENT GLOBAL IMPRESSION OF CHANGE (PGI-C) ............  
APPENDIX 15 PATIENT GLOBAL IMPRESSION OF SEVERITY (PGI-S) ..... .....  
APPENDIX [ADDRESS_756610] .................................... ........................................  
 








Clinical Protocol
BMS-986166 and BMS-986195IM018005
S1P Receptor Modulator and Branebrutinib
Protocol Amendment No.: 01Date: 30-Jun-2021 12
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
1 SYNOPSIS
Protocol Title: A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group 
Study of BMS-986166 or Branebrutinib for the Treatment of Patients with 
Moderate to Severe Atopic Dermatitis
Short Title: BMS-986166 or Branebrutinib for Tr eatment of Atopic Dermatitis
Study Phase: 2
Rationale:
Atopic dermatitis (AD) is a common, chronic inflammatory skin c ondition, with approximately 
40% of patients meeting the criteria for moderate-to-severe disease. The substa ntial biological 
heterogeneity of AD warrants ne w medications acting through diff erent mechanisms to 
comprehensively treat patients, such that they all achieve remi ssion or near-remission. Thus, 
moderate-to-severe AD represents a clear unmet need. Signals tra nsduced by [CONTACT_576910]-1-phosphate (S1P) and by [CONTACT_576911] (BTK) are implicated in the 
pathobiology of AD, making these pathways attractive targets fo r potential AD therapi[INVESTIGATOR_014]. 
Study IM018005 w ill evaluate the efficacy and safety of BMS- 986166 (the prodrug of 
BMS-986166-P [BMT-121795]), a sphingosine-1-phosphate (S1P) rec eptor modulator); and of 
branebrutinib, an oral, potent, and highly selective irreversib le inhibitor of BTK. Each will be 
administered as a single agent to a population of AD participan ts having moderate-to-severe 
disease who are intolerant o f treatment or inad equately treated  and are candidates for systemic 
therapy. IM018005 is a Phase 2 s tudy to assess the clinical ben efit measured primarily by [CONTACT_576912] (EASI) score provided by 
[CONTACT_264535] 3 dose levels of BMS-986166 and of a single dose level of branebrutinib after 16 weeks 
of treatment. Should this study demonstrate plausible efficacy a nd safety of either or both of these 
agents, their evaluation will be expanded with confirmatory stu dies.
Study Population:
Males and females aged  18 (or local age of ma jority) to 65, inc lusive, with confirmed 
moderate-to-severe AD who are candidates for systemic therapy. 
Protocol Amendment No.: 01
Date: 30-Jun-2021 13
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Objectives and Endpoints:
Objectives Endpoints
Primary
â€¢To evaluate the eff icacy of BMS-986166 and of 
branebrutinib, each versus placebo, at Week 16 in 
participants with moderate-to-severe AD.â€¢Mean percentage change from baseline in EASI 
score at Week 16
Secondary
â€¢To further evaluate the efficacy of BMS-986166 and 
of branebrutinib, each versus placebo, at Week 16 in 
participants with moderate-to-severe AD.â€¢Proportion of participants exhibiting a vIGA-AD 
score of 0 (cleared) or 1 (almost cleared) AND a â‰¥ 2 point reduction from baseline at Week 16
â€¢Proportion of participants  exhibiting a â‰¥ 50% 
(EASI-50) reduction from baseline in EASI score at 
Week 16
â€¢Proportion of participants exhibiting a â‰¥ 4-point
improvement from baseline in Pruritus NRS at Week 16
â€¢Mean percentage change from baseline in Pruritus 
NRS at Week 16
â€¢Mean change from baseline in percentage of affected 
BSA at Week 16
â€¢To assess the safety and tolerab ility of BMS-986166 
and of branebrutinib in participants with moderate-to-severe AD.â€¢Incidence and severity of all AE and SAE 
â€¢Incidence and severity of clinically significant 
changes in vital signs, ECG, OCT, PFT, and safety laboratory tests 
Abbreviations: AD = atopic dermatitis; AE = adverse event; BSA =  body s urface area; EASI = Eczema Area and 
Severity Index; ECG = electrocardi ogram; NRS = numerical rating scale; SAE = serious adverse event; OCT = optical 
coherence tomography; PFT = pulmonary function test; vIGA-AD = V alidated Investigator Global Assessment Scale 
for Atopic Dermatitis
Overall Design:
This is a Phase 2, m ulticenter, randomized , double-blind, placebo-c ontrolled, [ADDRESS_756611] confirmed moderate-to -severe AD. Participants will be assessed for clinical 
responses to placeb o, BMS-986166, or branebrutinib for 16 weeks and monitored for 
treatment-emergent safety outcomes for a total of approximately  29 weeks.
White blood cell (WBC) c ounts and lymphocyte counts w ill be monitored centrally and will not 
be provided to the site to prevent potential unblinding of the i nvestigator. 
An external independent Data Monitoring Committee (DMC) w ill be empaneled to monitor for 
safety with periodic and as-needed review. 
Protocol Amendment No.: 01
Date: 30-Jun-2021 14
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Figure 1-1: Study Design Schematic
Abbreviations: n = number of participants; PO = taken orally; QD = once daily; R = randomization; V = visits
Study day visits will be Â± 3 days, except for Day 8 visit (Â± 1 days).
Screening Period Days -[ADDRESS_756612] be completed within 35 days 
of signing the informed consent form. Participants who experienc e an AD flare, defined as
doubling of the EASI score between Screening and Baseline, or w orsening that requires 
administration of prohibited medications within 3 weeks of rand omization s hould be discontinued 
from the study. 
Treatment Period, Days 1 to 113
On Day 1, eligible participants  will be randomly  allocated to r eceive: place bo, BMS-986166 
0.25 mg orally (PO) once d aily (QD), BMS- 986166 0.5 mg PO QD, B MS-986166 0.75 mg PO 
QD, or branebrutinib 9 mg PO QD for 16 weeks. Randomization will be in a 1:1:1:1:1 ratio.
Participants will visit the clinic 7 times (including baseline)  during the treatment period. Safety 
and efficacy will be asse ssed at each of these visits. This visi t density is intended to balance, on 
the one hand, monitoring of sufficiently high resolution to det ect infections, excessively low 
leukocyte counts, inefficacy and/ or flares, and other problems in a timely fashion; with on the other 
hand, subject burdens and potential risk of SARS -CoV-2 (severe acute respi[INVESTIGATOR_18960] 2) exposure associated  with clinic visits. This freq uency reflects customary practice 
in the field, as reflected in other clinical studies of medicines having similar mechanisms.
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756613] 7 days of topi[INVESTIGATOR_487047] t reatment w ill be immediately 
discontinued from study treatment and considered treatment fail ures for categorical endpoints. 
Follow-up Period, Days 114 to 169
Follow-up after dosing cessation is planned for approximately 6 0 days (5x mean half-life for 
BMS-986166), with visits on Days 127, 141 and 169; participants  will be followed for disease 
activity, safety, and washout of pharmacodynamics (PD) effects.  If applicable, participants will be 
followed until absolute neutrophil count (ANC) > 1500/ Î¼L and absolute lymphocyte count (ALC) 
> 1000/Î¼L â€“ demonstrating sufficient was hout of pharmacodynamics (PD) effects to permit 
discharge from the study.
Number of Participants: 
Approximately 150 participants will be randomized 1:1:1:1:1 into  5 parallel treatment groups.
Treatment Arms and Duration:
Participants will be randomized to one of the following dose le vels of BMS-986166 or 
branebrutinib or placebo in blinded fashion: 
â€¢BMS-986166 0.25 mg PO QD
â€¢BMS-986166 0.50 mg PO QD
â€¢BMS-986166 0.75 mg PO QD
â€¢Branebrutinib 9 mg PO QD
â€¢Placebo PO QD
â€¢The first dose of d ouble-blind study medication (BMS-986166 or branebrutinib or placebo) 
will be taken in the morning on D ay 1 after fasting for at leas t 8 hours. 
â€¢Study medication should be taken at approximately the same time  each day.
â€¢Participants will take [ADDRESS_756614] bottles.
Study Treatment
Treatment 
GroupDouble-
blind KitBottle A Bottle B Bottle C
Placebo
Each kit 
contains
Bottle A,
Bottle B, 
Bottle CPlacebo capsule Placebo capsule Placebo capsule
`166 0.25 mg QD `166 capsule, 0.25 mg Placebo capsule Placebo caps ule
`166 0.5 mg QD `166 capsule, 0.25 mg `166 capsule, 0.25 mg Placebo  capsule
`166 0.75 mg QD `166 capsule, 0.25 mg `166 capsule, 0.25 mg `166 c apsule, 0.25 mg 
BRA 9 mg QD BRA capsule, 3 mg BRA capsule, 3 mg BRA capsule, 3 mg
Abbreviations: â€˜166 = BMS-986166-04; BRA = branebrutinib; QD = once daily
Note: all capsules are identical in size (size 0).
Protocol Amendment No.: 01
Date: 30-Jun-2021 16
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Data Monitoring Committee: Yes
Statistical Considerations: 
The sample size calculation is driven by [CONTACT_576913] m ean percentage change from 
baseline in EASI score at Week 16 between BMS-986166 or branebr utinib versus placebo. 
Thirty participants per group w ill provide 84% power to detect a treatment difference (versus 
placebo) of 30% at the type  I error of  Î± = 0.05 (1-sid ed), assuming a common standard deviation 
of 43%. The assumed treatment difference of 30% is similar to the mean difference observed from 
historical data on approved drugs across different mechanism of actions. No adjustment will be 
made for multiplicity.
Assuming a 15% dropout rate (ie, the fraction of participants n ot completing Week 16 assessment), 
25 participants per group will still provide 78% power to detec t a treatment difference of 30%.
An interim analysis (IA) may be performed when approximately 50 % of the participants have 
reached Week 16 or discontinued. Safety and eff icacy analysis will be performed to accelerate 
internal decision making. The IA w ill be performed by [CONTACT_576914]. The study team w ill remain blinded during IA.
Protocol Amendment No.: 01
Date: 30-Jun-2021 17
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
2 SCHEDULE OF ACTIVITIES
Table 2-1: Screening Procedural Outline (IM108005)
ProcedureScreening
Visit
(Day -35 to -1)Notes
Administrative and Historical 
Assessments
Informed Consent XA participant is considered enrolled when a protocol-specific i nformed consent form (ICF) 
is signed. If re-enrolled, the participant must be reconsented and assigned a new participant 
number from IRT.
Optional ICFs Xâ€¢AD-related Genomics and Pharmacogenetics
â€¢12-hour Pharmacokinetics sample
â€¢Skin Biopsy
Enrollment in the IRT System XContact [CONTACT_576915]. If participant does not meet eligibility criteria, contact [CONTACT_576916]-fail participant.
Inclusion/Exclusion Criteria X
Demographics Collection X
Atopy History with Targeted Questionnaire; AD-related TreatmentX
Medical History X
Prior and Concomitant Medication Use XIncludes prescription, over-the-counter medications, and herbal  supplements. All 
concomitant medications to be reviewed by [CONTACT_576917].
Disease Assessment
DLQI XPatient reported [ADDRESS_756615] week. ( Appendix 12 )
POEM XPatient reported 7-item questionnaire to evaluate atopic dermat itis symptoms in the past 
7 days. (Appendix 13)
EASI X EASI score 12 or higher at screening ( Appendix 9)
vIGA-AD X vIGA-AD â‰¥ 3 ( Appendix 8)
BSA Assessment X BSA â‰¥ 10% affected ( Appendix 10)
Protocol Amendment No.: 01
Date: 30-Jun-2021 18
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 2-1: Screening Procedural Outline (IM108005)
ProcedureScreening
Visit
(Day -35 to -1)Notes
Pruritus and Sleep Quality NRS XParticipants will be trained at Screening, and will be familiari zed with its use at that time. 
The diary will be completed every day at waking thenceforth. Da ta collected starting on 
Day -6 will be used for analysis. ( Appendix 11)
Safety Activities
Counseling on Contraception Use X
Vital Signs XIncludes body temperature, respi[INVESTIGATOR_697], blood pressure and heart rate. Blood pressure 
and heart rate should be measured after the participant has been  supi[INVESTIGATOR_576832] 
[ADDRESS_756616] Radiography X PA & lateral CXR
Pulmonary Function Test X FEV1, FVC, and DLCO
Visual Acuity Testing and Optical 
Coherence TomographyX
Laboratory Tests
Hematology X CBC with differential
Chemistry Panel X Includes liver function testing 
Lipid Panel X Non-fasting
Hemoglobin A1c X
Coagulation Panel X PT and INR
Screening for Drugs of Abuse (urine or serum)X Performed locally and entered by [CONTACT_576918] X
Urinalysis (UA) X Abnormal results trigger reflex microscopic exa m
Protocol Amendment No.: 01
Date: 30-Jun-2021 19
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 2-1: Screening Procedural Outline (IM108005)
ProcedureScreening
Visit
(Day -35 to -1)Notes
Pregnancy Test X WOCBP only; performed locally
Follicle Stimulating Hormone (FSH) X For select women only, serum  FSH level will be determined to confirm menopausal status
FSH and LH, and Total Testosterone X Male participants only. Samp les should be taken in the morning
Hepatitis and HIV Screening X Includes HCV antibody, HBsAg, HBcAb , and HIV antibodies
QuantiFERON-TB Gold test X
SARS-CoV-2: RT-PCR test or Antigen test X
COVID-19 Mitigation XMeasures (eg, viral testing, temperature readings, interviews, social distancing, PPE, etc.) 
required by [CONTACT_576919].
Abbreviations: AD = Atopic Dermatitis; BSA = Body Surface Area; CBC = Complete Blood Count;  COVID- 19 = corona virus disease 2019; CXR = Chest X-ray; 
DLCO = Diffusion Capacity; DLQI = Dermatology Life Quality Index; EASI = Eczema Area and Severity Index; ECG = electrocardiogr am; eCRF = Electronic 
Case Report Form; eGFR = estimated Glomerular Filtration Rate; FEV1 = Forced Expi[INVESTIGATOR_1814] 1 second; FVC = Forced Vital  Capacity; FSH = Follicle 
Stimulating Hormone; HBcAb = Hepatitis B core antibody; HBsAb =  Hepatitis B surface antibody; HBsAg = Hepatitis B surface antigen; HCV = Hepatitis C 
virus; HIV = Human Immunodeficiency virus; ICF = Informed Conse nt Form; INR = international normalized ratio; IRT = Interactive Response Technology; LH 
= Luteinizing hormone; NRS = Numerical Rating Scale; PA = Posteroanterior; POEM = Patient Oriented Eczema Measure; PPE = Perso nal Protective Equipment; 
PT = prothrombin time; RT-PCR = Reverse transcriptase polymerase chain reaction; SAE = Serious Adverse Event; SARS-CoV-2 = severe  acute respi[INVESTIGATOR_11520] 2; TB = Tuberc ulosis; UA = urinalysis; vIG A-AD = validated Investigator Global Assessment scale for Atopi c Dermatitis; WOCBP = 
Women of Childbearing Potential. 
Protocol Amendment No.: 01
Date: 30-Jun-2021 20
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 2-2: On-treatment Procedural Outline (IM018005)
ProcedureDay 1a
(Rand)Day 8
W1
(Â± 1 
days)Day 15
W2
(Â± 3 
days)Day 29
W4
(Â± 3 
days)Day 57
W8
(Â± 3 
days)Day 85a
W12
(Â± 3 
days)Day 113
(EOT)
W16
(Â± 3 
days)Notes
Administrative and Historical 
Assessments
Inclusion/Exclusion Criteria XReview of inclusion/exclusion criteria that are specified on or defined relative to the 
randomization day
Randomization via IRT X
Disease/Efficacy Assessment
EASI X X X X X X XEASI at baseline must be â‰¥ 16 (prior to randomization).
vIGA-AD X X X X X X X
BSA Assessment X X X X X X X
Pruritus and Sleep Quality NRS X X X X X X XWill be collected daily in an electronic diary â€“
represents preceding [ADDRESS_756617] X XFEV1, FVC & DLCO may be collected within 
a window of Â± 5 days of visit.
Visual Acuity Testing and Optical Coherence TomographyXXMay be collected within a window of Â± 7 days of visit.
Safety Activities
Body Weight X X
Protocol Amendment No.: 01
Date: 30-Jun-2021 21
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 2-2: On-treatment Procedural Outline (IM018005)
ProcedureDay 1a
(Rand)Day 8
W1
(Â± 1 
days)Day 15
W2
(Â± 3 
days)Day 29
W4
(Â± 3 
days)Day 57
W8
(Â± 3 
days)Day 85a
W12
(Â± 3 
days)Day 113
(EOT)
W16
(Â± 3 
days)Notes
Vital Signs XbX XXX X XIncludes body temperature, respi[INVESTIGATOR_697], 
blood pressure and heart rate. Blood pressure and heart rate should be measured after the 
participant has been supi[INVESTIGATOR_1919] 
[ADDRESS_756618] visit.
SARS-CoV-2: RT-PCR test or Antigen testXParticipants must have a negative SARS-CoV-[ADDRESS_756619] practices.
COVID-19 Mitigation X X X X X X XMeasures (eg, temperature readings, 
interviews, social distancing, PPE, etc.) 
required by [CONTACT_576920].
Concomitant Medication Use X X X X X X X
Laboratory Tests
Hematology (CBC) X X X X X X X
Chemistry Panel X X X X X X X
Protocol Amendment No.: 01
Date: 30-Jun-2021 22
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 2-2: On-treatment Procedural Outline (IM018005)
ProcedureDay 1a
(Rand)Day 8
W1
(Â± 1 
days)Day 15
W2
(Â± 3 
days)Day 29
W4
(Â± 3 
days)Day 57
W8
(Â± 3 
days)Day 85a
W12
(Â± 3 
days)Day 113
(EOT)
W16
(Â± 3 
days)Notes
eGFR calculation X X X X X X X
Urinalysis (UA) X XAbnormal results trigger reflex microscopic 
exam.
Pregnancy Test X X X X X X X WOCBP only; performed locally.
Drugs of abuse (urine or serum) XPredose, performed locally and entered into the eCRF by [CONTACT_576921], LH, and Total 
TestosteroneXXMale participants only. Samples should be taken in the morning.
SARS-CoV-2 Serology XSerum to be collected for optional
measurements of anti-SARS-CoV-2 IgM 
and/or IgG and/or IgA.
Pharmacokinetics Assessments
Collect Blood or Plasma Samples for PKSee Table 9.5.1-[ADDRESS_756620] Engagement
Biomarker samples collection See Table 9.8-1
Study Treatment
Access/Login IRT X X X XRegister visit in the IRT every 4 weeks (Â± 3 
days).
Study Drug Dispensing X X X X Dispense study drug every 4 weeks (Â± 3  days).
Protocol Amendment No.: 01
Date: 30-Jun-2021 23
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 2-2: On-treatment Procedural Outline (IM018005)
ProcedureDay 1a
(Rand)Day 8
W1
(Â± 1 
days)Day 15
W2
(Â± 3 
days)Day 29
W4
(Â± 3 
days)Day 57
W8
(Â± 3 
days)Day 85a
W12
(Â± 3 
days)Day 113
(EOT)
W16
(Â± 3 
days)Notes
Study Drug Compliance Check X X X X X XParticipants must bring their pi[INVESTIGATOR_576833].
aThe visit duration on Days 1 and 85 will be approximately 7 hour s for either PK and/or 12-lead  ECG collection. At selected sites , the visit duration will be 
approximately 12 hours for PK.
bDay 1 visit to include vital signs recorded predose then hourly  at 1, 2, 3, 4, 5, and 6 hours (Â± 10 minutes) post-dose.
cDay [ADDRESS_756621] ECGs recorded at 1, 2, 4, and 6 hours  (Â± 10 minutes) post-dose.
Abbreviations: AD = atopic dermatitis; AE = adverse event; BSA = body s urface area; CBC = complete bl ood c ount; COVID-19 = coronavirus disease 2019; 
DLCO = Diffusion Capacity; DLQI = Dermatology Life Quality Inde x; EASI = Eczema Area and Severity Index; ECG = electrocardiogr am; eGFR = estimated 
Glomerular Filtration Rate; EOT = end of treatment; FEV1 = Forc ed Expi[INVESTIGATOR_1814] 1 second;  FVC = Forced Vital Capacity; F SH = Follicle Stimulating 
Hormone; ICF = informed consent form; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; IRT = Interactiv e Response Technology; 
LH = Luteinizing hormone; NRS = Numerical Rating Scale; PGI-C =  Patient Global Impression of Change; PGI-S = Patient Global Impression of Severity; PK = 
pharmacokinetics; POEM = Patient Oriented Eczema Measure; RT-PCR  = Reverse transcriptase polymerase chain reaction; SAE = serious adverse event; SARS-
CoV-2 = severe acute respi[INVESTIGATOR_6507] 2; UA = ur inalysis; vIGA-AD = Validated Investigator Global Assessment scale for Atopic Dermatitis; W 
= week; WOCBP = Women of Childbearing Potential.
Protocol Amendment No.: 01
Date: 30-Jun-2021 24
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 2-3: Post-treatment Follow-up and Additional Visit Types
ProcedureDay 127
(Â± 3 days) 
W18Day 141
(Â± 3 days) 
W20Day 169
(Â± 3 days) 
W24 EOSaStudy 
WithdrawalUnscheduledbNotes
Administrative Activities
Contact [CONTACT_576922] X X
Disease/Efficacy Assessment
EASI X X X X X
vIGA-AD X X X X X
BSA assessment X X X X X
Pruritus and Sleep Quality 
NRSXX X XWill be collected daily in an electronic diary â€“represents preceding [ADDRESS_756622] X X
Visual Acuity Testing and 
Optical Coherence 
TomographyXX
Safety Activities
Body Weight X X X Data will be collected at each specified visit.
Vital Signs X X X X XBody temperature, blood pressure, respi[INVESTIGATOR_862], and heart rate. Data will be collected at 
each specified visit.
Protocol Amendment No.: 01
Date: 30-Jun-2021 25
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 2-3: Post-treatment Follow-up and Additional Visit Types
ProcedureDay 127
(Â± 3 days) 
W18Day 141
(Â± 3 days) 
W20Day 169
(Â± 3 days) 
W24 EOSaStudy 
WithdrawalUnscheduledbNotes
Complete Physical 
ExaminationX X Data will be collected at each specified visit.
Targeted Physical ExaminationX X X Data will be collected at each specified visit.
12-lead ECG X X X X X Data will be collected at each specified visit.
AE and SAE Assessment X X X X X Data will be collected at each specif ied visit.
Concomitant Medication Use X X X X X Data will be collected at each s pecified visit.
Laboratory Tests
Hematology (CBC) XX X X X Data will be collected at each specified visit.
Chemistry Panel X X X X X Data will be collected at each specified vi sit.
eGFR calculation X X X X X Data will be collected at each specified visit.
Urinalysis (UA) X X XAbnormal results trigger reflex microscopic 
exam. Data will be collected at each specified 
visit.
Pregnancy Test X X X XWOCBP only; performed locally. Data will be collected at each specified visit.
FSH and LH, and Total TestosteroneXXMale participants only. Samples should be taken in the morning.
SARS-CoV-2 Serology X X For contingent/optional analysis
Protocol Amendment No.: 01
Date: 30-Jun-2021 26
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 2-3: Post-treatment Follow-up and Additional Visit Types
ProcedureDay 127
(Â± 3 days) 
W18Day 141
(Â± 3 days) 
W20Day 169
(Â± 3 days) 
W24 EOSaStudy 
WithdrawalUnscheduledbNotes
Biomarker Assessments and 
Pathway Engagement
Biomarker samples collection See Table 9.8-1
aParticipants follow-up may be ex tended as needed until absolute lymphocyte count is > 1000/ Î¼L and absolute neutrophil count is > 1500/ Î¼L.
bAd hoc safety procedures required to address the circumstances and  if applicable EASI, vIGA, BSA and DLQI assessments
Abbreviations: AD = Atopic Dermatitis; AE = Adverse Event; BSA = Body Surface Area; CBC = Complete Bl ood Count; DLQI = Dermatology Life Qu ality 
Index; EASI = Eczema Area and Severity Index; ECG = electrocard iogram; eGFR = estimated Glomerular Filtration R ate; EOS = end of st udy; FSH = Fo llicle 
Stimulating Hormone; ICF = Informed Consent Form; IRT = Interactive Response Technology; LH = Luteinizing hormone; NRS = Numer ical Rating Scale; PGI-
C=Patient Global Impression of Change; PGI-S=Patient Global Imp ression of Severity; PK = pharmacokinetics; POEM=Patient Orient ed Eczema Measure; SAE = 
serious adverse event; SARS-CoV-2 = severe acute respi[INVESTIGATOR_303193] 2; UA = urinalysis; vIGA-AD = validated Investigator Global Assessment 
scale for Atopic Dermatitis; WOCBP = women of childbearing pote ntial.
Protocol Amendment No.: 01
Date: 30-Jun-2021 27
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
When multiple assessments are conducted at a single visit, the following is the order in which they 
should be performed:
1) Safety assessments (eg, vitals, electrocardiograms [ECG], adv erse events [AEs])
2) Laboratory tests (eg, safety laboratory tests, pharmacokinetic assessments, biomarker 
assessments)
3) Clinical efficacy assessments
4) Treatment dosing
3 INTRODUCTION
IM018005 is a Phase 2 study to assess the clinical benefit prov ided by [CONTACT_264535] 3 dose levels of 
BMS-986166, a modulat or of sphi ngosine-1-phosphate receptor 1 (S1PR1), and of a single dose 
level of branebrutinib (an inhibitor of Bruton Tyrosine Kinase [BTK]) in participants with 
moderate-to-severe atopic dermatitis (AD). 
Interventions that are safe and highly effective in a large maj ority of AD patients with moderate 
or severe disease remains an unmet medical need ( Section 3.1.1 ). Despi[INVESTIGATOR_576834] (anti-interleukin-4 receptor alpha monoclonal antibod y) for the treatment of AD, after 
16 weeks of treatment, approximately 40% of patients with moderate or severe AD, demonstrated 
a reduction of the Investigators ÍƒGlobal Assessment (IGA) to either 1 (almost clear) or 0 (clear) . 
The substantial biological heterogeneity of AD warrants developm ent of new medications acting 
through differe nt mechanisms to tr eat patients, so that all may achieve remission or near-remission.
Signals transduced by [CONTACT_576923]-1-phosphate (S1P) and by [CONTACT_576924] (Section 3.1.2), making these pathways attractive targets for potential AD 
therapi[INVESTIGATOR_014]. 
BMS-986166 a nd branebrutinib demonstrated satisfactory safety, tolerability, pharmacokinetics 
(PK), and pharmacodynamics (PD) in Phase 1 clinical studies fol lowing extensive and promising 
nonclinical evaluations ( Section 3.2 ). Thus, they are being evaluated in this Phase [ADDRESS_756623] ing 3% to 10% of the US 
population.1Worldwide, it affects up to 20% of children and 3% of adults, w ith higher prevalence 
in younger children (ages 6 years to 7 years as compared with a ges 13 years to 14 years) and also 
in some countries which have emerged as regions of relatively h igh prevalence.2In the majority 
of cases, AD has an onset before age 5 years, and prevalence da ta in children show a slight female 
to male preponderance (1.3 to 1).3Persistent AD may be present in approximately 50% of patients 
diagnosed with atopic dermatitis during childhood.4,5Of those affected, about 40% have 
moderate-to-severe disease.6Beyond the characteristic skin pathology, AD is associated with  
increased anxiety, depression, sleep disorders, reduced product ivity, and impaired activity â€“ all of 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756624] 
increased risk of other atopic disorders, including asthma, all ergic rhinitis, and chronic sinusitis 
with nasal polyposis.8,9,10Taken together, the burdens of AD resulted in an estimated > $[ADDRESS_756625] been associated with greater disease severity.13,14Enhanced allergen/antigen 
penetration through an impaired skin barrier resulting in a typ e 2 helper T-lymphocyte (Th2)-type 
milieu has been proposed as a critical link between the primary  barrier defect in patients and Th2 
polarization.15Th2 differentiation of naive CD4+ T-cells predominates in AD ca using an increased 
producti on of interleukins (IL), primarily IL- 4, IL-5, and IL-1 3 (Figure 3.1.1-1 ), which then leads 
to an increased level of immunoglobulin E (IgE), and correspond ing inhibition of type 1 helper 
T-lymphocyte (Th1) differentiation. In 80% of AD patients, the disease is asso ciated with 
hypersensitivity to environmental or food allergens, increased sp ecific serum IgE levels, and 
eosinophilia.16,17Thus, AD is often part of (even the first manifestation of) a m ulti-system, 
Th2-dependent disease constellation that can include allergy, e levated IgE, and asthma.18,19,27The 
barrier defects, other genetic and environmental factors, and e xaggerated Th2 biology also involve 
activation of dermal keratinocytes and Langerhans cells, accomp anied by [CONTACT_576925] â€“ potentially accompanied by [CONTACT_576926]20and 
possibly immune -mediated phenomena in a fraction of cases.21This pathobiology further worsens 
barrier function and causes the chronic , self-sustaining syndrome of s kin rash, pruritu s, xerosis, 
and gram-positive skin dysbiosis that im poses the personal and societal  burdens summar ized above 
(Figure 3.1.1-1). 
Until recently, treatment for moderat e or severe AD involved hydration of the skin, and/or 
application of topi[INVESTIGATOR_2855] t reatments  such as glucocorticoids, calcineurin inhibitors, phosphodiesterase 
4 (PDE4) inhibitors, tar, vitamin D, or d ilute bleach. Severe, complex, or refractory cases invoked 
wet-wrap dressings, phototherapy , or systemic tr eatment with glucocorticoids, cyclosporine, and 
azathioprine -- for most patients, these  approaches were, at best, partially satisf actory.10More 
recently, biologic and small molecule  therapi[INVESTIGATOR_576835] (Figure 3.1.1-1).22In particular, the recent European Medicines Agency (EMA) 
and FDA approvals of dupi[INVESTIGATOR_12458] (an ti-IL-4RÎ±monoclonal antibody) represent a significant 
advance for AD patients.29Neverthele ss, AD exhibits biological and clinical heterogeneity,23,24
and new medications employing different mechanisms are needed t o provide a complete treatment 
armamentarium; indeed, the placeb o-adjusted fraction of patient s with moderate or severe AD 
demonstrating a reduction of Investigatorsâ€™ Global Assessment ( IGA) to either 1 (almost clear) or 
Protocol Amendment No.: 01
Date: 30-Jun-2021 29
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
0 (clear) after 16 weeks of dupi[INVESTIGATOR_576836] ~36%.25,26Furthermore, dupi[INVESTIGATOR_576837], discomfort, and 
injection-site reactions. New treatments for moderate and severe AD thus still represent a clear 
unmet need.
Figure 3.1.1-1: Schemat ic of Selected Immune Mechanisms in Atopi c Dermatitis
Abbreviations: DC = dendritic cell; IgE = immunoglobulin E; IL = interleukin; ILC2 = type 2 innate lymphoid cell; 
LC = Langerhans cell; S. aureus = Staphylococcus aureus; TSLP =  thymic stromal lymphopoietin.
Schematic model of interpla y between microbiome, skin barrier, and immunity in atopic derm atitis highlighting targets 
of novel biologic agents.22
3.1.2 Rationale for Study Drug Mechanisms
Exaggerated activation, local proliferation, and in-migration o f leukocytes in the skin characterize 
AD ( Figure 3.1.2-1 ).27,28Th2 cells contribute by [CONTACT_576927]-4, -5, and -13, which, amo ngst 
other effects, recruit and activate eosinophils. Together, the Th2 cells and eosinophils directly and 
indirectly contribute to multiple phenomena associated with AD â€“ including IL-[ADDRESS_756626] the intense itch associated with the disease. Products of these cells are validated 
targets of both approved and experimental treatments for AD, in cluding dupi[INVESTIGATOR_12458] (anti-IL-
4RÎ±);29and nemolizumab (anti-IL -31).30,31Th2 cells and a subset of myeloid dendritic cell (DC) 
also play significant roles; their fun ction and products have likewise been targeted by [CONTACT_576928][INVESTIGATOR_014] (Figure 3.1.1-1). 
Protocol Amendment No.: 01
Date: 30-Jun-2021 30
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
S1P is a lysophospholipid mediat or that evokes a variety of cel lular responses by [CONTACT_576929] 5 members of a G- protein coupled receptor family: S1PR1, 2, 3, 4, 5.32S1PR1 is ubiquitously 
distributed across multiple tissues, notably endothelial cells and lymphoid cells. Among its 
numerous biological activities, S1PR1 controls the egress of ly mphocytes from peripheral 
lymphoid organs and their subsequent peripheral localization. T hus, S1PR1 has been targeted in 
the treatment of immune-mediated diseases.33In particular, S1P also figures prominently in the 
migratory behavior and activat ion states of th e cells operative  in AD;34and is important to 
keratinocyte homeostasis,35,36accordingly, S1PR modulation is a promising approach for the 
treatment of AD. The dotted boxes in Figure 3.1.2-[ADDRESS_756627] (S1PR1 full agonist, S1PR4/[ADDRESS_756628]) etrasimod is already being studied in a Phase 2 study for this indication.37
BMS-986166 (henceforth meaning either the parent or its phospho rylated derivative, depending 
on context) differentiates from other S1PR drugs by [CONTACT_57216] i ts partial agonist activity on S1PR1 
(Section 3.2 ) â€“ leading to reduced macular, pulmonary, and cardiac liabiliti es both in vivo 
nonclinical and in vitro pharmacology models.38Furthermore, the safety data for BMS-986166 
from two Phase 1 studies of healthy participants (IM018001 and IM018003) demonstrated no 
significant effects on ECG (after the first dose or after multi ple doses), vital signs, and clinical 
laboratory parameters at the doses to be tested in this study.
Based on the preceding, BMS-986166 is an appropriate investigat ional drug for AD. For 
justification of doses, refer to Section 5.5.1 .
Protocol Amendment No.: 01
Date: 30-Jun-2021 31
2.0 Approved 930158234 2.0v
Approved
1.0
v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
BTK inhibition is thus expected to block antigen-dependent B-cell signaling and function without 
depleting B-cells43, lead to decreases in IC-med iated production of pro-inflammatory cytokines, 
reduce IC signaling to monocytic cells, and block Fc ÎµRI-mediated activation of basophils and 
eosinophils by [CONTACT_20435]-specific IgE.47Many of the processes mediated by [CONTACT_576930]-mediated diseases, including AD,48making it a plausible target for the treatment of 
multiple immune-mediated disorders, including AD. 
Branebrutinib is an oral, potent, and highly selective, irrever sible inhibitor of BTK that covalently 
modifies a cysteine residue within the active site of the enzym e; it is thus an appropriate 
investigational drug for AD in this st udy. For justif ication of dose , refer to Section 5.5.[ADDRESS_756629]-c lear status in investigato r assessments, despi[INVESTIGATOR_576838] ( Section 3.1.1 ).
AD, like most inflammatory disorders, exhibits a waxing and wan ing course; thus, careful patient 
selection is required to avoi d unexpected â€œregression to the meanâ€ and other confounding effects 
in clinical studies. This study will recruit adult participants  with moderate or severe chronic AD 
of at least 2-years duration. T hey must also demonstrate Eczema  Area and Severity Index (EASI) 
score â‰¥ 16, validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) â‰¥ 3, 
and â‰¥ 10% body surface area (BSA) affected by [CONTACT_576931]. In addition, a stable regimen 
(â‰¥ 4 weeks) of topi[INVESTIGATOR_11930], calcineurin inhibitors or biologics must have failed to 
provide adequate res ponse within the 6 months prior to randomization. Consistent us e of additive-
free, basic bland emollients twice-daily for â‰¥ 7 days before th e baseline visit and throughout the 
treatment period w ill be mandatory. These factors w ill min imize selection of patients with 
inconsistent or exceptionally variable disease. Only adults wil l be studied due to the early 
developmental phases of both active investigational products. 3.1.4 Rationales for Primary and Secondary Efficacy Endpoints
The primary eff icacy endpoint is mean percentage reduction from  baseline in EASI score at 
Week 16. The EASI is a widely used clinical study e ndpoint in AD. Thus, it allows 
contextualization with the full spectrum of approved and experi mental drugs â€“ offering maximum 
opportunity for benchmarking and modeling of the relationships between PK, PD, safety, and 
efficacy. This study w ill use it on a conti nuous scale to  maximize s tatistical efficiency â€“ though 
the categorical endpoints of EASI-50/75/90 will be assessed as secondary/exploratory endpoints. 
(Table 4-1)
The secondary endpoints include the mean reduction in affected BSA, the proportion of 
participants achieving EASI-50, and the proporti on of parti cipants achieving a score of â€œclearedâ€ 
or â€œalmost clearedâ€ on the vIGA-AD and pruritus NRS (4-poi nt improvement and mean % 
change). These endpoints are important adjuncts to the continuo us-scale EASI and can provide 
insight into the registrational plausibility of the study drugs . The FDA, in particular, has assigned 
significant weight to the vIGA-AD response in registrational pa ckages of other compounds.
Protocol Amendment No.: 01
Date: 30-Jun-2021 33
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
3.1.5 Research Hypothesis
Inhibition of S1PR1, 4, 5 or BT K with BMS- 986166 or bra nebrutin ib, respectively, will safely 
reduce disease activity in participants with moderate-to-severe  AD.
3.2 Background
3.2.1 BMS-986166
A detailed description of pharmacology, toxicology, and clinical safety can be found in 
BMS-986166 investigator brochure.38Key highlights are provided below.
[IP_ADDRESS] In Vitro Pharmacology
BMS-986166 is  a novel prodrug that is phosphorylated  to its pharmacologi cally active moiety, 
BMS-986166-P (BMT-121795). BMS-986166-P is a sphingosine 1 phosp hate (S1P) receptor 
modulator; a biased agonist o f S1PR1, wit h agonist activit y for S1PR4 and S1P R5. BMS-986166-P 
relies predominantly on sphingosine kinase 2 (SphK2), similar t o fingolimod (FTY-720, 
GILENYAÂ®). Importantly however, BMS-986166-P differentiates from fingo limod phosphate 
(FTY-P) and other S1PR1 agonists in its differential effects on  various signaling pathways 
downstream of S1PR1, ie, it is a biased ligand.49
BMS-986166-P fully displaces S1P binding to S1PR1 transfected C hinese hamster ovary (CHO) 
cells with an half max imal inhibitory concentration (IC50) of 0.[ADDRESS_756630] 
in a cyclic adenosine monophosphate (cAMP) assay in these cells  with an EC50 of 0.0079 nM, 
comparable to fingolimod phosphate. In an S1PR1 GTP Î³S binding assay in S1PR1/CHO cells, 
however, BMS-986166-P acts a s a partial agonist with maximum ef ficacy that reaches only 79% 
of the maximum efficacy of endogenous ligand S1P. In an S1PR1 i nternalization assay (in 
S1PR1/CHO/ green fluorescent protein [GFP] cells), BMS-986166-P also acts as a partial agonist 
with an efficacy that reaches 72% of maximum effect observed wi th S1P. This partial agonism is 
unique to BMS-986166-P, as fingolimod phosphate and S1PR1 select ive agents (eg, BAF-312, 
KRP-203, and CS-0777) are S1PR1 full agonists in both the GTP Î³S and the internalization assays. 
Lastly, in an S1PR1 extracellular  signal-related kinase (ERK)-p hosphorylation assay (in 
S1PR1/CHO cells), BMS-986166-P is shown to be a full agonist bu t with an EC50 more than 
100-fold higher than the EC50 of fingolimod phosphate. Taken to gether, the above demonstrate 
the biased agonism properties of BMS-986166-P.
Despi[INVESTIGATOR_118492]-mentioned differences in receptor pharmacolog y in S1PR1/CHO cells, 
BMS-986166-P completely blocks S1P-induced T- cell chemotaxis in a pr imary T-cell system, 
similar to fingolimod phosphate. Lastly, similar to fingolimod phosphate, BMS-986166-P is a 
potent agonist for S1PR4 and S1PR5 receptors with EC50 values c omparable to fingolimod 
phosphate: 3.[ADDRESS_756631] 
activity in the S1PR1 internalization assay (S1PR1/CHO cells) and right-shifted potency in ERK 
Protocol Amendment No.: 01
Date: 30-Jun-2021 34
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
phosphorylation assays (vs. fingolimod phosphate). BMS-986166 t hus demonstrates differentiated 
in vitro pharmacology relative to prior-generation S1PR1 modula tors, offering promise for 
improved clinical performance.
[IP_ADDRESS] In Vivo Pharmacology
S1PR1 agonists cause lymphocyte sequestration in lymphoid organ s, which results in rapid 
lymphopenia. Accordingly, in rats receiving vehicle or escalati ng doses of BMS-986166, 
BMS-[ADDRESS_756632]-dose, 
achieving a decline of ~80% compared with vehicle-treated contr ols. The EC50 was determined 
to be 6.[ADDRESS_756633] hypersensiti vity was induced in BALB/c mic e by [CONTACT_576932] 
0.5% fluorescein isothiocyanate  (FITC) on Days 0 and 5 of the s tudy and challenging the ears with 
the same solution on Days 11, 12, and 13. Treatments included BMS-986166 administered via oral 
gavage at 0.1, 0.5, or 2 mg/kg/day or dexamethasone at 1 mg/kg/ day with first dose initiated on 
the day before sensitization. BMS-[ADDRESS_756634] ef ficacy in this 14-day 
FITC-induced AD model based on the dose-dependent reduction in 1) ear swelling, 2) total serum 
IgE levels, 3) ear histology scores, 4) scratching events, 5) s kin inflammatory cytokine gene 
expression (Th1, Th2, Th17, Th22), and 6) the numbers of infilt rating immune cells.50The effect 
for BMS-986166 at 2 mg/kg was comparable to that of the dexamethasone positive control. BMS-986166 thus modulates the complex inflammatory pathways involve d in this model of AD disease 
pathogenesis. 
BMS-986166 has also demonstrated maximal lymphopenia and effica cy in the experimental 
allergic encephalomyelitis rodent model of MS, and the MRL/lpr mouse lupus model -- similar to 
that of fingolimod, and eff icacy superior to anti-tumor necrosis factor (TNF) Î±antibody in 
oxazolone-induced mouse colitis models. Although these models d iffer phenomenologically from 
those of AD, the latter share key cellular and molecular mechan isms with the former,
51as 
demonstrated by [CONTACT_576933] S 1PR1 modulation in murine AD 
models.52
Taken together, the in vivo pharmacology properties of BMS-986166 support efficacy testing in 
human immune-mediated diseases, including AD.
[IP_ADDRESS] Nonclinical Toxicology
A comprehensive nonclinical toxi cology program was executed for  BMS-986166 and is 
summarized in BMS-986166 Investigator Brochure (IB).38Results of 6-month and 9-month good 
laboratory practice (GLP) toxicity studies in rats and dogs, re spectively, are highlighted below.
In a 6-month repeat dose, oral GLP toxicity study in rats with an 8-week recovery period, 
BMS-986166 was administered at doses of 0 (vehicle), 1, 3, or 1 0 mg/kg/day to groups of 
25 rats/sex. Potential effects of BMS-986166 on mating and ferti lity in male rats and early 
embryonic development of their offspring were also evaluated.53BMS-986166 was well tolerated 
Protocol Amendment No.: 01
Date: 30-Jun-2021 35
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
at doses of up to 10 mg/kg/da y with no BMS-986166-related clini cal observations or effects on 
physical and ophthalmologic examinations, NCV measurements, mal e reproductive performance 
and early embryonic development of their offspring, and coagulation and urinalysis parameters. 
Findings consistent with the intended pharmacology of BMS-[ZIP_CODE] 6 were observed at all doses 
(â‰¥ 1 mg/kg/day; mean sex-combined AUC[0-24] â‰¥ 1.13 Î¼gÂ·h/mL), in cluding decreased 
lymphocytes in blood and lymphoid tissue. All BMS-986166-relate d changes were partially or 
completely reversible following the 8-week post-dose recovery p eriod. As there were no adverse 
findings at any dose, the NOAEL wa s considered to be 10 mg/kg/da y (mean sex-combined 
AUC[0-24h] 7.29 Î¼ gÂ·h/mL for BMS-986166 and AUC[0-24h] 22.3 Î¼gÂ·h/m L for BMS-986166-
P).
In a 9-month repeat dose, oral GLP toxicity study in dogs with a 12-week recovery period, 
BMS-986166 was administered by [CONTACT_4644] 0 (control; males/females), 0.1 (males), 
0.3 (males/females), 1 (males/females) and 3 (females) mg/kg/day  to groups of 4 to 6 dogs per 
sex.54BMS-986166 was clinically well tolerated whe n administered at a n oral dose of 
â‰¤ 1 mg/kg/day in males (mean AUC[0-24h] 4.44 Î¼gÂ·h/mL), and â‰¤ 3 mg/kg/day in females (mean 
AUC[0-24h] 7.51 Î¼gÂ·h/mL) with no drug-rel ated clinical observati ons or effects on neurological, 
ECG or ophthalmic examinations; respi[INVESTIGATOR_185212]; coagul ation, urinalysis or urine 
chemistry parameters; and organ weights or gross pathology. Fin dings consistent with the intended 
pharmacology were observed at all doses included decreases in lym phocytes in blood and 
lymphoid tissue. There were no adverse BMS-986166-related findings at 0.1 mg/kg/day in males and â‰¤ 3 mg/kg/day in females; however, adverse changes of semin iferous tubule 
degeneration/atrophy of the testis that were reversible were observed in males at 0.3 mg/kg/day and 1 mg/kg/day. Therefore, the NOAEL was considered to be 0.1 mg/kg/day in males and 
3 mg/kg/day in females (AUC[0- 24h] 0.528 Î¼gÂ·h/mL and 7.51 Î¼gÂ·h/mL , respectively, for 
BMS-986166, and AUC[0-24h] 2.16 Î¼gÂ·h/mL for males at  0.1 mg/kg/day, and 25.3 Î¼gÂ·h/mL for 
females at 3 mg/kg/day for BMS-986166-P).
[IP_ADDRESS] Pharmacokinetic Drug Interaction Summary
A complete summary of the nonclinical PK of BMS-986166 can be f ound in the IB. Drug-drug 
interaction (DDI) potential of BMS-986166 is briefly discussed in this section. In vitro data in 
human liver microsomes suggested that BMS-986166 is metabo lized via cytochrome P 450 
(CYP)3A4/3A5 (~68%) and CYP2C8 (~36%).
55Thus, the PK of BMS-986166 may be altered 
when co-administered with CYP3A4/3A5 inhibitors or inducers.
In vitro studies with recombinant enzymes showed that BMS-[ZIP_CODE] 6 did not inhibit uridine 
diphosphate glucuronosyltransferase (UGT)1A1 at clinically rele vant concentrations.56In human 
liver microsomes, BMS-986166 was not a reversible or time-depen dent inhibitor of CYP1A2, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 (IC50 > 6 Î¼M).56In 
cryopreserved human hepatocytes, BMS-986166 was not an inducer of CYP1A2, CYP2B6, or 
CYP3A4 (EC50 > 2.5 Î¼M).56
Protocol Amendment No.: 01
Date: 30-Jun-2021 36
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
BMS-986166 did not inhibit digoxin transport in Caco-2 cells (I C50 > 15 Î¼M),56suggesting that 
it is not a P-glycoprotein (P-gp) inhibitor. In vitro studies w ith cells expressing single transporters 
showed that BMS-[ADDRESS_756635] cancer 
resistance protein (BCRP), organic anion transporting polypepti de (OATP1)B1, OATP1B3, bile 
salt export pump, organic anion transporter (OAT)1, OAT3, sodiu m taurocholate co-transporting 
polypeptide, or multidrug resi stance-associated protein 2 (IC50  > 16.7 Î¼M).[ADDRESS_756636] been no formal clinical DDI studies with BM S-986166.
[IP_ADDRESS] Clinical Safety
Clinical safety of BMS-986166 has been evaluated in 2 studies p erformed in healthy participants.
Study IM018001
Study IM018001 was a randomized, double-blind, placebo-controll ed study evaluating the safety, 
tolerability, PK, and PD of single ascending doses (SAD) of BMS -[ADDRESS_756637] of food and pH on the r elative 
bioavailability of BMS -986166. It was performed in healthy wome n not of childbearing potential 
(WNOCBP) and in males. BMS-986166 was administered as SAD (Pane ls 1-3), an intrasubject 
ascending dose titration (Panel 4), and as a single fixed dose with or without food and famotidine 
(Panel 5a/b/c). 
â€¢In Panels 1-3, eligible participants were randomized in a 4:1 ra tio to receive an oral solution 
formation of BMS-986166 or placebo. The doses for Panels 1, 2, and 3 were 0.75 mg, 2.0 mg, 
and 5.0 mg, respectively.
â€¢Panel 4 enrolled 16 participants who were randomized in a 3:1 ra tio to receive double-blind 
treatment with an oral solid dosage formulation of BMS-986166 o r placebo. Participants
randomized to BMS- 986166 received increasing daily doses of 0.2 5 mg, 0.5 mg, 0.75 mg, 
1.0 mg, and 1.5 mg. 
â€¢Panel 5 enrolled 24 participants who were randomized in a 1:1:1 ratio to receive a single dose 
of 2.0 mg BMS-986166 solid dosage formulation in the fasted sta te (Panel 5a), in the fed state 
(Panel 5b), or 2 hours following administration of 40 mg famoti dine (Panel 5c). Panel 5 did 
not include a placebo lead-in period. 
Sixty participants received BMS-986166 in this study. Single or al doses of BMS-986166 were 
administered to 48 participants at doses of 0.75 mg (8 particip ants), 2.0 mg (32 participants), or 
5.0 mg (8 participants). The other 12 participants received multi ple oral doses of BMS-986166, 
which were titrated from 0.25 mg to 1.5 mg over a dosing peri od of 16 days. BMS- 986166 was 
administered as an oral solution formulation to 24 participants  (8 participants each at doses of 
0.75 mg, 2.0 mg, or 5.0 mg) and as  a capsule formulation in the o ther 36 participants. Ten 
participants received matching placebo.
BMS-986166 was well tolerated by [CONTACT_576934] 0.75 mg t o 5.0 mg, or a s multiple oral doses with titration from 0.25 mg to 
Protocol Amendment No.: 01
Date: 30-Jun-2021 37
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
1.5 mg over 16 days. All AEs reported in the study were assessed  as non-serious, mild in intensity 
(Grade 1), and unrelated to st udy tr eatment. There were no d eaths, SAEs, or treatment 
discontinuations due to AEs. Treatment-emergent AEs were report ed with similar frequency for 
BMS-986166-treated participants (any dose) and placebo particip ants. Among participants 
receiving BMS-986166, there were no dose-related trends in the frequency of AEs, nor were there 
any meaningful differences in the AE profile when BMS-986166 was administered as a solid 
dosage versus solution formulation or following administration of BMS-986166 with a high-fat 
meal or famotidine compared with administration of BMS-986166 al one under fasting conditions.
Transient, dose-dependent reductions in mean absolute lymphocyt e count (ALC) deemed not 
clinically relevant were observed following treatment with BMS-[ADDRESS_756638] that was expected based on the mechanism of action of  BMS-986166 and that was 
evaluated as a PD endpoint in this study. Furthermore, no subjec t experienced an infection that 
was attributed to study treatment and could potentially be rela ted to lymphopenia. 
Cardiac monitoring and frequent ECG analyses were performed thr oughout the study. Though 
dose-dependent decreases in hourly heart rate (HR) were observe d following administration of 
single doses of BMS-986166, no adverse treatment-related reducti ons in HR or other ECG 
abnormalities were identified. For the interval from [ADDRESS_756639] decreases in hourly HR were - 0.29 beats per 
minute (bpm), -6.[ADDRESS_756640] dose pan els met the prospective definition for tr eatment-related bradycardia during 
the 0 to 12-hour and/or 0 to 24-hour time intervals (ie, median time-matched largest decrease from 
baseline in hourly HR showed a â‰¥ 7 bpm difference for active relative to placebo); however, no 
subject had a reduction in HR below an absolute value of [ADDRESS_756641] experienced an 
AE of syncope, dizziness, atrioventricular (AV) block, or other  event that could be attributed to a
reduction in HR. It is important to note that the 2.0 mg and 5. 0 mg doses administered in Study 
IM018-001 are well above the dose levels to be administered in this Phase 2 study (IM018-005). 
Section 5.5.[ADDRESS_756642] 
increases in QTcF with increasing concentration of either analy te; the apparent slight decrease in 
QTcF with increasing concentration of BMS-[ADDRESS_756643] association with unexpected 
infection risk, or an increased risk of clinically significant bradycardia, AV conduction 
delays/blocks, or hypotension.
Protocol Amendment No.: 01
Date: 30-Jun-2021 38
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Study IM018003
Study IM018003 was a randomized, double-blind, placebo-controll ed study designed to assess the 
safety, tolerability, PK, and PD of MAD of BMS-986166 for 28 da ys in healthy male or fe male 
(WNOCBP) participants. There were 3 sequential multiple-dose pa nels designated as Panels 1, 2, 
and 3. A total of 32 participants received QD doses of blinded s tudy treatment for 28 days; 
24 participants received B MS-986166 at doses of 0.25, 0.75, or 1 .5 mg (8 participants per dose), 
and 8 participants received placebo.
â€¢Multiple oral doses of BMS-986166 up to 1.5 mg QD for 28 days w ere safe and generally well 
tolerated in the healthy participants in this study.
â€¢No drug-related SAEs or deaths occurred during this study. One subject administered placebo 
had an SAE reported as vasovagal symptoms graded as moderate (Grade 2).
â€¢Twenty-two of 24 participants (91.7%) experienced AEs following administration of 
BMS-986166, and 6 of 8 participants (75.0%) had AEs following administration of placebo. 
The most frequently occurring AEs during BMS-986166 administrat ion were lymphopenia 
(N=15; 62.5%) versus 0 in placebo arm, which is consistent with  the pharmacolo gy of the drug; 
contact [CONTACT_576935] (N=8; 33.3%) 
versus 1 (12.5%) in placebo group, increased blood creatine pho sphokinase (N=7; 29.2%) 
versus 3 (37.5%) in placebo group, and headache (N=5; 20.8%) ve rsus 1 (12.5%) in placebo 
group.
â€¢Eighteen of 24 participants (75.0%) administered BMS-986166 expe rienced AEs assessed as 
drug-related by i nvestigators, all graded as mild (Grade 1). The most frequent were 
lymphopenia (N=15; 46.9%), head ache (N=3; 9.4%), and alanine am inotransferase (ALT) 
increased (N=3; 9.4%), which were generally dose dependent.
â€¢Of the 32 participants treated, 2 participan ts (6.3%) discontinue d treatment due to AEs. One 
subject (12.5%) in the 1.5 mg BMS-986166 QD dose group had a si ngle premature ventricular 
contraction (PVC) with retrograde sinus node activation (listed  as sinus node exit block), which 
was followed by a 3-b eat run of non-sustaine d ventricular tachy cardia (NSVT) and [ADDRESS_756644] in the placebo gro up had a decrease in serum 
testosterone lasting 38 days.
â€¢There was a dose-related trend in the AE observance of mild lym phopenia, the intended 
mechanism of action of BMS-986166, occurring after multiple ora l doses of BMS-986166 
â‰¥ 0.75 mg QD. There were no other treatment, or dose-related tren ds in the frequency of 
clinical laboratory abnormalities after multiple oral doses of BMS-986166 up to 1.5 mg QD 
for 28 days.
â€¢There were no apparent dose-related trends in the 12- lead ECG par ameters (ie, HR; and PR, 
QRS, QTcF, and QT intervals).
â€¢There was a dose-related decrease in mean HR, recorded by [CONTACT_576936] 1, after administration of BMS-[ADDRESS_756645] who had symptoms of pre-syncope at the 0.25 mg 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756646] with pre-syncope.
â€¢Statistical analysis of continuous cardiac monitoring data iden tified no treatment-related 
bradycardia (ie, maximal median HR decrease of â‰¥ 7 bpm compared with time-matched 
predose levels vs placebo participants) in hourly HR at nadir f ollowing multiple oral doses up 
to 1.5 mg BMS-986166.
â€¢Results from the BMS-986166 treatment panels over the 0 to 672 hour (Day 28) study interval 
yielded largest decreases in nadir hourly HR (time matched) fro m placebo of 0.83 bpm, 
3.46 bpm, and 5.54 bpm at the 0.25 mg, 0.75 mg, and 1.5 mg dose levels, respectively.
â€¢There were no clinically meaningful changes in vital signs or p hysical examination findings 
(see Section 9.2.8 ).
In summary, the safety data from Study IM018003 indicated that (1) multiple ascending doses of 
BMS-986166 up to 1.5 mg were generally safe and well-tolerated,  and with no association with 
unexpected infection risk, or an increased risk of symptomatic bradycardia, AV conduction 
delays/blocks, or hypotension; and (2) no dose initiation titra tion is required.
Taken together, results of Phase 1 studies with BMS-986166 demo nstrate a satisfactory safety 
profile for its investigation in patients with immune-mediated diseases.
3.2.2 Branebrutinib
A detailed description of pharmacology, toxicology, and clinica l safety can be found in the 
branebrutinib IB.47Key highlights appear below.
[IP_ADDRESS] In Vitro Pharmacology
Branebrutinib is a potent inhib itor of BTK (IC50 = 0.1 nM) that  covalently modifies a cysteine 
residue (Cys-481) within the active site of the enzyme. Against a panel of 245 kinases, the 
compound was s hown to inhibit BTK with greater than 5,000-fold selectivity over all but 4 kinases. 
The highly related kinase Tec was inhibited 9-fold less potentl y than BTK. Of particular note, 
branebrutinib was > 10,000-fold selective over members of the e pi[INVESTIGATOR_3506] 
(EGFR) family of kinases. In contrast, ibrutinib inhibited thes e EGFR kinase family members with 
much greater potency, with only 10- to 110-fold selectivity for BTK.57Ibrutinib shows 3-fold 
selectivity for BTK over Tec. 
Branebrutinib potently inhibited multiple functio nal endpoints in primary human B-cells 
stimulated through the BCR (IC50 values < 1 nM), including production of inflammatory 
cytokines, cell proliferatio n, and surface expression of CD 86. Branebrutinib also inhibited Fc Î³R 
(FcÎ³RIIa and Fc Î³RIIIa)-dependent IL -6 production stimulated from peripheral blood mononuclear 
cells (PBMCs) stimulated by [CONTACT_202132]-containing ICs with a potency ( IC50 = 0.3 nM) equivalent to 
those measured against BCR-dependent endpoints in B-cells. In a ssays using human whole blood, 
branebrutinib was shown to inhibit BCR-s timulated expression of CD 69 on B-cells wit h an IC50 
value of 11 nM. Measurements of BTK inactivation in human whole blood showed a similar IC50 
value of 5 nM. Branebrutinib rapi[INVESTIGATOR_576839] a time- dependent and concentration-
Protocol Amendment No.: 01
Date: 30-Jun-2021 40
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
dependent manner when added to human whole blood. The second-or der rate constant for the 
inactivation of BTK in human whole blood by [CONTACT_576937] d etermined to be 3.5 Ã—10-4nM-1
â€¢ min-1. This represents a rate of inactivation 3 times faster than th at measured with ibrutinib 
(1.2Ã—10-4nM-1â€¢ min-1).57
[IP_ADDRESS] In Vivo Pharmacology
A single oral administration of branebrutinib at 1 mg/kg to mic e resulted in BTK inactivation of 
89%, 82%, and 72% in b lood, pop liteal lymph nodes, and spleens, respectively, at [ADDRESS_756647]-dose. The compound dose-dependently inactivated BTK in who le blood after a single oral 
administration, with the dose producing 50% effect (ED50) values  of 0.12 and 0.07 mg/kg PO at 
[ADDRESS_756648]-dose, respectively. Ibrutinib at 1 mg /kg provided only 37% and 42% 
BTK inactivation at 4 and 24 hours, respectively, in the same e xperiment, and demonstrates the 
considerably greater potency of branebrutinib in vivo. After 24  hours, the recovery of available 
BTK active sites in both blood and spleens due to new protein synthesis was measured at a rate of 
25% to 35% per day.58
Branebrutinib was highly effective in New Zealand black/white l upus-prone mice -- dose-
dependently inhibiting the increase in severe proteinuria, a me asure of the underlying ne phritis. 
All dose levels als o protected from the disease- related death i n these mice over the course of 
treatment. Serum anti-double-stranded deoxyribonucleic acid (an ti-dsDNA) titers, which 
progressively increased over the course of the study in vehicle control mice, were also inhibited in 
a dose-dependent manner by [CONTACT_576938]. 
Branebrutinib also demonstrated robust efficacy in the mouse co llagen-induced arthritis and 
collagen antibody-induced arthritis models, demonstrating its ab ility to attenuate Fc receptor and 
B-cell r eceptor signaling associated with disease biology, incl uding clinically evident disease, 
histological joint damage, and bone mineral density loss. In bo th models, maximal efficacy was 
observed with  â‰¥95% inactivation of BTK in vivo.
In summary, branebrutinib is a potent and highly selective smal l-molecule, irreversible inhibitor 
of BTK that blocks antigen receptor-dependent signaling and fun ctional endpoints in human 
B-cells, including the production of proinflammatory cytokines,  co-stimulation molecule (eg, 
CD86) expression, and proliferation with IC50 values of < 1 nM. The compound also potently 
inhibited BTK-dependent cytokine production from PBMCs stimulated through the low-affinity 
activating Fc Î³Rs. In human whole blood, branebrutinib rapi[INVESTIGATOR_576840] . Branebrutinib 
was highly efficacious in all tested murine models of immune-associated diseases. Many of  the 
BTK-associated pathobiologic mechan isms common to these mouse a utoimmunity models apply 
to AD as well (Section 3.1 ). 
[IP_ADDRESS] Nonclinical Toxicology
Branebrutinib was studied in a comprehensive nonclinical toxico logy program. Results of 6-month 
and 9-month GLP toxicity studies in rats and dogs, respectively, are highlighted below. 
In a 6-month oral toxicity study in rats with a 5-week recovery ,59branebrutinib was administered 
by [CONTACT_576939] 0 (vehicle), 1, 5, or 20 mg/kg /day to groups of 25 rats/sex. Satellite 
Protocol Amendment No.: 01
Date: 30-Jun-2021 41
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
animals consisting of 25 naÃ¯ve female rats (untreated) per grou p were used for mating and fertility 
assessment of the males in each dose group. 
Branebrutinib was clinically well tolerated by [CONTACT_576940] 6 month s at oral  doses â‰¤20 mg/kg/day with 
no BMS-986195-related eff ects on survival; body weight or food consumption; physical or 
ophthalmic examinations; male reproductive performance (mating and fertility) or early 
embryonic development of the offspring sired by [CONTACT_576941]; coagulation, urinalysis or urine 
chemistry parameters; or organ weights. The suppression of T ce ll-dependent antibody response 
(TDAR) to keyhole limpet hemocyanin (KLH) and decreases in B ly mphocytes at all doses were 
consistent with the pharmacologic activity of branebrutinib. Th e primary effects were noted in the 
pancreas at all doses and were char acterized microscopi [INVESTIGATOR_576841], peri-islet pi[INVESTIGATOR_2517], 
islet hemorrhage, mononuclear cell infiltration, and acinar atr ophy. These pancreatic findings were 
not considered adverse, as they  represent exacerbation of an ag e-related background pancreatic 
finding specific to rats, which has been reported from emerging  literature for this class of 
compound.60Comparing the pancreatic findings across studies, there was no progression of the 
lesions, in terms of severity, after 6 months of dosing, when c ompared with the lesions seen in 
studies of shorter duration (2 weeks61and 1 month of dosing62,63). For these reasons, it was 
considered unlikely that the pancreatic lesions observed in rats  treated with BTK inhibitors would 
have any relevance to the safety assessment for human participa nts treated with this drug class, 
and this was acknowledged by [CONTACT_1622]. As a result, conclusions from earlier studies of shorter 
duration that these findings were adverse in the rat should not  preclude dosing at equivalent 
exposures in humans. Therefore, the NOAEL was considered to be the high dose of 20 mg/kg/day 
(mean sex-combined AUC[0-24h] 61.9 Î¼gÂ·h/mL).
In a 9-month oral toxicity study in dogs with a 4-week recovery ,64branebrutinib was administered 
by [CONTACT_4644] 0 (vehicle), 0.5, 3, or 15 mg/kg/day to groups of 6 dogs per sex. 
Overall, branebrutinib was tolerated by [CONTACT_576942] 9 months at or al doses  â‰¤15 mg/kg/day with no 
branebrutinib-r elated clin ical observation s, effects on body weights and body weight gains, food 
consumption, physical and ophthalmic examinations, electrocardi ology, urinalysis and urine 
chemistry parameters, organ weights changes and gross pathology  findings. Consistent with the 
expected pharmacology of branebrutinib, the pr imary findings at â‰¥ 0.5 mg/kg/day were minimal 
to mild or moderate germinal cen ter lymphoid depletion in lymph  nodes, spleen, and/or 
gut-associated lymphoid tissue (GALT), and suppression of TDAR to KLH. Based on the absence 
of adverse findings at any dose tested, the NOAEL was considered to be 15 mg/kg/day (mean sex-
combined AUC[0-24h] 113 Î¼gÂ·h/mL at Week 39).
[IP_ADDRESS] Pharmacokinetic Drug Interaction Summary
Data from the in vitro DDI interacti on studies of branebrutinib with  multiple CYP and UGT 
enzymes and multiple drug transporters predicted DDI potential with substrates of CYP3A4 (both 
as inhibitor and inducer), CYP2C8 enzymes, and BCRP drug transp orter. In the clinical DDI 
studies, co-administration of branebrutinib (9 mg QD for 14 day s, Study IM014013) did not have 
an effect on the exposures of the corresponding substrates of m ultiple CYP enzymes, including 
the PK of midazolam (sensitive substrate of CYP3A4) or pravastatin (OATP1B1 and OATP1B3), 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756649] (CYP2C8) with mild increase in its exposure (1.556Ã— 
Cmax and 1.270Ã— AUC[INF]). Additionally, a mild increase in digo xin (P-gp substrate) Cmax 
(1.565Ã—), and AUC (1.209Ã— AUC[INF]) were also observed in the cl inical DDI study with 
branebrutinib. Overall, the data suggest that CYP3A4 inhibitory and in duction properties of
branebrutinib may â€œbalanceâ€ each other in vivo and co-administration o f branebrutinib with
substrates of P-gp (such as digoxin) or CYP2C8 with narrow therapeu tic index shoul d be avoided or 
restricted or their serum concentrations be monitored in the prese nce of branebrutinib.
Furthermore, in clinical DDI studies (IM014013, IM014023), brane brutinib showed no clinically 
relevant interactions either with oral contraceptives (ethinyles tradiol/norethindrone) or with 
methotrexate. In another clinical DDI study (IM014032), the effect of coadministration of multiple 
oral doses (9 mg, QD) of branebrutinib on the single-dose PK of rosuvastatin (10 mg) in healthy 
participants was assessed. Rosuvastatin is a sensitive substrat e of the BCRP drug transporter.  
Despi[INVESTIGATOR_576842]50 of 1.[ADDRESS_756650] on the plasma exposure of 
rosuvastatin following a single dose in healthy volunteers.
On the other hand, a human absorption, distribution, metabolism,  and excretion (ADME) study 
(IM014016) showed the major metabo lic clearance pathway for branebrutinib to be enzyme-
mediated glutathione conjugation catalyzed by [CONTACT_576943]-S-transferase (GST) enzymes 
(please refer to the IB for details). Therefore, clinically sig nificant effect on branebrutinib exposure 
is not likely to occur when co-administrated with other agents that are inhibitors of major drug-
metabolizing enzymes such as CYPs and UGTs.In summary, branebrutinib is unlikely to be a clinically signif icant victim of PK drug interactions. 
It also has low likelihood of being a PK drug-interaction perpe trator through most metabolic 
enzymes and transporters. However, it may act as a weak inhibit or of CYP2C8 and P-gp at 
clinically relevant concentrations. 
[IP_ADDRESS] Clinical Safety
Clinical safety of branebrutinib has been evaluated in 4 studie s performed in healthy participants. 
Currently 2 studies are ongoing: IM014029 (a Phase 2a study of branebrutinib in systemic lupus 
erythematosus, primary Sjogrenâ€™s syndrome, and rheumatoid arthr itis), and IM014032 (a Phase 1 
study of drug interactions between branebrutinib and rosuvastat in); neither of these [ADDRESS_756651] sufficient data to report.
Studies IM014001, IM014013, IM014016, and IM014023
The FIH study in healthy pa rticipants (Study IM014001)65included a randomized, placebo-
controlled, double-blind, SAD (Part A) and MAD (P art B; 14 days) - study (non-Japanese des cent); 
a randomized, placebo-controlled, double-blind, MAD study (Japa nese descent; Part C); and an 
open-label, non-randomized, single-sequence relative bioavailab ility and food effect st udy (4 
single doses, 4 days apart; Part D). Evaluations included safet y and tolerability, PK, PD, target 
engagement characteristics, effects in Japanese participants, a nd clinical pharmacology 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756652] and bioavailability of a suitable formulation for use in patients with 
rheumatoid arthritis (RA). Doses and dose escalation were plann ed so that the projected mean 
AUC would not exceed the proposed maximum AUC (5400 ngÂ·hr/mL), p roviding approximately 
a 10-fold safety margin from the AUC in rats (20 mg/kg/day). 
There were no deaths in the study.  
 
 
 
 
 
Other than this event, there were  no AEs leading to discontinuation, 
and all AEs were mild or moder ate in intensity. In the SAD panels (Part A), 30 participants 
received branebrutinib (0.3, 1, 3, 10, or 30 mg as oral solutio n) and 10 received placebo. Eighteen 
participants (60%) who received branebrutinib experienced at le ast 1 AE. AEs that occurred for 
> [ADDRESS_756653] were: headache (4), upper respi[INVESTIGATOR_40938] n (3), dizziness (3), nausea (2), rash 
(2), throat irritati on (2), myalgia (2), and dysmenorrhea (2). Nine participants who received 
branebrutinib had AEs classified as related to study drug by [CONTACT_3433] e investigator as follows: headache 
(2); rash (2); and dizziness, dysgeusia, oral herpes, influenza -like illness, malaise, hot flush, 
nausea, tongue ulceration, and dry lips (1 each). Among the 10 participants who received placebo 
in Part A, 5 (50.0%) experienced at least 1 AE; headache was re ported for 3 participants, and 
epi[INVESTIGATOR_576843] 2 participants (other events were reported for [ADDRESS_756654] each).In the MAD panels (Part B), 24 participants received branebruti nib (0.3, 1, 3, or 10 mg as oral 
solution) and 8 received placebo QD for 14 days. Seventeen part icipants (70.8%) of [ADDRESS_756655] freq uently reported AEs were 
headache (8); upper respi[INVESTIGATOR_1092] (4); oral herpe s (3); abdominal pain (2); nausea (2); 
and tension headache (2). The abdominal pain events were not as sociated with abnormalities in 
amylase or lipase values. They were considered unrelated to bra nebrutinib and they resolved 
without treatment. Ten participants who received branebrutinib experienced at least 1 AE that was 
classified as related to study drug by [CONTACT_576944]: headache (5), oral herpes (3, all 
had history of oral ulcers), abdominal pain, chills, conjunctiv itis allergic, cough, dry skin, 
dyspepsia, eye irritation, mouth ulceration, nasal congestion, nausea, oropharyngeal pain, tension 
headache, and upper respi[INVESTIGATOR_1092] (1 each). Among  the 8 participants who received 
placebo in Part B, 7 (87.5%) experienced at least 1 AE (only mu sculoskeletal pain  [2] was reported 
for more than [ADDRESS_756656]).In Part C, 9 participants (Japanese MAD) had AEs: 7 participant s (38.9%) following treatment 
with branebrutinib; and 2 participants (33.3%) after having rec eived placebo. In Part D, 
14 participants received 4 doses of branebrutinib 10 mg as follo ws: solution formulation under 
fasted condition on Day 1, solut ion/fed on Day 5, suspension/fa sted on Day 9, and suspension/fed 
on Day 13. Six participants (42.9%) experienced at least [ADDRESS_756657] discomfort (2). The AEs of che st discomfort (2) and influenza-
like illness were assessed as related to branebrutinib by [CONTACT_941] i nvestigator.
Protocol Amendment No.: 01
Date: 30-Jun-2021 44
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Overall, in Study IM014001, no clin ically meaningful safety sig nals were identified based on 
assessments of AEs, ECGs, vital signs, and clinical laboratory tests. There was no relationship of 
frequency and severity of AE with dose levels. Safety and toler ability of branebrutinib are 
favorable, based on the observed data from the FIH study.
In Study IM014013, a DDI study in 26 healthy male pa rticipants to assess the effects of 
co-administration of branebrutinib on the PK of methotrexate (M TX) and on a cocktail of probe 
substrates, there were no deaths and no other SAEs, other signi ficant AEs, or AEs leading to 
discontinuation. Caffeine, montelukast, flurbiprofen, omeprazol e, midazolam, pravastatin, and 
digoxin (probe substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4, OATP1B1, 
OATP1B3, and P-gp, respectively) alone, and in combination with  branebrutinib were generally 
safe and well tolerated in healthy male participants. 
In Study IM014016, an ADME study in 9 healthy male participants  who received 
[14C]branebrutinib, there were no deaths and no other SAEs, other significant AEs, or AEs leading 
to discontinuation. A total of 3 AEs was reported by 3/9 (33.3%) participants. No 
treatment-emergent adverse events (TEAEs) were considered relat ed to branebrutinib, and all 
TEAEs were considered mild in severity and were resolved by [CONTACT_576945]. There were no 
clinically relevant changes in laboratory results, ECG interval s, or vital signs reported.
In Study IM014023, a study in 24 h ealthy f emale participants designed to investigate the effects 
on PK, as well as the safety and tolerability of branebrutinib c o-administered with the high-dose 
OC LoestrinÂ®, there were no deaths and no other SAEs, other significant AEs, or AEs leading to discontinuation. Overall, [ADDRESS_756658] common TEAEs were headache (5 participants); hepatic enzyme increased (3 participants); and ALT increased, back pain, dry e ye, nausea, and rash papular (all 
reported in 2 participants each). Hepatic marker measurements s howed no elevations in total 
bilirubin and alkaline phosphatase but did include elevations o f aspartate aminotransferase (AST). 
All changes in ALT and AST were < 3Ã— the upper limit of normal (ULN) and most were < 2Ã— 
ULN. They did not require discontinuation of treatment of the s tudy drug and resolved without 
treatment.
Taken together, results of Phase 1 studies with branebrutinib d emonstrate a satisfactory safety 
profile for its investigation in patients with immune-mediated diseases.
3.3 Benefit/Risk Assessment
AD is a common, chronic, or recurrent inflammatory skin conditi on with significant associated 
social and financial burden. AD affects adults and children with worldwide prevalence rates of 1% 
to 20%. Using US census estimates, based on recent epi[INVESTIGATOR_46294], 16.[ADDRESS_756659] a diagnosis of AD, with 6.6 million meeting criteria for moderate-to-severe disease.
6
Characterized by [CONTACT_576946], scaling, xerosis, an d eczematous lesions whose features 
include erythema, induration/papulation, excoriations, and lich enification, severe disease can be 
debilitating due to several fact ors: psychiatric disorders, sle ep loss, and impaired quality of life 
(QOL). The majority of AD patients exhibit hypersensitivity to environmental or food allergens 
characterized by [CONTACT_576947].16,17 ,66Compromised skin barrier 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756660] limited efficacy,  and long-term application of 
topi[INVESTIGATOR_576844]-effects of acn eiform eruptions, dyspi[INVESTIGATOR_371], skin 
atrophy, and risks associated with systemic absorption.67Systemic immunosuppressant drugs are 
generally more effective than topi[INVESTIGATOR_12969], but they are associated with more substantial 
toxic effects, including diab etes, hyperten sion, and osteoporos is.67Moreover, systemic 
cyclosporin and corticosteroids may result in prominent rebound  effects after treatment 
discontinuation. Subsequently, cyclosporine is dosed for a limi ted duration, with a requirement of 
monitoring of renal function and hypertension.68Other immunosuppressants such as azathioprine 
(AZA), mycophenolate mofetil ( MMF), and methotrexate MTX, are also used with caution in 
severe refractory patients, due to less evident efficacy and po tential serious adverse effects. 
An unmet need therefore remains for effective and safe, long-te rm oral medications for patients 
with moderate-to-severe AD. Given the supportive mechanistic bi ol o g y  of  t h e  2  a g e n t s  b e i n g  
evaluated in this study ( Section 3.1.2 ), it is hypothesized that participants will benefit from
participation by [CONTACT_576948] d associated discomfort.
Furthermore, nonclinical and Phase 1 results with both molecule s (Sections 3.2.1 and 3.2.2) 
suggest that this reduction in disease activity can be undertak en safely. Appropriate safety 
monitoring, frequent visits, and other risk-minimization measur es such as ongoing safety review 
and Data Monitoring Committee (DMC) ove rsight w ill be implemented to ensure that the safety 
of the participants is adequately monitored (Section 9.4 ). In summary, the Sponsor believes that 
the -benefit-risk relationship of participation is favorable fo r patients with moderate or severe AD.
3.3.[ADDRESS_756661] implemen tation of  adequate safety margins co mpared to the projected steady 
state AUC at the clinical dose of 0.75 mg (approximately 23Ã— in  rats and female dogs, or 2Ã— in 
male dogs for BMS-986166; or approx imately  112Ã— in r ats, 127Ã— in female dogs, or 11Ã— in male 
dogs for BMS-986166-P) based on the AUC at the NOAEL in the 6- a nd 9-month rat and dog 
studies (10 mg/kg/day in rats and 0.1 mg/kg/day or 3 mg/kg/day i n male and female dogs, 
respectively) and is within the range of doses tested in MAD study IM018003.
The potential beneficial effects of S1PR1 have been documented  in pharmacology studies, 
demonstrating its potential benefit for disorders of immune activatio n (Section 3.2.1). Mo reover 
fingolimod (Gilenya) is an S1P receptor-analogue, acting as a n onselective potent ago nist of 
S1PR1, 3, 4, and 5. Gilenya was the first S1PR agonist approved for clinical use for re lapsing 
multiple sclerosis (MS).69S1P content appears to be of g reat signif icance for the homeost asis of 
the skin. Diminished S1P concentration is linked to increased e ndocytosis capacity of DC and 
Protocol Amendment No.: 01
Date: 30-Jun-2021 46
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
proliferation of keratinocytes, and, although not measured in t he skin of patients with AD, reduced 
S1P level is found in skin lesions of atopic dogs.70
In terms of risk, findings in nonclinical toxicology studies were consistent with expectations based 
on the phar macology of BMS-986166 a nd included on-target PD effects such a s dose-dependent 
lymphocyte redu ction in peripheral blood, increases/decreases i n lymphoid cellularity in lymphoid 
organs, and suppression of the T- cell-dependent a ntibody respon se. Increases in trabecular bone 
were noted in the rat 6-month study, and testicular toxicity wa s noted in dogs in the 10-week and 
9-month toxicity studies. All findings showed evidence of rever sibility. For the purposes of 
monitoring the testicular finding, participants with history of  significant testicular or epi[INVESTIGATOR_576845], and male sex hormones (follicle-stimu lating hormone (FSH), luteinizing 
hormone (LH) and total  testosterone) w ill be assessed at baseline and different time points 
throughout the treatment period and until study discharge.
Nonclinical studies have shown that BMS-986166 has a reduced ri sk for cardiovascular effects, 
macular edema, and pulmonary toxicity, compared with other memb ers of the class.
Clinical safety of BMS-986166 was summarized in Section [IP_ADDRESS] .
Based upon nonclinical toxicology findings and the mechanism of  action of the compound 
(immunosuppression), this study incorporates appropriate assess ments and risk-mitigation 
approaches (including careful  consideration of appropriate excl usion criteria and monitoring of 
participants during and after dosing) in combination with conve ntional safety monitoring. These 
include assessment for latent tuberculosis (TB) infection (LTBI) and chronic viral infections, and 
ongoing clinical and laboratory monitoring to reduce the risk from infection, Pulmonary function 
tests (PFTs), optical coherence tomography (OCT) and close monit oring of vitals and ECGs. 
Frequent study visits are employed to enhance safety monitoring  and reduce risk.
Possible CYP3A4-mediated DDI is anticipated with BMS-[ADDRESS_756662] been reduced, while 
Protocol Amendment No.: 01
Date: 30-Jun-2021 47
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
retaining marked peripheral lymphopenia. More detailed informat ion about the known and 
expected benefits and risks and reasonably anticipated AEs (see  Section 9.2.8 ) of BMS-986166 
may be found in the IB.38
3.3.2 Branebrutinib
Assessments of benefit and risk rely on nonclinical data and on  data from completed Phase 1 
studies in healthy participants. The proposed 9 mg QD dosing re gimen reflects implementation of 
appropriate safety margins (> 500Ã— based on the AUC in rats and dogs at the NOAEL 
[20 mg/kg/day and 15 mg/kg/day in rats and dogs, respectively]) and is within the range of doses 
tested in the FIH study (Study IM014001).
The potential salutary effects of BTK inhibition by [CONTACT_576949], demonstrating its potential benefit for d isorders of immune activation 
(Section 3.2.2 ); and clinical data support the use of BTK inhibitors for the treatment of RA.71
Because of the functional roles of BTK-expressing immunocytes ( eg, mast cells, B-cells, and DC) 
in AD ( Figure 3.1.2-1 ), inhibition of BTK may reduce AD disease activity.
In terms of risk, findings in nonclinical toxicology studies were consistent with expectations based 
on the pharmacology of branebrutinib and included on-target PD effects such as reductions in 
B-cell activity, suppression of KLH-specific IgM and IgG respon ses, and/or dose-related germinal 
center lymphoid depletion of minimal to moderate severity in the GALT.
Branebrutinib-related pancreatic tox icity was identified in oral Sprague-Dawley rat toxicity studie s 
with up to [ADDRESS_756663] relevance to the safety 
assessment for human participants treated with this drug class.  Nonetheless, specific monitoring 
of pancreatic function, including assessments of, fasting gluco se levels, were implemented in the 
Phase 1 studies to minimize unwanted risks to the healthy parti cipants, and no 
branebrutinibâ€‘related elevations in these parameters were ident ified.
With the exception of an unrelated SAE that was consistent with  the subjectâ€™s medical history, AE 
in the FIH study (Study IM014001) were mild to moderate, revers ible, and consistent with 
expectations based on nonclinical experience.
Based upon nonclinical toxicology findings and the mechanism of  action of the compound 
(immunosuppression), this study incorporates appropriate assess ments and risk-mitigation 
approaches (including careful  consideration of appropriate excl usion criteria and monitoring of 
participants during and after dosing) in combination with conve ntional safety monitoring. These 
include assessment for LTBI and chronic viral infections, and o ngoing clinical and laboratory 
monitoring to reduce the risk from infection. Frequent study vi sits are employed to enhance safety 
monitoring and reduce risk.
Protocol Amendment No.: 01
Date: 30-Jun-2021 48
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
While blood BTK occupancy persisted longer (~50% at ~7 days and 30% at 10 days) after the 
cessation of multiple doses of branebrutinib as observed in the  FIH study (14-day MAD), 
pharmacological inhibition of ex vivo lymphocyte stimulation st arted to wane within ~[ADDRESS_756664], and >95% inhibition 
in the whole blood is required to clearly inhib it lymphocyte fu nction. Thus, [ADDRESS_756665] that X-li nked agammaglobuline mia (XLA) is essentially never noted in h eterozygous 
females (BTK is a gene that escapes X-inactivation), it is anti cipated the PD effects will wash out 
within 1 to 2 weeks after end of treatment.
The risk for DDIs with branebrutinib has been assessed in Study  IM014013.72The potential for 
clinically relevant DDIs of branebrutinib with substrates of a number of enzymes and transporters 
(CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and organic anion tra nsporting polypeptide 
OATP1B1 and 1B3) is likely to be minimal based on the low proje cted therapeutic concentration 
(Cmax < 0.20 Î¼M) and high serum protein binding. Branebrutinib may affect the PK of drugs that 
are sensitive substrates of CYP2C8 and P-gp as a weak inhibitor , based on the results of Study 
IM014013 and in vitro studies. Therefore, until more knowledge is gained, drugs that are sensitive substrates of CYP2C8 and P-gp (like digoxin) are restricted or excluded based on their therapeutic 
window and metabolism in this study . If such sensitive substr ates must be used, therapeutic drug 
levels monitoring is recommended. 
In vivo studies to evaluate the developmental and reproductive effects of branebrutinib have shown 
developmental toxicity in rabbits (at an exposure multiple of 53Ã— relative to the dose of 9 mg 
proposed for this study) that were associated with maternal and  developmental toxicity.
47At the 
NOAEL of 40 mg/kg/day, the safety margin was 16 Ã—compared with the human AUC at 10 mg 
MAD. Branebrutinib was not associated with maternal or developm ental toxicity in pregnant rats 
at exposure multiples up to 437 Ã—(versus human AUC at 10 mg MAD). To ensure safety, the study 
will require WOCBP to use highly effective contraception, and p regnant women will not be 
enrolled in this study . It is not known whether brane brutinib passes into human milk. Therefore, 
breastfeeding women will also not be enrolled in this study. Th e DDI study with oral 
contraceptives (Study IM014023) demonstrated lack of PK interac tion,73which ensures efficacy 
of hormonal cont raception co-administered wit h branebrutinib. 
Ibrutinib, an irreversible inhibitor of BTK used for the first line treatment of chronic lymphocytic 
leukemia (CLL) or mantle cell lymphoma (MCL), has been shown in  randomized trials to increase 
the risk for incid ent atrial fibrillation as compared to altern ate treatments.74Atrial fibrillation (AF) 
and atrial flutter (ra nge, 6 to 9%) have o ccurred in patients t reated with i brutinib, particularly in 
patients with cardiac risk factors, acute infections, and a pre vious history of atrial fibrillation.[ADDRESS_756666] that i brutinib-med iated AF results from off-target kinase inhibition 
-- particularly that of C-terminal SRC-kinase,76though on-target mechanisms cannot yet be ruled 
out.77Because newer BTK inhibitors are more specific to the Tec kinase family than ibrutinib, 
they may not carry this mechanistic liability78though clinical confirmation is currently lacking .
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756667] 12-lead ECG will be collected and r eviewed with every subsequent 
visit.
In sum, the potential benefits and risks of branebrutinib for p atients with moderate or severe AD 
support its investigation in this protocol. More d etailed information a bout the known and expected benefits  and risks and reasonably 
anticipated adverse events (AEs) of branebrutinib may be found in the IB.
3.3.3 COVID-19-associated Risks
[IP_ADDRESS] BMS-986166
 
 
 
 
 
 
 
 
[IP_ADDRESS] Branebrutinib
Risk from
 severe acute respi[INVESTIGATOR_6507] 2 (SARS -CoV-2) is linked to the 
immune response following exposure. The immune system must cont rol viral replication and 
cytopathology,79while avoiding the exa ggerated inflammation associated with sev ere COVID-
19.80It is reasonable to hypothesize that BTK function may influence  both these aspects of the 
response to SARS-CoV-2. BTK is central to activation, prolifera tion, and survival responses 
downstream of the B cell antigen r eceptor and other receptors on B cells and key myeloid cell 
types. Details of BTK signaling are summarized in Section 3.2 of this protocol, S ection 2 of the 
IB, and references therein. Notably, however, signaling through BTK depends both on the latterâ€™s 
kinase activity, and on its â€œscaffoldingâ€ activity (ie, physical association with other 
proteins).43,81,[ADDRESS_756668] of de ficiency in both BTK activities c an be gained by [CONTACT_576950]-19 
outcomes in patients with XLA , a genetic immunodeficiency chara cterized by [CONTACT_576951] B cell c ounts and serum immunoglobulins caused by [CONTACT_576952] . XLA patients 
demonstrate high susceptib ility to b acterial and some viral infections that is largely am eliorated 
by [CONTACT_576953] c antibiotics.83  Published cases 
Protocol Amendment No.: 01
Date: 30-Jun-2021 50
2.0 Approved 930158234 2.0v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Abbreviations: AD = atopic dermatitis; AE = adverse event; ALC =  absolute lymphocyte count; AUC(0-T) = area 
under concentration-time curve from time zero to the time of th e last quantifiable concentration; AUC(TAU) = area 
under concentration-time curve within a dosing interval; BSA = body surface area; BTK = Bruton Tyrosine Kinase; 
Cmax = maximum concentration; DLQI = Dermatology Life Quality I ndex; EASI = Eczema Area and Severity Index; 
ECG = electrocardiogram; FEV1 = forced expi[INVESTIGATOR_3741] 1 s econd; IgE = immunoglobulin E; NRS = numerical 
rating scale; OCT = optical cohe rence tomography; PD = pharmaco dynamic; PFT = pulmona ry function test; PK = 
Pharmacokinetics; POEM = Patient Oriented Eczema Measure; SAE =  serious adverse event; SARS-CoV-2 =  severe 
acute respi[INVESTIGATOR_6507] 2; vIGA-AD = Validated I nvestigator Global Assessment Scale for Atopic 
Dermatitis
5 STUDY DESIGN
5.1 Overall Design
This is a Phase 2, multicenter randomized, double-blind, placeb o-controlled, 5 parallel-group, 
study of BMS-986166 or branebrutinib to evaluate the efficacy and safety of 3 dose levels of 
BMS-986166 and a single dose level of branebrutinib in participants with moderate-to-severe AD who are intolerant of treatment, or inadequately treated and ar e candidates for systemic therapy. 
The overall study design is outlined in Figure 5.1-1 .
The study consists of:  
â€¢A Screening Phase of up to [ADDRESS_756669] 
moderate-to-severe AD, and meet the other entry criteria for th e study ( Section 6 ); 
â€¢A Treatment Phase of approximately 16 weeks during which partic ipants will be assessed for 
clinical responses to eith er placebo, BMS-986166, or branebruti nib; 
â€¢A Follow-up Phase of approximately 8 weeks. 
Total duration of participation in the study will be approximate ly 29 weeks, although follow-up 
maybe extended until ALC recovers  to the pre-specified threshol d (Section 5.1.3).  
White blood cell (WBC) c ounts and lymphocyte counts will be mon itored centrally (and will not 
be provided to the site) to prevent potential unblinding of the investigator.
An external independent DMC will be empaneled to review safety on a periodic and as-needed 
basis. 
Protocol Amendment No.: 01
Date: 30-Jun-2021 54
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Figure 5.1-1: Study Design Schematic
Abbreviations: n = number; PO = taken orally; QD = once daily; R = randomization; V = visits
Study day visits will be Â± 3 days, except for the Day 7 visit ( Â± 1 days).
Physical examinations, vital sign measurements, 12-lead ECG, OCT, PFT, and clinical laboratory 
evaluations will be performed at selected times throughout the dosing interval. Participants will be monitored for adverse events throughout the study. 
Blood samples w ill be collected for PK and PD analysis as described in Sections 9.5 and 9.8, 
respectively.5.1.1 Screening Period Days -35 to -1
Eligibility will be based on specified inclusion and exclusion c riteria ( Sections 6.1  and 6.2), 
medical history, disease activity, and safety assessments. Scre ening and randomization must be 
completed within 35 days of signing the ICF. Participants who experience an AD flare defined as
doubling of the EASI score between Screening and Baseline or wor sening that requires 
administration of prohibited medications within 3 weeks of rand omization s hould be discontinued 
from the study. 
Participants that experience an AD flare prior to randomization  should be discontinued from the 
study. 
5.1.2 Treatment Period, Days 1-113
On Day 1, eligible participants will be randomly allocated to receive one of: p lacebo, BM S-986166 
0.25 mg PO QD, BMS-986166 0.5 mg PO QD, BMS-986166 0.75 mg PO QD,  or branebrutinib 
9 mg PO QD for 16 weeks. Randomization will be in a 1:1:1:1:1 ra tio. Blinded treatment 
assignment will be managed by [CONTACT_185686] (I RT).
Protocol Amendment No.: 01
Date: 30-Jun-2021 55
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Participants will visit the clinic 7 times (including baseline) during the treatment period.  Safety 
and efficacy will be assessed at each of these visits. This vis it density is intended to allow 
monitoring of sufficiently high resolution t o detect infections, excessively low leukocyte counts, 
inefficacy and/or flares, and other problems in a timely fashio n; with on the other hand, participant 
burdens and risk of SARS-CoV-2 (severe acute respi[INVESTIGATOR_576846] 2) exposure 
associated with clinic visits. This frequency reflects customar y practice in the f ield as reflected in 
other published studies.31
Participants may receive topi[INVESTIGATOR_576847] 4 as 
described in Section 7.7.2 . After Week 4, participants  receiving rescue treatments w ill be 
considered tr eatment f ailures for categorical endpoints, those who require systemic rescue therapy 
will be immediately discontinued from study treatment. 
5.1.3 Follow-up Period, Days 114-169
Follow-up after dosing cessation is planned for approximately 6 0 days (5x T-HALF for 
BMS-986166), with visits on Days 127, 141 and 169; participants  will be followed for disease 
activity, safety, and washout of PD effects. If applicable, participants w ill be followed until 
absolute neutrophil count (ANC) > 1500/ Î¼L and ALC > 1000/ Î¼L, demonstrating sufficient 
washout of PD effects to permit discharge from the study.
5.1.[ADDRESS_756670] at regular, pre-specified intervals and on  an ad hoc basis if warranted, 
safety review meetings throughout the study to ensure that the benefit and risks of study 
participation remain acceptable. Ad hoc meetings may be initiat ed by [CONTACT_576954]. 
Blinded suspected, unexpected serious adverse reactions (S[LOCATION_003]Rs) will be sent to the DMC 
members on an ongoing basis. SAEs will be sent to the DMC on a monthly basis or on an ongoing 
basis as requested by [CONTACT_1363]. 
The DMC will review safety dat a, including, but not limited to,  SAEs and adverse events of interest 
(AEIs). At the request of the DMC, designated personnel will pro vide further information,
including select efficacy data as needed for the medical assessm ent for a specific case.
The DMC may also consider external data from other BMS- [ADDRESS_756671] of the study.
Protocol Amendment No.: 01
Date: 30-Jun-2021 56
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Based on the DMCâ€™s assessment, recommendations of protocol modi fications or other actions may 
occur. In addition, hold of enrollment, pending more detailed a ssessment may be requested by [CONTACT_109393].
Details of the DMC responsibilities and procedures will be specified in the DMC Charter.
5.2 Number of Participants
Approximately 150 participants will  be randomized 1:1:1:1:[ADDRESS_756672] participant (either last visit at which the last endpoint data 
is collected or last contact [CONTACT_576955] a phone call). Stud y completion is defined as the final 
date on which data for the study was or is expected to be collected, if this is not the same.
5.4 Scientific Rationale for Study Design
This is a randomized, double-bli nd, placebo-controlled, 5 paral lel-group study t o evaluate the 
efficacy and safety of 3 dose levels of BMS-986166 and a single  dose level of branebrutinib in 
participants with moderate-to-severe AD who are intolerant of t reatment, or inadequ ately treated 
and are candidates for systemic therapy (ie, not adequately con trolled by a stable regimen [â‰¥ 4 
weeks] of topi[INVESTIGATOR_11930], calcineurin inhibitors or biologics, or not eligible for topi [INVESTIGATOR_576848]). 
Two mechanistically distinct compounds will be simultaneously t ested for the first time in this AD 
population. This is  being done for the following reasons:
â€¢It is more efficient than 2 separate studies since a single con trol group is used for both 
compounds â€“ reducing the number of participants with burdensome AD symptoms who must 
be treated with placebo.
â€¢While not a formal head-to-head comparison, this design best sup ports th e main purpose of 
this study to evaluate provisional efficacy of two different me chanisms in AD â€“ enabling 
Sponsor decision to advance one or both to Phase 2b/[ADDRESS_756673] given the small size of this study, and the well-known  variability in placebo 
responses in AD â€“ ranging from ~10% to >30% EASI reduction in Ph ase 2 
studies.
30,103, 104,105
oThe effects of the 2 compounds on complex exploratory biomarker s (eg, messenger 
ribonucleic acid [mRNA] profiling of skin biopsies) can be measured at the same sites, 
over the same time interval, and in the same experimental batch  runs â€“ maximizing 
comparability.
â€¢Each compound has extensi ve PK-PD characteri zation, both in nonclinical experiments and in 
Phase 1 studies, and both mechanisms are extensively described in the literature. Together, this 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756674], an d data interpretation t o occur 
despi[INVESTIGATOR_576849] 2 compounds simul taneously.
A parallel group design is bei ng employed because (1) the time course of treatment is relatively 
long (~16 weeks), (2) BMS-986166 has a T-HALF (~12 days), and ( 3) IP-related changes in 
disease activity of a complex immunologic phenomenon like AD do  not occur or â€œwash outâ€ over 
usefully predictable times. These factors obviate crossover designs.
Five treatm ent groups w ill be evaluated: 1 fo r placebo, 1 for the favored dose of branebrutinib 
(Section 5.5.2 ), and [ADDRESS_756675] promising doses of BMS-986166  (Section 5.5.1 ).
Sixteen weeksâ€™ treatment dur ation w ill be employed because it p rovides sufficient time for each 
mechanism to act, allows time for BMS- 986166 to reach steady state, and provides a reasonable 
observation time t o observe AEs. Study tr eatment durations of 12 to 16 weeks are customary in 
this field (eg, in the dupi[INVESTIGATOR_576850] 2 program s).41,106The Follow-up phase 
lasts approximately 60 days to allow 5 mean half-lives of BMS-98 6166 to pass after the final dose 
before participants are disc harged from the study, for safety m onitoring. This also allows sufficient 
time for branebrutinib r eceptor occupancy to decay to baseline.47Acceptable washout of 
BMS-986166 PD effects (ALC counts) w ill also be explicitly assessed before par ticipants are 
discharged from the study.
5.5 Justification for Dose
5.5.1 BMS-986166
The BMS-986166 doses to be evaluated in this study (0.25 mg, 0.5 mg, and 0.75 mg) are based on 
their safety, tolerability, PK, and PD findings from FIH studie s, as well as on nonclinical 
evaluations as detailed in Section 3.2.1 . 
The model predictions for participants receiving the 0.5 mg dose  of BMS-986166, with average 
exposures, will typi[INVESTIGATOR_576851] r than 75% of baseline ALC values 
and a 2-beat/minute net decrease in HR versus placebo. Translat ion of exposure-response analyses 
using ALC, and its relationship to efficacy in preclinical mode ls lends confidence to the efficacy 
hypothesis at similar exposures yielding similar PD effects in humans. 
Safety â€“ In study IM018003, multiple oral doses of BMS-[ADDRESS_756676] frequently occurring AEs 
during BMS-986166 administration were lymphopenia (N=15; 62.5%)  which is consistent with 
the pharmacology of the drug; con tact dermatitis (N=8; 33.3%), associated with ECG electrode 
contact [CONTACT_576956] (N=7; 29.2%), assessed by [CONTACT_576957], were of equal frequenc y in the placebo and BMS-986166 
cohorts; and headache (N=5; 20.8%). Safety results were similar ly low and reversible between the 
0.[ADDRESS_756677] l evel (NOAEL) in pi[INVESTIGATOR_576852]-state 
exposures at 0.75 mg PO QD.
Protocol Amendment No.: 01
Date: 30-Jun-2021 58
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
PK â€“ In the multiple ascending dose (MAD) study  IM018003, healthy  participants received 
BMS-986166 solution formulation  at dose levels  of 0.25, 0.75, a nd 1.5 mg PO QD for 28 days. 
Increases in whole blood maximum observed concentration (Cmax) and area under the 
concentration-time curve (AUC) over the dosing interval (AUC[TA U]) were approximately  dose 
proportional within the dose levels tested. The mean half-life (T-HALF) at Day 28 ranged from 
276 to 321 hours across the dose range tested, indicating that BMS-986166 was slowly eliminated 
from the body. Consequentl y, as exp ected, accumulation after 28 days of dosing (near steady-state)  
was approximately 14-fold.
PD â€“ Key PD biomarkers in Study IM018003 were peripheral blood absolute lymphocyte counts 
(ALC) and heart rate. Lymphocyte count, is a PD endpoint that r oughly reflects efficacy 
endpoints â€“ based on clinical results with preceding S1P receptor  modulators such that exposure 
associated with a lymphocyte reduction below approximately 1,00 0 lymphocytes/ Î¼L are also 
associated with satisfactory efficacy in MS.107In a real-world examination of ALC responses to 
fingolimod in MS patients, typi[INVESTIGATOR_576853] 65% -
90% were noted.108
In Study IM018003, predictable, dose-dependent lymphocyte reduc tions reaching median nadirs 
(ie, largest percent reduction) of 53.7% (range: 31.7% to 55.9%), 75.9% (range: 63.3% to 85.8%), 
and 81.9% (range: 37.9% to 92.2%) occurred at the 0.25 mg, 0.75  mg, and 1.5 mg dose levels, 
respectively, by [CONTACT_2006] 28 of dosing.38In the 0.75 mg group 37.5% and 12.5% of patients 
experienced Grade 2 and 3 reduction of lymphocytes respectively  without clinically meaningful 
infection implications.
In the same study, continuous Holter monitoring revealed roughl y dose-dependent reductions in 
median time-matched nadir heart rates. These were of the order of 8 to 9 absolute beats/minute at 
the highest dose (1.5 mg) and reached maximum effect by 48 hour s. At the 0.25 mg and 0.75 mg 
dose levels, placebo-controlled reductions in median time-matche d nadir heart rates were always 
below 4 beats/minute. By 12-lead ECG, there were no discernible  differences in heart rate from 
placebo at the end of the study (Clinical Study Report IM018003). Based on the results from the FIH studies, a comprehensive popu lation exposure-response and 
safety model was developed for both BMS-[ADDRESS_756678] the effects of BMS-986166 
and BMS-986166-P on PD (ALC) and s afety (HR) parameters. This mod eling of the relationships 
between dose, exposure, PD, and measures of lymphocyte and heart  rate reduction, predicted that 
a 0.5 mg PO QD dose would lead to median nadir ALC greater than 75% of baseline and a 
2-beat/minute net decrease in HR versus placebo ( Figure 5.5.1-1 ). Hence, 0.[ADDRESS_756679]-suited  for monotherapy.  
 
Protocol Amendment No.: 01
Date: 30-Jun-2021 59
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
 
Figure 5.5.1-1: M
odel-predicted Re ductions in Heart Rate and Lymphocyte Count by 
[CONTACT_576958] 90% confidence intervals around the median lines. The dashed horizontal line at -8 bpm 
represents a drop of 8 bpm relative to placebo. The dashed hori zontal line at -70 % represents a drop of 70% in ALC. 
The three vertical dotted lines represent the 0.25 mg, 0.5 mg, and 0.75 mg doses being investigated in this study.
Abbreviations: ALC = absolute lymphocyte; bpm = beats per minute; HR = heart rate
Source: BMS data on file.
Thus, the selected doses of 0.25 mg, 0.5 mg, and 0.75 mg of BMS -986166 are predicted to provide 
optimal evaluation of efficacy a nd safety for thi s proof-of-con cept study. 
5.5.2 Branebrutinib
The selection of the branebrutinib dose and regimen (9 mg, QD) to be assessed in the current study 
was based on findings in the FIH and nonclinical studies as det ailed in Section 3.2.2 .
Safety: The drug was well-tolerated at all dose levels, and most AEs observed were s imilar in 
participants receiving pl acebo and active treatment. The most common AEs included headac he 
and upper respi[INVESTIGATOR_1092]. Based on the AUC in rats  and dogs at th e NOAEL after 
chronic daily administration (rat, 6 months; dog, 9 months), the safety multiple in humans after 
multiple doses of 10 mg is > 500Ã—.12  
PK: In the MAD panels of the FIH study (Study IM014001), h ealthy participants r eceived 
branebrutinib solution QD for 14 days at 4 dos e levels (0.3, 1,  3, and 10 mg). Increases in Cmax 
and AUC[TAU] were approximately dose proportional within the do se levels tested. T-HALF was 
shorter than 2 hours across the dose range tested, indicating t hat branebrutinib was rapi[INVESTIGATOR_576854]. Consequently, no accumulation was obs erved at steady state after 
multiple daily dosing. 
PD: Biomarkers evaluated in Study IM014001 were BTK occupancy by  [CONTACT_576959] (enzyme 
occupancy [EO]), inhibition of ex-vivo stimulated cluster of di fferentiation CD69 expression, and 
plasma CXC motif chemokine ligand 13 (CXCL13) levels. 
Protocol Amendment No.: 01
Date: 30-Jun-2021 60
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Doses yielding high ( â‰¥ 95%) BTK occupancy are thought necessary for optimal clinical efficacy 
because only at such doses did (1) in vivo pharmacologic studie s of experimental autoimmunity 
(eg, murine collagen-induced arthritis) show maximum efficacy, and (2) deep tissue (eg, sp leen)
EO rapi[INVESTIGATOR_576855]. 
The maximum occupancy reached â‰¥  99% at branebrutinib doses of 1  mg and a bove (100%; 
maximum occupancy at doses â‰¥ 3 mg); however, maximum occupancy was achieved faster and 
maintained longer at 3 mg and 10 mg doses (solution formulation) . Furthermore, a high and 
sustained (~100%) BTK occupancy was achieved with the [ADDRESS_756680] inhibition of plasma leve ls of CXCL13 was also obtained 
at the 10 mg dose level. Considering the higher variability and  expression of BTK in patients with 
immune mediated disorders4, the 10 mg dose with the solution formulation is expected to m ore 
stably and completely inhibit BTK47-- for optimal chronic tr eatment of a larger proportion of 
patients. Moreover, based on the nonclinical branebrutinib expos ure in rats and dogs at the 
NOAEL after chronic daily administration (rat, 6 months; dog, 9  months), the safety multiple in 
humans after multiple doses of 10 mg is > 500Ã—.12  
Relationship of 9 mg capsule dose to the 10 mg solution dose in  Study IM014001:
The comparison of exposure between the branebrutinib 10 mg solu tion formulation from Study 
IM014001 and the branebrutinib 9 mg capsule form ulation (3 Ã— 3 mg) from Day [ADDRESS_756681] of branebrutinib on the  PK of combined oral 
contraceptives, demonstrated comparable exposure for Cmax and A UC(TAU) with only slight 
delay in time to maximum concentration (Tmax) for capsule formu lation. Thus, the use of 3 Ã— 
[ADDRESS_756682] an 
efficacy signal was chosen to be 9 mg branebrutinib administere d as 3 Ã— [ADDRESS_756683] be met.
6.1 Inclusion Criteria
1) Signed Written Informed Consent
a) Understanding of, and willingness to participate in the study  after completing all informed 
consent procedures â€“ demonstrated by a signed ICF
b) Willingness and ability to complete all study-specific proced ures and visits
2) Type of Participant and Target Disease Characteristics
a) Chronic AD diagnosed according to the Eichenfield modificatio n of Hanifinâ€™s and Rajkaâ€™s 
(E-HR) criteria109at Screening ( Appendix 5 )
b) Disease duration of at least 24 months since diagnosis by [CONTACT_576960].: 01
Date: 30-Jun-2021 61
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
c) EASI score â‰¥ 12 at Screening visit and â‰¥ 16 at Baseline visit
d) vIGA-AD â‰¥ 3 at Screening and Baseline visitse) â‰¥ 10% BSA affected by [CONTACT_576961]
f) Documented history of inadequate control of AD by a stable regi men (â‰¥ 4 weeks) of topi[INVESTIGATOR_030], calcineurin inhibitors or biologics, within 6 months of randomization, or 
inappropriateness of therapy due to side effects or safety risk s leading to prior 
discontinuation.
â™¦Inadequate response is defined as either or both of: 
â™¦Failure to achieve and maintain a disease activity state compara ble to vIGA-AD
0 = clear to 2 = mild, desp ite treatment with a daily regimen of topi[INVESTIGATOR_11930]
(TCS) of medium to higher potency (Â± topi[INVESTIGATOR_576856] [TCI] as 
appropriate), app lied for at least [ADDRESS_756684] prescribing information, whichever was shorter, or
â™¦Necessity of systemic therapy to control disease.
g) Application of fixed doses of an additive-free, basic bland e mollient twice-daily for 
â‰¥ 7 days before baseline visit and for the durati on of the study  participant to the guidance 
in Section 7.7.3.
h) Participants must have documentation of pos itive Varicella Zo s t e r  v i r u s  ( V Z V )  I g G  
antibody status or complete VZV vaccination at least 90 days pr ior to randomization.
3) Age and Reproductive Status
Investigators shall counsel women of child bearing potential (W OCBP), and male participants 
who are sexually active with WOCBP, on the importance of pregnan cy prevention, the 
implications of an unexpected pregnancy, and the potential of f etal tox icity occurring due to 
transmission of study  drug, present i n seminal fluid, to a deve lopi[INVESTIGATOR_16103], even if the 
participant has undergone a successful vasectomy or if the partner is pregnant.
â€¢The investigator shall evaluate the effectiveness of the contra ceptive method in relationship to 
the first dose of study intervention.
â€¢Local laws and regulations may re quire the use of alternative a nd/or additional contraception 
methods.
a) Female Participants 
i) Females aged 18 (or local age of majority) to 65, inclusive.
ii) Women of non-childbearing potential (WONCBP) are exempt from  contraceptive 
requirements. WONCBP must have documented proof that they are n ot of childbearing 
potential.
iii) Women of childbearing potential (WOCBP) must have a negativ e, highly sensitive 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units  of HCG, or as required 
by [CONTACT_427]) within 24 hours prior to the start of stud y treatment.
Protocol Amendment No.: 01
Date: 30-Jun-2021 62
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
(1) If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.
iv) Additional requirements for pregnancy testing during and aft er study intervention are 
located in Section 2 , Schedule of Activities.
v) The investigator is responsible for review of medical history , menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.
vi) WOCBP must agree to follow instructions for method(s) of con traception defined in 
Appendix 4  and as described below and included in the ICF.
vii) WOCBP are not permitted to use hormonal contraception metho ds alone as a highly 
effective method (as described in Appendix 4).
viii) A female participant is eligible to participate if she is not pregnant or breastfeeding, 
and at least one of the following conditions applies:
(1) Is not a WOCBP
OR
(2) Is a WOCBP and using a contraceptive method that is highly e ffective (with a 
failure rate of < 1% pe r year), with low user dependency, as described in 
Appendix [ADDRESS_756685] 
dose of study intervention, and agrees not to donate eggs (ova,  oocytes) for the 
purpose of reproduction for the same time period.
b) Male Participants
i) Males, ages 18 (or local age of majority) to 65, inclusive.
ii) Males who are sexually active with WOCBP must agree to follo w instructions for 
method(s) of contraception defined in Appendix 4 and as describ ed below.
iii) Azoos permic males are not exempt from contr aceptive requirements and will be 
required to always use a latex or other synthetic condom during  any sexual activity 
(eg, vaginal, anal, oral) with WOCBP even if the participant has undergone a successful 
vasectomy or if the partner is pregnant.
iv) Male participants w ill be required to always use a latex or other synthetic c ondom 
during any sexual activity (eg, vaginal, anal, oral) with WOCBP ; even if the 
participants have undergone a successful vasectomy or if their partner is already 
pregnant or breastfeeding. Males s hould continue to use a condom during the 
intervention period and for at least [ADDRESS_756686] do se of study intervention.
v) Female partners of males participating in the study s hould be advised to use highly 
effective methods of contraception during the study interventio n period and for at least 
[ADDRESS_756687] dose of the male participantâ€™s study in tervention.
vi) Male participants must refr ain from donating sperm during the intervention period and 
for at least [ADDRESS_756688] dose of study intervention .
vii) Breastfeeding partners should be advised to consult their h ealth care providers about 
using appropriate highly effective contraception during the tim e the participant is 
required to use condoms.
Protocol Amendment No.: 01
Date: 30-Jun-2021 63
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
6.2 Exclusion Criteria
1) Medical Conditions
a) Any major illness/condition or evidence of an unstable clinica l condition (eg, cardiac, 
renal, hepatic, hematologic, gastrointestinal, endocrine, pulmo nary, neurologic, 
immunologic, psychiatric) or local active infection/infectious illness that, in the 
investigatorâ€™s judgment, w ill substantially increase the risk to the par ticipant if he or she 
participates in the study or interfere with the interpretation of study results.
b) Pregnancy, lactation, or plans for either during the study or  the post-study prohibition 
period (see  Inclusion Criteria  for prohibition period duration).
c) Clinically relevant cardiovascular conditions, including histo ry or presence of:
i) Recent (within the last 6 months) occurrence of myocardial in farction, unstable angina, 
stroke, transient ischemic attack, decompensated heart failure requiring hospi[INVESTIGATOR_059], 
sick sinus syndrome, Class III/IV heart failure ( Appendix 6)
ii) Prolonged QTcF interval (QTcF > 450 msec males, > 470 msec females), or at additional 
risk for QT prolongation (eg, hypokalemia, hypomagnesemia, cong enital long-QT 
syndrome) 
iii) A ny prior history of atrial fibrillation or flutter 
iv)Treatment with C lass Ia or Class III anti-arrhythmic drugs or treatment with  2 or more 
agents in combination known to prolong PR interval
v) Patients with other pre-exist ing stable cardiac conditions who have not been cleared for 
the study by [CONTACT_576962] a cardiologis t
d) Clinically relevant pulmo nary conditions, including:
i) Unstable asthma or chronic obstructive pulmonary disease (COP D) (eg, acute epi[INVESTIGATOR_576857] [nocturnal epi[INVESTIGATOR_1841], sudden epi[INVESTIGATOR_576858]] despi[INVESTIGATOR_040] a stable regimen of relevant medications); pri or epi[INVESTIGATOR_1865](s) of life-
threatening asthma or COPD; or asthma or COPD that requires systemic glucocorticoid 
or biologic treatment, or inh aled budesonide or equivalent at > 1200 Î¼g/day or 
fluticasone propi[INVESTIGATOR_543235] > 880 Î¼g/day along with another anti- asthma/COPD drug 
such as a long-acting beta-agonist.
ii) Severe untreated sleep apnea
iii) Forced expi[INVESTIGATOR_12194] (FEV1) or forced vital cap acity (FVC) < 70% of predicted 
values at screening
e) Cancer or history of cancer or lymphoproliferative disease (o ther than adequately treated 
cutaneous basal cell or squamous cell carcinoma with no evidenc e of recurrence within the 
previous 5 years), including pre-lymphoma (pseudolymphoma of th e orbit and small 
intestine, lymphomatoid granulomatosis, angioimmunoblastic lymp hadenopathy, and 
lymphoid interstitial pneumonitis)
Protocol Amendment No.: 01
Date: 30-Jun-2021 64
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
f) History of diabetes mellitus type 1, or uncontrolled diabetes  mellitus type 2 with 
hemoglobin A1c > 8%, or diabetic patients with significant co-m orbid conditions such as 
retinopathy or nephropathy
g) Participants with a history of retinopathy, uveitis or other clinically significant ocular 
disease
h) Participants with any history of testicular or epi[INVESTIGATOR_576859]/disorder except 
uncomplicated epi[INVESTIGATOR_576860] s.
i) Current or recent (within 3 months before rando mization clin ically signif icant) 
gastrointestinal disease, including gastrointestinal surgery, t hat could impact the absorption 
of study treatment
j) Any major surgery within the last [ADDRESS_756689] do se of study treatment, or any 
surgery planned during the course of the study.
k) History of any serious condition induced by [CONTACT_576963] o ther hypersensitivity (such as 
anaphylaxis or hepatotoxicity).
l) Participants with non-AD concomitant illness (eg, asthma) tha t, in the opi[INVESTIGATOR_1070], is likely to require systemic corticosteroid or b iologic therapy during the study
2) Infection Risk-related Criteria
a) Any of the following TB criteria:
i) History of active TB prior to screening visit, regardless of c ompletion of adequate 
treatment
ii) Signs or symptoms of active TB (eg, fever, cough, night swea ts, and weight loss) 
during screening as judged by [CONTACT_576964]) Any imaging of the chest (e g, chest x-ray, chest CT scan) obtained during the 
screening period, or anytime within 6 months prior to screening with documentation, 
showing evidence of current active or old pulmonary TB
iv) LTBI defined by [CONTACT_82736]-TB Gold testing at screening, in  the absence of 
clinical manifestations 
Note 1: Participant may be eligible if (i) there are no current signs o r symptoms of 
active TB and (ii) participant has received adequate documented  treatment for LTBI 
within 1 year of screening.
Note 2: An indeterminate QuantiFERON-TB Gold test may be repeated once during 
screening. If the repeat test is positive or indeterminate, the participant is excluded.
b) Hepatitis C, Hepatitis B, or HIV infection as demonstrated, by a positive bl ood screen for 
HCV antibody a nd confirmed by [CONTACT_576965], hepatitis B surface antigen 
(HBsAg), hepatitis B core antibody (HBcAb), or HIV-1 and -2 antibody. 
i) Participants who have been vaccinated for hepatitis B (hepati tis B surface antibody 
[HbsAb]-positive) are not excluded.
Protocol Amendment No.: 01
Date: 30-Jun-2021 65
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
ii) Indeterminate tests require negative reflex testing results, or they are exclusionary.
iii) HCV history a nd documented 24-week sustained virologic response are permitte d.
c) History of congenital or acquired immunodeficiency
d) Participants with any acute or chronic bacterial, fungal (except history of tinea pedis or 
ongoing onychomycosis will not be exclusionary) or viral infect ion, as well as any febrile 
illness within 14 days of screening
e) Known active infection, or any major epi[INVESTIGATOR_35794] (IM or IV) antimicrobial agents (eg, antibiotics, antiviral, 
antifungal, or antiparasitic agents) within 2 weeks of the scre ening visit, and/or completion 
of oral antimicrobial agents wi thin 2 weeks of randomization, a nd/or recurrence prior to 
randomization.
f) Previous history of recurrent herpes zoster (more than 1 epis ode), disseminated herpes 
simplex before randomization or a history of diss eminated/complicated herpes zoster 
infection (multidermatomal involvement, ophthalmic zoster, eczema herpeticum, central 
nervous system involvement, or postherpetic neuralgia)
g) History of atypi[INVESTIGATOR_2855]/opportunistic infection (eg, pneumocystis, cytomegalovirus, invasive 
fungal infections, atypi[INVESTIGATOR_4017], etc.).
h) Presence of the following COVID- 19-related exclusion criteria
i) Symptoms of COVID-19 at screening or randomization
ii) COVID-19 (either suspected or confirmed) within 12 weeks of s creening, at 
screening, and/or Day 1. 
iii) Know n or suspected current sequelae of any sort following any prior  epi[INVESTIGATOR_576861]-19.
iv) COVID-19 vaccination withi n 14 days of screening or participant has plans to receive 
a vaccination during his/her participation in the study.
3) AD-related Criteria
a) High likelihood - based on participant history, and investigat or judgement â€“ of requiring 
rescue therapy in < 4 weeks prior to randomization (see Section 7.7.2 )
b) Evidence of acute flare between the Screening and Baseline/ R andomization (eg, doubling 
of the EASI score between Screening and Baseline, or worsening that requires 
administration of prohibited medications).
c) Skin lesion(s) and/or pruritus due to conditions other than A D that would interfere with the 
study specified assessments.
4) Prior/Concomitant Therapy
a) Treatment with anticoagulant or antiplatelet therapi[INVESTIGATOR_014], including aspi[INVESTIGATOR_145722], wit hin 2 weeks prior to randomization or duri ng the study.
Protocol Amendment No.: 01
Date: 30-Jun-2021 66
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
b) AD-related prescript ion or over-the-c ounter skin barrier treatments (eg, Cerave, Epi[INVESTIGATOR_12437], 
etc.) therapy within 2 weeks prior to randomization
c) Any bleach baths within 2 w eeks prior to randomization
d) Monoamine oxidase inhibitors (eg, selegiline, phenelzine) wit hin 2 weeks prior to 
randomization
e) Use of strong or moderate inhibitors or inducers of CYP2C8 or CYP3A4 within the longer 
of 5 PK half-lives or 14 days prior to randomization (inhibitor s), or within 3 weeks prior 
to randomization (inducers).
i) Please refer to Table 7.7.1-1 for examples.
ii) Sponsorâ€™s Medical M onitor should be consulted for any uncert ainties regarding 
CYP2C8 or CYP3A4 modulators.
f) Phosphodiestersase-4 (PDE4) inhibitors within 3 weeks prior t o randomization.
g) Use of phototherapy (ie, UVB, UVA) within 4 weeks prior to ra ndomization.
h) Leukotriene inhibitor treatment within 4 weeks prior to rando mization.
i) Diquafosol or rebamipi[INVESTIGATOR_265247] 4 weeks prior to rand omization.
j) Systemic corticosteroid treatment within 4 weeks prior to ran domization.
k) Systemic immunosuppressive drugs (CsA, MMF, AZA, MTX) or oral  preparations of 
herbal immunomodulatory medicatio ns within 8 weeks prior to randomization.
l) Exposure to JAK inhibitors such as tofacitinib, baricitinib, filgotinib, or upadacitinib 
within 8 weeks prior to randomization.
m) Intravenous (IV) immunoglobulin within 8 weeks prior to rando mization or during the 
study.
n) Allergen immunotherapy w ithin 4 months  of randomization.
o) Biologics depending on the type: 
i) Cell-depleting agents, including rituximab: within 6 months, or until the targeted 
population (eg, CD19+ lymphocyte counts for rituximab) returns to normal, 
whichever is longer
ii) Biologics such as tocilizumab and anakinra within 8 weeks prior to randomization
iii) Othe r biologics: within the longe r of 5 half-lives (if known) or 6 months of 
randomizat ion (eg. dupi[INVESTIGATOR_12458]) 
p) Prior exposure to BTK inhibitors such as ibrutinib, acalabrut inib, or expe rimental drugs 
(eg, BMS-986166 or branebrutinib, tirabrutinib, vecabrutinib, zanibrutinib, ARQ- 531, 
GDC-0853, or others) at any time.
q) Prior exposure to S1PR modulators (eg, fingo limod, etrasimod, ozanimod, etc.) at any 
time.
Protocol Amendment No.: 01
Date: 30-Jun-2021 67
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
r) Use of any immunomodulator or investigational drug not listed  above within the longer of 
5 PK half-lives, 5 PD half-lives, or 6 months of rando mization.
5) Laboratory Test and Procedural Findings
a) The following test findings at Screening or Baseline
i) WBC count < 3000/ Î¼L or > 14,000/ Î¼L
ii) ANC < the lower of: lower limit of normal (LLN) or 1500/Î¼ L 
iii) AL C < 1000/ Î¼L 
iv) Platelet count < 100,000/ Î¼L
v) Serum creatinine > 2 mg/dL
vi) Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73  m2as calculated using 
the Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD-EPI)  equation110:
eGFR = 141 Ã— min(Scr/Îº, 1)Î±Ã— max(Scr/Îº, 1)-1.209 Ã— 0.993AgeÃ— 1.018 [if female] Ã— 
1.159 [if black] -- where Scr is serum creatinine, Îº is 0.7 for f emales and 0.9 for 
males, Î± is -0.329 for females a nd -0.411 for males, min indica tes the minimum of 
Scr/Îºor 1, and max indicates the maximum of Scr/Îº or 1.
vii) AST or ALT >1.5x ULN
viii) Total bili rubin > 2 mg/dL (34 Î¼mol/L)
ix) Hemoglobin <10 g/dLx) ECG: HR < 55 bpm; PR â‰¥ 210 msec; QRS â‰¥ 120 msec; QTcF >450 msec males, > 
470 msec females, or any clinically significant heart conductio n abnormality (eg, left 
bundle branch block, atrial fibrillation).
xi) Abnormality on posteroanterior + lateral chest radiograph, t aken during the Screening 
period that is relevant to safe conduct of this study.
xii) Abnormality on optical coherence tomography (OCT) testing s uggestive of macular 
or choroidal pathology beyond that expected for a healthy perso n of the participantâ€™s 
age.
xiii) Heart  rate < 55 bpm or > [ADDRESS_756690]
xiv) Blood pressure > Grade 1 hypertension (> 159 mmHg systolic and > 99 mmHg 
diastolic) according to the 2018 European Society of Cardiology /European Society of 
Hypertension guidelines for the management of arterial hyperten sion
111
xv) Any other clinically significant laboratory or procedure abn ormalities that, in the 
opi[INVESTIGATOR_871], might pose unacceptable risk to th e participant during the 
study.
6) Other Exclusion Criteria
a) Use of a tanning booth/ parlor or signi ficant change in sun exposure within 4 weeks of the 
Screening visit.
Protocol Amendment No.: 01
Date: 30-Jun-2021 68
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
b) Onset of a new exercise routine or major change to a previous  exercise routine within 
2 weeks prior to randomization.
c) Prisoners or participants who are involuntarily incarcerated.  (Note: under certain specific 
circumstances and participant to local law a person who has bee n imprisoned after 
enrollment may be  permitted to continue as a participant. Stric t conditions apply and 
[COMPANY_016] approval is required.)
d) Employment by [CONTACT_1034], clinical research organizations, o r study site.
e) Participants who are compulsorily detained for treatment of e ither a psychiatric or physical 
(eg, infectious disease) illness.
f) Recent (within 6 months of study drug administration) drug or  alcohol abuse as defined in 
DSM-5, Diagnostic Criteria for Drug and Alcohol Abuse ( Appendix 7)
g) Inability to comply with restrictions as listed in Section 6.3 and prohibited/restricted 
treatments in Section 7.7.1 . 
h) Inability to toler ate oral medication.
i) Inability to be  venipunctured and/or tolerate venous access.
Eligibility criteria for this study have been carefully conside red to ensure the safety of the study 
participants and that the results of the study can be used. It is imperative that participants fully 
meet all eligibility criteria.
6.3 Lifestyle Restrictions
Lifestyle restrictions are listed below.
6.3.1 Meals and Dietary Restrictions
With the exception of the 8-hour fasting requirement pri or to bl ood sample collection for safety 
and PK testing on Day 1 and Day 85, no meal or dietary restricti ons are required for this study. A 
light meal/snack may be provided af ter the 2-hour PK sample and /or ECG collection insofar as to 
not interfere with obtaining either.
However, participants are advised to abstain from excessive con sumption of quinine (tonic w ater), 
grapefruit and Seville oranges. 
St. Johnâ€™s wort and herbal medications are not allowed.
6.3.[ADDRESS_756691] ug and 
Alcohol Abuse defined in the DSM-5 (Appendix 7) within six months  prior to randomization, 
there are no restrictions on caffeine, alcohol, or tobacco use for this study. However, participants 
who use tobacco or alcohol should be counseled for potential contraindications with non-study 
treatments as appropriate, and continued study participation sh ould be based on investigator 
judgment.
Protocol Amendment No.: 01
Date: 30-Jun-2021 69
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
6.3.3 Activity
The use of contraceptives during sexual activity is mandatory a s stated in Section 6.1 .
Use of tanning beds is prohibited during the study.
6.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but who 
are not subsequently randomized in the study/included in the an alysis population. A minimal set 
of screen failure information is required to ensure transparent  reporting of screen failure 
participants, to meet the Consolidated Sta ndards of Reporting T rials (CONSORT) publishing 
requirements, as applicable, and to respond to queries from reg ulatory authorities. Minimal 
information includes date of consent, demography, screen failur e details, eligibility criteria, and 
any serious AEs.
6.4.1 Retesting During Screening or Lead-In Period
Participant Re-enrollment: This study permits the re-enrollment  of a participant that has 
discontinued the study as a pre -treatment fail ure (ie, particip ant has not been randomized / has not 
been treated) due to an issue that is transient. If re-enrolled , the participant must be re-consented.
Retesting of laboratory parameters and/or other assessments wit hin any single Screening or 
Lead-in period will be permitted one time (in addition to any p arameters that require a 
confirmatory value).The most current result prior to Rando mization is the value by [CONTACT_576966], as it represents the participantâ€™s most current, clinical state.
7 TREATMENT
Study treatment is defined as any investigational treatment(s),  marketed product(s), placebo or 
medical device intended to be admin istered to a study participa nt according to the study 
randomizatio n or treatment allocation
Study treatment includes both Inve stigational [Medicinal] Produ ct (IP/IMP) and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and ca n consist of the following:
An investigational product, als o known as investigational medic inal product in some regions, is 
defined a pharmaceutical form of an active substance or placebo  being tested or used as a reference 
in a clinical study, including products already with a marketin g authorization but used or 
assembled (formulated or packaged) differently than the authori zed form, or used for an 
unauthorized indication, or when used to gain further informati on about the authorized form.
Other medications used as support or escape medicati on for preventative,  diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diag nosis, may be considered as non-
investigational products.
Protocol Amendment No.: 01
Date: 30-Jun-2021 70
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 7-1: Study Treatments for IM018005
Product Description / Class 
and Dosage FormPotency IP Blinded or Open 
LabelPackaging Storage Conditions
(per label)
BMS-986166-04 capsule 0.25 mg IP Blinded Bottle Refer to the label on the 
container
Branebrutinib capsule
(BMS-986195-01)3 mg IP Blinded Bottle Refer to the label on the 
container
Placebo capsule NA IP Blinded Bottle Refer to the label on the 
container
Abbreviations: IP = investigational product; NA = not applicabl e 
Protocol Amendment No.: 01
Date: 30-Jun-2021 71
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
7.1 Treatments Administered
The selection and timing of dose for each participant is as fol lows.
Table 7.1-1: Selection and Timing of Dose
Study Treatment Unit dose strength(s) /
Dosage level(s)Dosage formulation
Frequency of AdministrationRoute of 
Administration
BMS-986166 0.25 mg / 0.25 mg QD Oral
BMS-986166 0.25 mg / 0.50 mg QD Oral
BMS-986166 0.25 mg / 0.75 mg QD Oral
Branebrutinib 3 mg / 9 mg QD Oral
Placebo NA QD Oral
Abbreviations: NA = not applicable; QD = once daily
Participants will be randomized to one of the following dose le vels of BMS-986166 or 
branebrutinib or placebo in blinded fashion: 
ÂƒBMS-986166 0.25 mg PO QD 
ÂƒBMS-986166 0.50 mg PO QD
ÂƒBMS-986166 0.75 mg PO QD
ÂƒBranebrutinib 9 mg PO QD
ÂƒPlacebo PO QD
â€¢The first dose of d ouble-blind study medication (BMS-986166 or branebrutinib or placebo) 
will be taken in the morning on D ay 1 after fasting for at leas t 8 hours. 
â€¢Study medication should be taken at approximately the same time  each day.
â€¢Participants will take [ADDRESS_756692] bottle.
The actual IP taken by [CONTACT_576967] i n Table 7.1-2.
Table 7.1-2: Investigational Product: as Di spensed to Participants
Treatment 
GroupDouble-blind 
KitBottle A Bottle B Bottle C
Placebo
Each kit 
contains 
Bottle A, 
Bottle B,
Bottle CPlacebo capsule Placebo capsule Placebo capsule
`166 0.25 mg QD `166 capsule, 0.25 mg Placebo capsule Placebo caps ule
`166 0.5 mg QD `166 capsule, 0.25 mg `166 capsule, 0.25 mg Placebo capsule
`166 0.75 mg QD `166 capsule, 0.25 mg `166 capsule, 0.25 mg `166 c apsule, 0.25 mg 
BRA 9 mg QD BRA capsule, 3 mg BRA capsule, 3 mg BRA capsule, 3 mg
Abbreviations: â€˜166 = BMS-986166-04; BRA = branebrutinib; QD = daily
Note: all capsules are identical (size 0).
In the morning on Day 1, after fasting for at least 8 hours, ea ch participant will r eceive an oral 
dose of BMS-986166 or branebrutinib or placebo, each consisting  of 3 capsules. At the time of 
Protocol Amendment No.: 01
Date: 30-Jun-2021 72
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
dosing, 240 mL of water w ill be administered to the par ticipant along with his/her dose of study 
drug. The time of dose administration will be called â€œ0â€ hour. A light meal/snack may be provided 
after the 2-hour PK sample and/or ECG collection insofar as to not interfere with obtaining either.
Storage of investigational product will be according to the lab el on the container and/or packaging.
Restrictions related to food and fluid intake are described in Section 6.3.
7.2 Method of Treatment Assignment
After the participantâ€™s initial eligibility is established and informed consent has been obtained, the 
participant must be entered into the study via the IRT to obtain  a participant number. Specific 
instructions for using the IRT will be provided to the investig ational site in a separate document.  
The investigator or designee will register the participant for screening by [CONTACT_576968].
Once it is determined that th e participant meets the eligibilit y criteria following screening,  
participant will be centrally randomized through the IRT.The study will not allow parti cipant replacement due to an AE.
7.[ADDRESS_756693] is critical to the participant's manage ment, the blind for that participant 
may be broken by [CONTACT_093]. The participantâ€™s safety tak es priority over any other 
considerations in determining if a treatment assignment should be unblinded.
Before breaking the blind of an individual participant's treatm ent, the investigator should 
determine that the unblinded information is necessary, ie, that it will alter the participant's 
immediate management. In many cases, particularly when the emer gency is clearly not related to 
the investigational product, the problem may be properly managed by [CONTACT_551297] t 
is receiving active product. It is highly desirable that the de cision to unblind treatment assignment 
be discussed with the Medical Monitor, but the i nvestigator always has ultimate authority for the 
decision to unblind. The actual task of unblinding can be deleg ated by [CONTACT_43073] a designee 
assigned the task on the Delegation of Authority. The Principal  Investigator [INVESTIGATOR_576862] y unblinding AFTER the decision  to unblind the participant has 
been documented.
For this study, the method of unblinding for emergency purposes  is through the IRT system. In 
case of an emergency, the investigator has unrestricted access to randomization information via
IRT and can break the blind through t he IRT system without prior approval from the Sponsor.
After the unblinding, the investigator shall notify the Medical  Monitor and/or Study Director. The 
method of unblinding for emergency purposes is described in the  IRT Manual. Participant and 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756694] be recorded on 
the appropriate study status page of the electronic case report  form (eCRF).
In cases of accidental unblinding, contact [CONTACT_122382].
Any request to unblind a participant for non-emergency purposes  should be discussed with the 
Medical Monitor.Designated staff of [COMPANY_016] Company may be unblinded (obtain the randomization 
codes) prior to database lock  to facilitate the bi oanalytical a nalysis of pharmacokinetic samples 
and immunogenicity. A bioa nalytical scientist in the Bioanalyti cal Sciences department of Bristol 
Myers Squibb Company (or a designee in the external central bio analytical laboratory) will be 
unblinded to (may obtain) the ra ndomized tr eatment assignments in order to min imize unn ecessary 
bioanalytical analysis of samples.
7.4 Dosage Modification
There is no provision for dose modification of study treatment.  If a participant interrupts treatment 
due to an AE, study treatment can be restarted in consultation with the Medical Monitor.
A Pharmacy Manual will not be provided for studies with oral dos e formulations.
Dose reductions or dose escalations are not permitted. All dose  modification rules apply to all arms 
given the blinded nature of this study.
7.5 Preparation/Handling/Storage/Accountability
The investigational product should be stored in a secure area a ccording to local regulations. It is 
the responsibility of the investigator to ensure that investiga tional product is only dispensed to 
study Participants. The investigational product must be dispens ed only from official study sites by 
[CONTACT_20443].
The product storage manager should ensure that the study treatm ent is stored in accordance with 
the environmental conditions (temperature, light, and humidity)  as determined by [CONTACT_20444]. If 
concerns regarding the quality or appearance of the study treat ment arise, the study tr eatment 
should not be dispensed and contact [CONTACT_20445].Study treatment not supplied by [CONTACT_82747] e with the package insert.
Investigational product documentation (whether supplied by [CONTACT_20447]) must be maintained that 
includes all processes required to ensure drug is accurately ad ministered. This includes 
documentation of drug stora ge, administration a nd, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).Further guidance and information for final disposition of unuse d study treatment are provided in 
Appendix 2.  
7.5.1 Retained Samples for Bioavailability / Bioequivalence / 
Biocomparability
Not applicable.
Protocol Amendment No.: 01
Date: 30-Jun-2021 74
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
7.6 Treatment Compliance
Study treatment compliance w ill be periodi cally monitored by [CONTACT_8249] ( Section 2 ). 
Drug accountability s hould be reviewed by [CONTACT_576969] t o confirm tr eatment 
compliance. Sites should discuss discrepancies with the partici pant at each on-tr eatment study 
visit. 
The study shall be conducted as described in this approved prot ocol. All revisions to the protocol 
must be discussed with, and be prepared by [CONTACT_20444]. The investigato r should not implement any 
deviation or change to the protocol without prior review and do cumented approval/favorable 
opi[INVESTIGATOR_30757] (IRB)/Independent E thics Commit tee (IEC) of an 
amendment, except where necessary to eliminate an immediate haz ard(s) to study participants.
7.7 Concomitant Therapy
7.7.1 Prohibited and/or Restricted Treatments
Prohibited and/or restricted med ications taken p rior to or duri ng the study (up through Study 
Day 149) are describe d below. Medications taken within [ADDRESS_756695] be 
recorded on the eCRF.
1) Use of Class Ia and  class III antiarrhythmic agents.
2) Table 7.7.1-1 presents prohibited and/or restricted potential medications.
Table 7.7.1-1: Prohibited and Restricted Medications
Type of MedicationExamples
(not exhaustive)Restriction Required Washout
Allergen 
immunotherapyvarious intradermal or 
sublingualProhibited during the study4 months prior to 
randomization
Anticoagulants or antiplatelet agentsaspi[INVESTIGATOR_248], clopi[INVESTIGATOR_7745], 
ticlopi[INVESTIGATOR_5325], warfarin, 
heparin, api[INVESTIGATOR_3822], etc.Prohibited during the study2 weeks or effective post-
discontinuation PD 
duration (whichever is 
longer) prior to 
randomization
Antihistamines -except fexofenadineDiphenhydramine, 
loratadineStable dose during the 
screening period; consistent 
use through the treatment 
periodNot applicable
BiologicsBelimumab, dupi[INVESTIGATOR_12458], 
or omalizumab Prohibited during the study6 months prior to 
randomization
Abatacept Prohibited during the study6 months prior to 
randomization
Other biologics, 
including tocilizumab, 
anakinraProhibited during the study 8 weeks prior to screening
Protocol Amendment No.: 01
Date: 30-Jun-2021 75
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Table 7.7.1-1: Prohibited and Restricted Medications
Type of MedicationExamples
(not exhaustive)Restriction Required Washout
Intravenous 
ImmunoglobulinProhibited during the study [ADDRESS_756696] follow stable regimen 
throughout study; cannot be 
used on as-needed basisNot applicable
Corticosteroid
-SystemicIM, IA, intrabursal, IV
Prednisone, 
dexamethasone Prohibited during the study4 weeks prior to 
randomization
Corticosteroid
-Topi[INVESTIGATOR_576863], 
hydrocortisoneAs rescue therapy until Week 
4 as detailed in Section 7.7.23 weeks prior to 
randomization
CYP2C8 and CYP3A4
-Strong or moderate 
inhibitors clopi[INVESTIGATOR_7745], gemfibrozil, 
clarithromycin, 
itraconazoleProhibited during the study5 PK half-lives or 14 days 
of randomization
CYP2C8 and CYP3A4
-Strong or moderate 
inducersrifampin, phenytoin Prohibited during the study3 weeks of the 
randomization
CYP2C8 or P-gp
Sensitive substrates with narrow therapeutic indicesRepaglinide, dabigatran, 
fexofenadineProhibited during the study 
(digoxin allowed under 
limited/urgent circumstances; 
see below)[ADDRESS_756697] agents other than influenza or SARS-CoV-2Live vaccines
Prohibited during the study90 days before and 60 days after EOT
Nonlive vaccines 
unassociated with 
influenza or SARS-
CoV-230 days before and 60 days 
after EOT
Protocol Amendment No.: 01
Date: 30-Jun-2021 76
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Table 7.7.1-1: Prohibited and Restricted Medications
Type of MedicationExamples
(not exhaustive)Restriction Required Washout
Immunization for 
influenza or SARS-CoV-2Live vaccines
Prohibited during the study90 days before and [ADDRESS_756698], crisaborole Prohibited during the study3 weeks prior to 
randomization
Phototherapy UVB, UVA Prohibited during the study4 weeks prior to 
randomization
S1P Receptor ModulatorsFingolimod, ozanimod, 
siponimod, etrasimodProhibited lifetime use Not applicable
rosiglitazoneDose up to 4 mg can be used, 
monitor glucose closelyNot applicable
Treatments to be restricted or suspended 
during the studytorasemideDose up to 10 mg can be 
usedNot applicable
digoxinFor acute use only, exclude 
at baseline; limit highest 
dose and monitor trough 
concentrations; stop 
treatment with IP during 
treatment with digoxin and 
for 3 days afterwardsNot applicable
Treatments
-OtherDiquafosol, rebamipi[INVESTIGATOR_576864]4 weeks prior to
randomization
Protocol Amendment No.: 01
Date: 30-Jun-2021 77
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
No concomitant medications (prescription, over-the-counter or h erbal) are to be administered 
during study unless they are prescribed for treatment of specif ic clinical events. Any concomitant 
therapi[INVESTIGATOR_576865], along with the reason f or its administration.
The investigator should con tact and c onfirm agreement with the BMS medical monitor (and 
acknowledgement from the contr act research organization med ical monit or) prior to the 
administration of any concomitant medications, excepting those needed for urgent/emergent 
treatment for which there is insufficient time for such contact .
7.7.[ADDRESS_756699] 4 wee ks of treatment may use the below 
topi[INVESTIGATOR_12450] (according to their respective label instruction s) as rescue therapy up until Week 4 
according to the investigatorâ€™s judgement. 
â€¢Fluocinolone acetonide 0.025% 
â€¢Hydrocortisone butyrate 0.1%
â€¢Mometasone furoate 0.1%
â€¢Triamcinolone acetonide 0.1%
Participants requiring and completing â‰¤ [ADDRESS_756700] 4 weeks 
of IP treatment initiation, will remain eligible to be counted as responders for categorical efficacy 
endpoints; their numerical endpoints will also be counted as if  they did not receive rescue therapy.
Participants either (1) requiring topi[INVESTIGATOR_576866] 4 weeks of IP treatment, or for more 
than 7 days, or (2) requiring systemic corticosteroid/immunosup pression or phototherapy will 
discontinue from study treatment and be considered treatment fa ilures for categorical endpoints.
Participants who discontinue s tudy treatment ar e to remain in t he study and complete all st udy 
visits and assessments unless they withdraw consent ( Section 8.2).
Statistical handling of d ata from participants requiring rescue medication appears in 
Section 10.3.1 .
7.7.3 Use of Concomitant Emollient
Application of fixed doses of an additive-free, basic bland emo llient twice-daily fo r â‰¥ 7 days before 
baseline visit and for the duration of the study is required.
Note: On study visit days, showering or bathing is permitted prior to attending the study visit, but 
participants must not moisturize or apply emollient. The additi ve-free, basic bland emollient is 
allowed after the visit.
7.8 Treatment After the End of the Study
At the end of the study, BMS will not continue  to provide BMS s upplied study treatment to 
participants/investigators unless BMS chooses to extend the stu dy. The investigator should ensure 
that the participant receives appropriate standard of care to t reat the condition under study.
Protocol Amendment No.: 01
Date: 30-Jun-2021 78
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
BMS reserves the right to terminate access to BMS supplied stud y treatment if any of the following 
occur: a) the study is terminated due to safety concerns; b) th e development of the study treatment 
is terminated for other reasons, including but not limited to l ack of efficacy and/or not meeting the 
study objectives; c) the participant can obtain medication from  a government sponsored or private 
healt h program. In all cases BMS will follow local regulations.
[ADDRESS_756701] (and non- investigational product at the 
discretion of the investigator) for a ny of the following reasons:
â€¢Participantâ€™s request to stop study tr eatment. Par ticipants who request to discontinue study 
treatment w ill remain in the study and must continue to be followed for pr otocol specified 
follow-up procedures. The only exception to this is when a part icipant specifically withdraws 
consent for any further contact [CONTACT_35859]/her or persons previou sly authorized by [CONTACT_104135]
â€¢Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the 
opi[INVESTIGATOR_871], indicates that continued participation in the study is not in the best interest of the participant
â€¢Termination of the study by [CONTACT_414]-Myers Squibb (BMS)
â€¢Loss of ability to freely provide c onsent through imprisonment or involuntary incarceration for 
treatment of eithe r a psychiatric or physical (eg, infectious disease) illness. (No te: Under 
specific circumstances and only in countries where local regula tions permit, a participant who 
has been imprisoned may be permitted to continue as a participant. Strict conditions apply and BMS approval is required.)
â€¢Asthma or COPD that requires systemic glucocorticoid or biologic  treatment, or inh aled 
budesonide or equivalent at >1200 Î¼g/day or fluticasone propi[INVESTIGATOR_576867] > 880 Î¼g/day along with 
another anti-asthma/COPD drug such as a long-acting beta-agonist .
â€¢Systemic or photo-based rescue therapy for AD ( Section 7.7.2 ),
â€¢Replication-competent (live) vaccine 
â€¢Grade 4 lymphopenia (ALC < 200) w ith repeat testing within 7 day s(according to the Common 
Toxicity Criteria for Adverse Events [CTCAE] version 5.0)
â€¢Elevation of ALT or AST > 5x ULN or concurrent elevations of ALT or AST > 3x ULN and 
bilirubin > 2x ULN
â€¢Decline in PFT values (FEV1 and/or FVC) below 30% of the baseli ne values
â€¢Diagnosis of macular edema, retinal or choroidal disease or syn drome
â€¢Grade 2 or higher cardiac or bone marrow adverse events (with exc eption of ALC) according 
to the CTCAE version 5.0.
â€¢Grade 3 for other system adverse events (according to the CTCAE version 5.0)
â€¢Missed dose of â‰¥ 3 consecutive days or overall compliance < 85%  over a pe riod of > 30 days 
starting from study Day 1.
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756702] immediately, within 24 hours of awareness of the 
pregnancy, notify the BMS Medical Monitor/designee of this even t. In most cases, the study 
treatment w ill be permanently discontinued in an appropri ate manner (eg, dose tapering if 
necessary for participant safety). Refer to Section 9.2.[ADDRESS_756703]-treat ment study follow-up or loses the 
ability to consent fr eely (ie, is imprisoned or involuntarily i ncarcerated for the treatment of either 
a psychiatric or physical illness).
If study treatment is discontinued prior to the participantâ€™s c ompletion of the study, the reason for 
the discontinuation must be documented in the participantâ€™s med ical records and en tered on the 
appropriate case report form (eCRF) page.8.1.[ADDRESS_756704] continue to be followed (i n this study or 
a rollover study) fo r collection of outcome and/ or survival follow-up data as required and in line 
with Section [ADDRESS_756705] with him/her or persons 
previously authorized by [CONTACT_193609] n. 
â€¢Participants should notify the investigator of the decision to w ithdraw consent from future 
follow-up in writing, whenever possible.
â€¢The withdrawal of consent should be explained in detail in the medical rec ords by [CONTACT_1275], as to whether the withdrawal is from further trea tment with study treatment only 
or also from study proce dures and/or post treatment study follow-up, and entered on the  
appropriate eCRF page.
â€¢In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly available information s hould be used to determine vital status only as appropriately 
directed in accordance with local law.
â€¢If the participant withdraws consent for disclosure of future i nformation, the sponsor may 
retain and continue to use any data collected before such a wit hdrawal of consent.
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756706] to Follow-Up
â€¢All reasonable efforts must be made to locate participants to d etermine and report their ongoing 
status. This include s follow-up with pers ons authorized by [CONTACT_2299].
â€¢Lost to follow-up is defined by  [CONTACT_193610] a minimum of three
documented phone calls, faxe s, or emails as well as lack of response by [CONTACT_102448]. All attempts should be documented in th e participantâ€™s medical records.
â€¢If it is determined that the participant has died, the site wil l use permissible local methods to 
obtain date and cause of death.
â€¢If investigatorâ€™s use of third-party representative to assist i n the follow- up portion of the study 
has been included in the participantâ€™s informed consent, then t he investigator may use a 
Sponsor retained third-party representative to assist site staf f with obtaining participantâ€™s 
contact [CONTACT_193611] s tatus data n ecessary to complete the follow-up 
portion of the study. 
â€¢The site staff and representative will consult publicly availab le sources, such as public h ealth 
registries and databases, in order to obtain updated contact [CONTACT_3031].
â€¢If after all attempts, the participant remains lost to follow-u p, then the last known alive date as 
determined by [CONTACT_82754] d in the participantâ€™s medical 
records.
9 STUDY ASSESSMENTS AND PROCEDURES
â€¢Study procedures and timing are summarized in the Schedule of A ctivities. 
â€¢Protocol waivers or exemptions are not allowed.
â€¢All immediate safety concerns must be discussed with the Sponso r immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatment.
â€¢Adherence to the study design requirements, including those spec ified in the Schedule of 
Activities, is essential and required for study conduct.
â€¢All screening evaluations must be completed and reviewed to con firm that potential 
participants meet all eligibility criteria before randomization . The investigator will maintain a 
screening log to record details of all participants screened an d to confirm eligibility or record 
reasons for screening failure, as applicable.
â€¢Procedures conducted as part of the participantâ€™s routine clini cal management (eg, blood count) 
and obtained before signing of  informed consent may be utilized  for screening or baseline 
purposes provided the procedure meets the protocol-defined criteria and has been performed 
within the timeframe defined in the Schedule of Activities.
9.1 Efficacy Assessments
Efficacy assessments completed by [CONTACT_576970] -AD, Eczema Area and Severity 
Index (EASI), and % Body Surface Area (BSA) worksheet. Every ef fort should be made to ensure 
that the same assessor conducts the assessments at all study vi sits for a given participant.
Protocol Amendment No.: 01
Date: 30-Jun-2021 81
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
9.1.1 Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-
AD)
The vIGA-AD is a static 5-point assessment intended to assess t he global severities of key acute 
clinical signs of AD, including erythema, induration/papulation , and oozing/crusting 
(lichenification excluded).112The rating of cleared (0), almost cleared (1), mild (2), modera te (3), 
and severe (4) w ill be assessed at each scheduled visit, and at unscheduled cli nic visits, if 
applicable. Refer to Appendix 8.
The vIGA-AD will be collected prior to the EASI.
9.1.2 Eczema Area and Severity Index (EASI)
The EASI is a validated, composite scoring system assessed by t he investigator based on the extent 
of each of the 4 body regions  (head and neck, upper limbs, lowe r limbs, and trunk) affected with 
AD and the intensity of each of  4 key signs of AD (eryth ema, induration/papulation, excoriation, 
and lichenification) and is based on a 4-point scale of 0 (abse nt), 1 (mild), 2 (moderate), and 3 
(severe).113For each of the [ADDRESS_756707]-inflammatory pi[INVESTIGATOR_576868]. The total EASI score ranges from 0 to 72. The EASI will be collected at each scheduled 
and unscheduled clinic visit, if applicable. Further details of  the evaluation a nd calculati on of the 
EASI score are provided in Appendix 9 .
9.1.3 Body Surface Area (BSA)
A widely used method of measuring BSA involvement by [CONTACT_22802], is the  rule of nines in which for 
each section of the body (the  possible highest score for each r egion is: head and neck [9%], anterior 
trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], genitals  [1%]) a nd w ill be 
reported as a percentage of all major body sections combined.114,115Participants will undergo this 
assessment at each scheduled and unscheduled clinic visit, if applicable. Refer to Appendix 10.
9.1.4 Pruritus and Sleep Quality Numerical Rating Scale (NRS)Participants will comp lete a d aily diary rec ording the intensity of their pruritus and the average 
quality of s leep they experienced during the preceding 24 hours. The intens ity of pruritus will be 
assessed using a validated 11-point NRS, ranging from 0 (â€œno itchingâ€) to 10 (â€œthe worst itching 
imaginableâ€). The quality of sleep will be assessed using a val idated 11-point NRS ranging from 
0 (â€œthe best possible sleepâ€) to 10 (â€œthe worst possible sleep) provided in Appendix 11.
116,117
9.1.5 Dermatology Life Quality Index (DLQI)
The DLQI is a 10-item, easy-to-use, self-administered, assessme nt of the participantsâ€™ perception 
of the impact of their skin disease on different aspects of the ir Quality of Life (QOL) over the 
previous week. The DLQI score ranges from 0 (no effect on the p articipantâ€™s life) to 30 (extremely 
large effect on the participantâ€™s life). For each item, the sca le is rated as follows: 0 =â€™not at allâ€™/â€™not 
relevantâ€™; 1=â€™a littleâ€™; 2=â€™a lotâ€™; 3=â€™very muchâ€™/â€™yesâ€™ in ques tion 7, with an overall scoring system 
of 0 to 30; a high score i s indicative of a poor QOL.118The DLQI will be assessed at every 
scheduled and unscheduled clinic visit, if applicable. Refer to  Appendix 12.
Protocol Amendment No.: 01
Date: 30-Jun-2021 82
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
9.1.6 Patient Oriented Eczema Measure (POEM)
The POEM is a validated tool used for monitoring atopic eczema severity. It is a 7-item 
questionnaire completed by [CONTACT_576971], sleep disturbance, skin bleeding, skin weepi[INVESTIGATOR_358541], skin cracking, skin 
flaking, and skin dryness. Each item has the following response  opti ons: 0 = No Days, 1 = 1-2
Days, 2 = 3-4 Days, 3 = 5-6 Days and 4 = Every Day. A total scor e is calculated by [CONTACT_576972] a score ranging from 0-28. The subject will  complete the questionnaire onsite 
at study visits. Refer to Appendix 13.
9.1.7 Patient Global Impression of Change (PGI-C)
The PGI-C is a global rating anchor scale and has been used acr oss different thera peutic categories 
to interpret the scores from participant-reported outcome measu rements. The PGI-C will be used 
in this study to confirm the threshold for meaningful change on  other patient reported outcomes 
instruments in the target patient population. Participants will  be asked the following question as 
per the schedule of assessments: â€œCompared to the beginning of the study, before you started the 
study tr eatment, whic h of the following best describes the skin symptoms of your ato pic dermatitis 
today?â€ The response choices will be as follows: much improved, moderately improved, a little 
improved, the same, a little worse, moderately worse, or much w orse. Refer to Appendix 14.
9.1.8 Patient Global Impression of Severity (PGI-S)
The PGI-S is a global rating anchor scale and has been used acr oss different therapeutic categories 
to interpret the scores from participant-reported outcome measu rements. The PGI-S will be used 
in this clinical trial to confirm the threshold for meaningful change on other PRO instruments in 
the target population. The PGI-S is not subject to recall error  and can be also used to assess change 
from baseline data. Participants w ill be asked the following question as per the schedule of 
assessments, â€œWhich of the following best describes the severit y of the skin symptoms of your 
atopic dermatitis over the past  7 days?â€ The response choices w ill be as follows: none, mild, 
moderate, severe, or very severe. Refer to Appendix 15.
9.2 Adverse Events
The definitions of an AE or serious adverse event (SAE) can be found in Appendix 3.
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver or surrogate). The investigator and any designees are responsible for detectin g, documenting, and reporting 
events that meet the definition of an AE or SAE and remain resp onsible for following up AEs that 
are serious, considered related to the study treatment or the s tudy, or that caused the participant to 
discontinue before completing the study. 
Contacts for SAE reporting specified in Appendix [ADDRESS_756708] (AEIs) are described in Section 9.2.8.
9.2.1 Time Period and Frequency for Collecting AE and SAE Information
Appendix 1  in the Investigatorâ€™s Brochure (IB) represent the Reference Sa fety Information to 
determine expectedness of serious adverse events for expedited r eporting.
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756709] report any SAE that occurs after these ti me periods and that is believed to 
be related to study drug or protocol-specified procedure (eg, a  follow-up skin biopsy).
â€¢Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate section of the CRF module.
â€¢All SAEs will be rec orded and reported to Sponsor or designee within 24 hours, as in dicated 
in Appendix 3. 
â€¢The investigator will submit any updated SAE data to the sponso r or designee within 24 hours
of updated information being available.
Investigators are not obligated to actively seek AEs or SAEs in former study participants. 
However, if the investigator learns of any SAE, including a dea th, at any time after a participant 
has been discharged from the study, and he/she considers the event reasonably related to the study 
treatment or study participation, t he investigator must promptl y notify the sponsor.
The method of evaluating and assessing causality of AEs and SAE s and the procedures for 
completing and reporting/transmitting SAE reports are provided in Appendix 3.
9.2.2 Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported  or elicited  during open-ended questioning, 
examination, or evaluation of a participant. Care should be tak en not to introduce bias when 
collecting AE and/or SAEs. Inquiry about specific AEs should be  guided by [CONTACT_193613], when appropriate for the program or protocol.
9.2.3 Follow-up of AEs and SAEs
â€¢Nonserious AEs should be follo wed to resolution  or stabilizatio n, or reported as SAEs if they 
become serious (see Section Appendix 3).
â€¢Follow-up is also required for nonserious AEs that cause interr uption or discontinuation of 
study treatment and for those present at the end of study treat ment as appropriate.
â€¢All identified nonserious AEs must be recorded and described on  the nonserious AE page of 
the CRF (paper or electronic). Completion of supplemental CRFs may be requested for AEs 
and/or laboratory abnormalities t hat are reported/identified du ring the course of the study.
After the initial AE/SAE report, the investigator is required t o proactively follow each participant 
at subsequent visits/contacts. All SAEs, and non-serious AEs of  interest (as defined in Section 9 )
will be followed until resolution, until the c ondition stabilizes, un til the event is otherwise 
explained, or until the participant is lost to follow-up (as de fined in Section 8.3 ).
Further informatio n on follow- up procedures is given in Appendi x 3.
Protocol Amendment No.: 01
Date: 30-Jun-2021 84
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
9.2.4 Regulatory Reporting Requirements for SAEs
â€¢Prompt notification by [CONTACT_104153] a 
product under clinical investigation are met.
â€¢An investigator who receives an i nvestigator safety report desc ribing SAEs or other specific 
safety information (eg, summary  or listing of SAEs) from the S ponsor w ill file it along with 
the Investigatorâ€™s Brochure and w ill notify the IRB/IEC, if appropri ate acc ording to local 
requirements.
Sponsor or designee will be reporting AEs to regulatory authori ties and ethics committees 
according to local applicable laws including European Directive  2001/20/EC and FDA Code of 
Federal Regulations 21 CFR Parts 312 and 320. A S[LOCATION_003]R (Suspecte d, Unexpected Serious 
Adverse Reaction) is a subset of SAEs and will be re ported to the appropriate regulatory authorities 
and investigators following local and global guidelines and requirements.
9.2.[ADDRESS_756710] immediately notif y the BMS 
Medical Monitor/designee of this event and complete and forward a Pregnancy Surveillance Form 
to BMS Designee within 24 hours of awareness of the event and in accordance with SAE reporting procedures described in Appendix 3.
If the investigator determines a possible favorable benefit/ris k ratio that warrants continuation of 
study treatment, or re-initiation of study treatment, a discuss ion between the investigator and the 
BMS Medical Monitor/designee must occur. 
Follow-up information regarding the course of the pregnancy, in cluding perinatal and neonatal 
outcome and, where applicable, offspring information must be re ported on the Pregnancy 
Surveillance Form.Any pregnancy that occurs in a female partner of a male study participant should be reported to 
Sponsor or designee. In order for Sponsor or designee to collec t any pregnancy surveillance
information from the female partne r, the fe male pa rtner must si gn an informed consent form for 
disclosure of this information. Information on this pregnancy w ill be collected on the Pregnancy 
Surveillance Form.If any sexual activity (eg, vaginal, anal, oral) has occurred b etween a male participant and a 
pregnant partner(s) without the  use of a condom during and at l east for [ADDRESS_756711] any pregnancy surve illance informatio n from the f emale 
partner, the female partner(s) must sign an informed consent fo rm for disclosure of this 
information. Infor mation on the pregnancy will be collected on the Pregnancy Surveillance Form.
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756712] result abnormalities should be ca ptured on the nonserious AE CRF 
page or SAE Report Form electronic, as appropriate. Paper forms  are only intended as a back-up 
option when the electronic system is not functioning.
â€¢Any laboratory test result that is clinically significant or me ets the definition of an SAE 
â€¢Any laboratory test result abnormality that required the partic ipant to have study treatment 
discontinued or interrupted
â€¢Any laboratory test result abnormality that required the partic ipant to r eceive sp ecific 
corrective therapy
It is expected that wherever possible, the clinical rather than  laboratory term would be used by [CONTACT_35867] (eg, anemia versus low hemoglobin value) .
Clinically significant changes, in the judgment of the investig ator, in laboratory parameters 
(abnormalities) will be recorde d as AEs. During the tr eatment period, all total WBC and WBC 
differential results will be blinded. Reductions in ALC levels is a known PD effect of 
BMS-986166. If any of the following results are observed, the i nvestigator will be notified and 
asked to repeat the laboratory tests within approximately 7 day s:
â€¢Absolute lymphocyte count [ALC] < 200 cells/Î¼L
â€¢Absolute neutrophil count [ANC] < 1000 cells/Î¼L
â€¢Total WBC > 20,000 cells/Î¼L
If the repeat values also exceed these limits, the investigator will be i nformed that the patientâ€™s 
results for the abnormal parameter  have fallen below the accept able threshold. 
If ANC or total WBC counts are confirmed below the acceptable limits, the Medical Monitor will 
contact [CONTACT_576973] f or risk of serious infection and 
appropriate follow-up, at the discretion of the investigator.
If the ALC is confirmed < 200 cells/Î¼L, the investigator will d iscontinue investigational drug and 
then consult with the Medical Monitor. Laboratory testing will be repeated weekly until ALC is 
> 500 cells/Î¼L.
If participants have elevatio ns in ALT and/or AST â‰¥ 3x the upper limit of normal (ULN), a retest 
should be performed as soon as possible but not later than [ADDRESS_756713] are < 3x ULN. 
If the ALT and/or AST stabilizes at a level > 3x ULN, the Medic al Monitor may agree to less 
frequent testing. Other liver-related laboratory testing, inclu ding international normalized ratio 
(INR), alkaline phosphatase (AP), g amma-glu tamyl transferase (GGT), hepatitis serologies, and 
other tests as deemed n ecessary by [CONTACT_576974] p erformed to better understand the 
observation.
Protocol Amendment No.: 01
Date: 30-Jun-2021 86
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
The investigator should establish causality. In addition, the c onfirmed elevation > 3x ULN is an 
AEI (see Section 9.2.8 ) and should be reported by [CONTACT_093]. At any time, if a ny of the 
following occur and there are no apparent alternative causes fo r the finding, the investigational 
drug must be permanently discontinued:
â€¢ALT or AST > 8x ULN or
â€¢ALT or AST > 5x ULN with confirmation, within 2 weeks or
â€¢ALT or AST > 3x ULN and (total bilirubin > 2x ULN or INR > 1.5) or
â€¢ALT or AST > 3x ULN with the appearance of fatigue, nausea, vom iting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%).
The investigator should establish causality. After discontinuat ion due to elevation of ALT or AST 
> 5x ULN or concurrent elevations of ALT or AST > 3x ULN and bi lirubin > 2x ULN, further 
liver function evaluation should be performed (for example, coa gulation panel and alkaline 
phosphatase) in consultation with the Medical Monitor.
9.2.7 Potential Drug Induced Liver Injury (DILI)
Wherever possible,  timely confirmation  of initial liver-rel ated laboratory  abnormalities s hould 
occur prior to the reporting of a potential DILI event. All occ urrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 9 and Appendix 3 for reporting details).
Potential drug induced liver injury is defined as: 
â€¢AT (ALT or AST) elevation > 3 times upper limit of normal (ULN) A ND
â€¢Total bilirubin > [ADDRESS_756714], without init ial findings of cholestasis ( elevated serum alkaline 
phosphatase) AND
â€¢No other immediately apparent possible causes of AT elevation a nd hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing ch ronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
9.2.[ADDRESS_756715] (AEIs)
Adverse events of interest (AEIs) are AEs for a particular prod uct or class of products that a 
Sponsor may wish to monitor carefully. AEIs may be serious or n onserious. Such events may 
require further investigation to better characterize and unders tand them in addition to the 
conventional safety monitoring employed in the study . In the brane brutinib clinical development 
program, infection AEs have been identified as potential AEIs; however, there has been no 
definitive assessment on the causal relationship between these events and treatment with 
branebrutinib. Therefore, additional information about infectio n AEs may be collected on the 
eCRF in order to better characterize and understand them.
Potential AEs of interest that may be a consequence of S1PR1 mo dulation will therefore be 
monitored in the IM018005 study. These AEs include:
Protocol Amendment No.: 01
Date: 30-Jun-2021 87
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
â€¢Bradycardia and heart conduction abnormalities:
Dose-related transient, reversible bradycardia and first-degree  atrioventricular block were 
reported primarily as first dose effects in fingolimod studies. The HR reduction observed with 
S1PR1 agonists is an expected effect of S1PR modulation and appears to be conducted through 
the same pathway as vagus nerve stimu lation. In additi on, these negative chronotropic effects 
of S1PR1 agonists appear to attenuate over time secondary to S1 PR desensitization and 
internalization on cardiac myocytes.119Because of its biased ligand properties, both 
nonclinical and clinical data suggest that this effect is less with BMS-986166 (Section 3.2 and
IB). 
Nevertheless, ECG assessment predose and at 1, 2, 4, and [ADDRESS_756716]-dose will be obtained; 
in addition to hourly monitoring of the HR and blood pressure o n Day 1. Standard 12-lead 
ECG will be collected and reviewed with every subsequent visit.  
Clinicians should be particularly mi ndful of participants who have a low HR at baseline 
(spontaneously or through drug-induced ÃŸ-receptor blockade), pr ior to administration of the 
investigation al drug. Atropi[INVESTIGATOR_576869]-l ine treatment of bradycardia, 
up to a maximum daily dose of 3 mg. Furthermore, the common gui delines for treatment of 
bradycardia (eg, Advanced Cardi ac Life Support [ACLS] guideline s) should be followed as 
appropriate.
â€¢Pulmonary effects:
An initial sharp decrease followed by a slow progressive decline over time in FEV1 was 
observed in fingolimod clinical studies. Nonclinical toxicity s tudies however with 
BMS-[ADDRESS_756717] not revealed the potential for pulmonary toxici ty at doses considerably 
higher than the pharmacologically active dose. PFTs including F EV1, FVC, and diffusion 
capacity of ca rbon monoxide (DLCO), will be measured in all par ticipants. Every participant 
whose PFTs are abnormal will be followed until such time as res olution is confirmed or no 
further improvement is expected by [CONTACT_093].Any condition that might affect the outcome of pulmonary functi on testing including infection, 
respi[INVESTIGATOR_1856], occupational exposures (including asbesto s) and cigarette smoking 
needs to be collected before PFT testing and transcribed to the  PFTs eCRF page. If participants 
experience a decline in PFT values (FEV1 and/or FVC) below 30% of the baseline values, 
treatment should be discontinued.If a participant discontinues due to a respi[INVESTIGATOR_229859], the inve stigator should ensure that the 
patient has adequate evaluations as clinically indicated by a p ulmonologist for the AE. Further 
evaluations will be c onducted until such time as resolution is confirmed or no further 
improvement is expected by [CONTACT_093] (based on a follow- up period of not less than 3 
months).
Protocol Amendment No.: 01
Date: 30-Jun-2021 88
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
â€¢Hepatotoxicity:
Fingolimod caused frequent , reversible liver enzyme elevations greater than 3-fold above the 
ULN in up to 12% of patients; this was a significant cause of c essation of therapy. In this study, 
clinical blood chemistry analyses to assess liver function test s (LFTs) will be performed. Every 
patient whose LFTs are abnormal will be followed until values return to baseline.
Refer to Section 9.2.6 and Section 9.2.7 for instructions regarding hepatotoxicity.
â€¢Macular edema:
Instances of serious macular edema were reported in fingolimod renal transplant studies, and 
a 0.8% incidence was reported as an SAE in fingolimod (1.25 mg dose) MS clinical studies. 
Nonclinical studies with BMS-[ADDRESS_756718] not revealed eye-relat ed toxicities. In this study, 
visual acuity (VA) testing and OCT will be performed in all par ticipants at screening and the 
end of study visits or early termination. In addition, particip ants will be questioned about visual 
signs or symptoms at each study vi sit and instructed to inform the investigator if they develop 
symptoms between visits. For participants with visual symptoms suggestive of macular edema, 
OCT and ophthalmologic examination, including visual acuity tes ting and dilated 
ophthalmoscopy, w ill also be pe rformed. Every participant whose ophthalmic evaluations 
reveal abnormalities will be followed until values return to ba seline.
Study drug must be discontinued in any participant who has a di agnosis of macular edema. 
Participants with a diagnosis of macular edema must be followed  up monthly or more 
frequently if needed based on the ophthalmologistâ€™s judgment. F urther ophth almological 
evaluations will be c onducted until such time as resolution is confirmed or no further 
improvement is expected by [CONTACT_1964] (based on a foll ow-up period of not less than 
3 months). If the participant does not show definite signs of i mprovement on examination [ADDRESS_756719] experienced in the manageme nt of this condition should 
be initiated.
â€¢Opportunistic or serious infections:
TB, serious bacterial infections, systemic fungal infections, v iral infections such as herpes 
infections (including herpes zoster and disseminated herpes sim plex), and protozoal infections 
should be reported as AEIs and treated accordingly.
Malignancies
Malignancies such as melanoma, basal cell carcinoma, breast can cer, lymphoma  (cutaneous 
T-cell lym phoproliferative disorders or diffuse B-cell lymphoma ), and seminoma have also 
been reported for the class of S1P receptor modulators. Maligna ncy should be reported as AEIs 
and referred accordingly to the appropriate specialist.Progressive multifocal leukoencephalopathy (PML)
PML is an opportunistic viral infection of the brain caused by [CONTACT_204896] 
(JCV) that typi[INVESTIGATOR_576870].: 01
Date: 30-Jun-2021 89
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
severe disability. JCV infection resulting in PML has been obse rved in patients treated with 
immunomodulatory therapi[INVESTIGATOR_576871] (eg, 
polytherapy with immunosuppressants, severely immunocompromised  patients). Typi[INVESTIGATOR_576872], progress over days to weeks,  and include progressive 
weakness on [ADDRESS_756720] consul tation should be ob tained and magnetic 
resonance imaging (MRI) should be requested and treatment should be discontinued.
Posterior reversible encephalopathy syndrome (PRES)
PRES is a syndrome characterized by [CONTACT_576975], confusion, seizures,
and visual loss. If a participant develops any unexpected neurological or psychiatric 
symptoms/signs (eg, cognitive deficits, behavioral changes, cor tical visual disturbances, or any 
other neurological cortical symptoms/signs), any symptom/sign s uggestive of an increase of 
intracranial pressure, or accelerated neurological deterioratio n, the physician should promptly 
schedule a comp lete physical and neurological examination and s hould consider an MRI. If 
PRES is suspected, treatment should be discontinued.
9.2.[ADDRESS_756721] udy 
treatment within a 24-hour time period will be considered an ov erdose. See Section 9 for AE 
assessment and reporting procedures regarding suspected overdose and intentional overdose.
Based on the IB, there has been no clinical experience nor know n specific antidote for overdose 
with either BMS-986166 or branebrutinib.38,47
In the event of an overdose, the investigator should:
1) Contact [CONTACT_27465].
2) Closely monitor the participant for AEs/SAEs and laboratory a bnormalities.
3) Obtain a plasma sample for PK analysis within 4 hours of the overdose if requested by [CONTACT_5134] (determined on a case-by-case basis).
4) Document the quantity of the excess dose as well as the durat ion of the overdosing in the eCRF.
Decisions regarding dose interruptions or modifications will be  made by [CONTACT_193614].
Protocol Amendment No.: 01
Date: 30-Jun-2021 90
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
9.4 Safety
An external, independent DMC will be empaneled to review safety  on a prescheduled and ad-hoc 
basis, in addition to contemporaneous safety monitoring by [CONTACT_3476]. Planned time points 
for all safety assessments are listed in the Schedule of Activi ties (Section 2 ).
9.4.1 Physical ExaminationsA complete physical examination w ill include general appearance, vital signs, eyes, ears, nose, 
mouth, throat, neck, respi[INVESTIGATOR_696], cardiovascular, respi[INVESTIGATOR_696], gastrointestinal/abdomen, lymphatic, 
musculoskeletal, skin, psychiatr ic, and neurologic examinations . 
A targeted physical examinatio n will include any organ system associated with an AE, or a 
laboratory abnormality. Refer to the Schedule of Activities (Section 2).The examination includes  
examination of the abdomen, con junctival mucosae, heart, lungs, lymph nodes, oral mucosa, skin, 
and any sites deemed necessary by [CONTACT_576976].
9.4.2 Vital signs
Refer to the Schedule of Activiti es (Section 2).
9.4.3 Electrocardiograms12-lead ECG will be performed at the visits indicated in the Sc hedule of Activi ties (Section 2). 
The participant will r emain supi[INVESTIGATOR_2525] [ADDRESS_756722] a screen ing interferon-gamma release ass ay (IGRA; eg, QuantiFERONÂ®-
TB Gold) performed centrally. If unable to ob tain central laboratory results, an IGRA test could 
be obtained locally, after consultation with the BMS Medical Mo nitor. A participant with an 
indeterminate IGRA test result must be retested for confirmatio n. If the second result is again 
indeterminate, the participant will be excluded from the study.  If the second result is positive, the 
participant should be considered as having LTBI provided there are no signs or symptoms of active 
TB. If the second result is negative, the participant may be el igible provided no other exclusion 
criterion for TB is met. A che st x-ray is also required during Screening.
9.4.[ADDRESS_756723] S1PR1 modulators 
such as fingolimod.
120,121It is hypothesized that the diffe rentiated biase d-ligand proper ties of 
BMS-986166 (Section [IP_ADDRESS] ) obviates this phenomenon and its downstream consequences such 
as pulmonary effects and macular edema in animals and humans; t his hypothesis is supported by 
[CONTACT_576977].38
Protocol Amendment No.: 01
Date: 30-Jun-2021 91
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
â€¢In both Studies IM018001122and IM018003,123there was no apparent effect of BMS-986166 
on pulmonary function including FVC, FEV1, or DLCO. Participant s underwent frequent 
safety assessments while in the clinic and during an extended f ollow-up period to monitor for 
AEs. Decline in PFT values (FEV1 and/or FVC) below 30% of the baseline values during 
treatment in this study (IM018005) w ill result in discontinuation from further study drug 
administration.
To monitor the potential pulmonary effects of BMS-986166, FEV1,  FVC, and DLCO 
measurements w ill be pe rformed as indicated the Schedule of Activities (Section 2 ).These tests 
will be performed at a qualified pulmonary function laboratory or respi[INVESTIGATOR_155761]. Please 
refer to the American Thoracic Society/European Respi[INVESTIGATOR_576873].124,125,126
9.4.6 Neurological Safety
Preclinical toxicity d ata in conjunction with large systemic ex posure (AUC-based) margins 
suggest a low safety concern for likely neurological effects in  human participants.
Consistent with the nonclinical results, comprehensive neurolog ical examination and nerve 
conduction velocity results for participants in Study IM018001101or IM018003102demonstrated 
no concerning treatment-eme rgent neurological findings following dosing with BMS-986166. 
Specific monitoring for neurologic toxicity, beyond standard sa fety measures, is not planned in 
Study IM018005.
9.4.[ADDRESS_756724] will be performed at scheduled times as indicated in the 
Schedule of A ctivities (Section 2). Diagno sis of macular edema, retinal or choroidal disease, or 
syndrome duri ng treatment will result in dis continuation from further study drug administration.
9.4.8 Ma le Sex Hormones
For the purpo ses of monitoring the preclinical testicular finding, participants with history of 
significant testicular or epi[INVESTIGATOR_576874], and male sex hormones 
(follicle-stimula ting hormone (FSH), luteinizing hormone (LH), and tota l testosterone) w ill be 
assessed at baseline and s elected time points throughout the tr eatment period and until study 
discharge.[ADDRESS_756725] b e available prior to dosing.
Protocol Amendment No.: 01
Date: 30-Jun-2021 92
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Hematology
Hemoglobin
Hematocrit
Total leukocyte count, including differential
Platelet count
Coagulation Panel
Prothrombin time/International normalized ratio (PT/INR)- screen ing only
Chemistry
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Total bilirubin
Direct bilirubin
Alkaline phosphatase
Lactate dehydrogenase (LDH)
Creatinine
Blood Urea Nitrogen (BUN)
Uric acid
Fasting glucose
Cholesterol & Lipid Panel
TestosteroneTotal ProteinAlbumin
Sodium
Potassium
Chloride
Calcium
Phosphorus
Magnesium
Creatine phosphokinase
eGFR calculation
Hemoglobin A1c
Follicle-stimulating hormone (FSH)
Luteinizing hormone (LH)
Urinalysis
Protein
Glucose
Blood
Leukocyte esterase
Specific gravity
pH
Microscopic examination of the sediment if blood, protein or le ukocytes esterase are positive 
on the dipstick
Screening Serology
Serum for hepatitis C antibody, hepatitis B surface antigen, he patitis B core antibody, HIV-1 
and -2 antibody (screening only)
Other Analyses
Test for drugs of abuse (urine or serum), (screening and predos e on Day 1)
Pregnancy test (WOCBP only).
Follicle s timulating hormone (FSH) (screening only for select wome n only)
QuantiFERON-TB Gold test (or equivalent if not available; scree ning only)
SARS-CoV-[ADDRESS_756726]
SARS-CoV-2: RT-PCR Test or Antigen test
Protocol Amendment No.: 01
Date: 30-Jun-2021 93
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
9.5 Pharmacokinetics
Pharmacokinetics of BMS-986166 and its major metabolites (BMS-9 [ZIP_CODE]-P) w ill be derived 
from blood concentration. Pharmacokinetics of branebrutinib will  be derived from plasma 
concentration. Blood (BMS-986166 and its major metabolite [BMS-9 [ZIP_CODE]-P]) and plasma 
(branebrutinib) samples will be analyzed by [CONTACT_576978]. Sa mples collected from participants 
who receive placebo will not be analyzed. In addition, blood an d plasma samples will be archived 
for potential additional  metabolites analysis, if the need aris es and to the extent possible. Detailed 
instructions for PK blood collection, labeling, processing, sto rage, and shippi[INVESTIGATOR_576875].The pharmacokinetic parameters to be assessed incl ude:
Cmax Maximum observed blood concentration for BMS-986166 and its  major 
metabolite BMS-986166-P 
Maximum observed plasma concentration for branebrutinib
Tmax Time of maximum observed blood or plasma concentration
AUC(0-T) Area under the blood or plasma concentration-time curve from time zero 
to time of last measured concentration wherever applicable
Ctrough Trough observed blood or plasma concentration wherever a pplicable
AUC(TAU) Area under the concentration-time curve in one dosing interval wherever 
applicable
Individual participant pharmac okinetic parameter v alues will be  derived by [CONTACT_105]-compartmental 
methods by a validated pharmacokinetic analysis program. Actual  times w ill be used for the 
analyses.
9.5.[ADDRESS_756727] 8 hours for the Day 1and 
Day 85 visits. As described in Section 2 , Schedule of Activities, the timing of other procedures at 
a given visit can be adjusted so that PK sampling can be perfor med at the scheduled time. If 
possible, PK samples should be co llected from participants who discontinue treatment due to an 
AE. Further details of blood collection and processing will be provided to sites.
Protocol Amendment No.: 01
Date: 30-Jun-2021 94
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Table 9.5.1-1: Pharmacokinetic Sampling Schedule for All Partici pants 
(IM018005)
Study Day of 
Sample CollectionEventTime Relative to 
BMS-986166 or 
Branebrutinib Dose (hr:min)BMS-986166 + 
BMS-986166-P
Blood Sample Branebrutinib 
Plasma 
Sample 
Day 1 (Week 0) 
(Randomization)aPredose 0:00 X X
0:30 X X
1:00 X X
2:00 X X
4:00 X X
6:00 X X
12:00bX
Day 29 (Week 4) Predose 0:00 X
Day 57 (Week 8) Predose 0:00 X
Day 85 (Week 12)aPredose 0:00 X X
0:30 X X
1:00 X X
2:00 X X
4:00 X X
6:00 X X
12:00bX
Day 113 (Week 16) Post Dose 24:00 X
Abbreviations: hr = hour; min = minute
aParticipant is r equired to fast for 8 hours. A light meal/snack  may be provided after the 2-hour PK collection insofar 
as to not interfere with obtaining PK sample.
bSamples collected from consenting participants at selected site s and will be analy zed for BMS-[ADDRESS_756728] be recorded. If samples cannot 
be taken within the specified time, then every effort s hould be made to take a sample as soon as 
possible. 
9.6 Pharmacodynamics
Pharmacodynamic blood samp ling should be performed at the nomin al time(s) specified in this 
clinical protocol. All actual PD bl ood sample collection times w ill be recorded in the source 
Protocol Amendment No.: 01
Date: 30-Jun-2021 95
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
documents and eCRF. Explanation should be provided in the sourc e documents and eCRF for 
missed or mishandled samples and for samples collected outside the following time windows 
(applicable to all parts of the study, as appropriate).
Exploratory analyses may not be conducted in all cohorts or at all timepoints in each cohort. The 
exact analyses and time points for each cohort w ill be communicated to the clinical site 
prospectively. For some exploratory analyses, samples will be c ollected and banked. Sel ect banked 
samples may be analyzed based on emerging PD and/or PK data.The sampling schedule for all biomarkers, including PD biomarke rs, is outlined in Table 9.8-1 . 
All samples will be collected predose.9.6.1 Blood Collection for Immunocyte Profiling
Blood samples will be collected and measured by [CONTACT_576979], but not limited to   Th1, Th 2, Th17, Tem, Tcm, Temra, B-cells 
subsets, basophils, eosinophils, and DCs by [CONTACT_576980].
On days when IP is administered, samples will be collected prior to dosing.
9.6.2 Blood Collection for Plasma Cytokines
Blood samples w ill be collected to explore the in vivo effects of BMS-986166 a nd branebrutinib 
on cytokines and other circulating proteins. Cytokines measured  may include, but not limited to 
TSLP, IFN- Èš, IL-1È˜, IL-1È™, IL-6, IL-17A, IL-17F, IL-31, IL-33, TNF- È˜, CRP, CXCL10, and 
CXCL13.
On days when IP is administered samples will be collected prior to dosing.
9.6.3 Blood Collection for Gene Expression
Blood samples will be collected to explore the effects of BMS-9 [ZIP_CODE] and branebrutinib on gene 
expression from total cells in whole blood or from purified cel l types. Samples will be collected 
and mRNA isolated for assessment of expression levels of genes encoding proteins including, but 
not limited to TSLP, IFN- Èš, IL-1È˜, IL-1È™, IL-6, IL-17A, IL-17F, IL-31, IL-33, TNF- È˜, CRP, 
CXCL10, CXCL13, and Th, B-cell, pDC, and eosinophil associated genes. Whole blood RNA will 
be analyzed pending efficacy results and may not be assessed fo r all time points and tr eatment 
arms.
On days when IP is administered samples will be collected prior to dosing.9.7 Pharmacogenomics
Whole-genome sequencing or singl e-nucleotide polymorphism (SNP)  analysis of DNA may be 
performed to determine if there is a genetic basis associated w ith the response to BMS-986166 
and/or branebrutinib. Variants examined will include, but are n ot limited to, genes with known 
relevance to small-molecule drug distribution and metabolism, a nd to AD pathogenesis such as 
filaggrin (FLG), human leukocyte antigen analyses, and mutation s/SNPs in disease relevant 
pathways such as genes involved in type I IFN signaling and the  JAK/ signal transducer and 
activator of transcription pathway. Epi[INVESTIGATOR_576876].
Protocol Amendment No.: 01
Date: 30-Jun-2021 96
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
9.7.1 ADME Sampling
A 6-mL whole blood sample will be drawn at baseline (Day 1, as indicated in Section 2 Schedule 
of Activities and Table 9.8-1 ) for potential analysis of DNA variants in ADME-related genes (see 
Appendix 16  which contains the lists of ADME-related genes from http://pha rmaadme.org, 
analyses will likely include these genes but may not be limited  to them). Further details of blood 
collection and processing will be provided to the site in the pr ocedure manual.
9.8 Biomarkers
The objectives of the biomarker work are to confirm target enga gement for BMS-986166 (S1PR) 
and branebrutinib (BTK), and to understand the biological conse quences of blocking these 
pathways in AD participants.  
 
 
Samples may also be used to  build or improve assays related 
to the above questions. The biomarker approaches for this study  are discussed in the following 
subsections in greater det ail, and will focus on le ukocyte counts and inflammatory signaling 
molecules in blood (eg, Th2 cells a nd eosinophils in whole bloo d, RAST, Serum IgE, and 
cytokines), gene expression analysis in blood and tissue, patho logic analyses of skin biopsies (eg, 
histology, lymphocyte and neutrophil infiltration, eosinophils,  mast cells), and proteomic/gene 
expression analyses of skin tape strippi[INVESTIGATOR_128876]. Where possi ble, blood and tissue samples will 
be collected at multiple timepoi nts to facilitate longitudinal analyses.
The collection of the stratum c orneum, the uppermost layer of t he epi[INVESTIGATOR_49196], by [CONTACT_12896]-strippi[INVESTIGATOR_576877] a simple and noninvasive manner. This technique 
has been used to determine different skin biomarkers such as in terleukin (IL)-1 cytokines, 
enzymes, lipi[INVESTIGATOR_805], and filaggrin degradation products. Details on the use of tape strippi[INVESTIGATOR_576878]128,129,130,131will be provided in the 
Study Laboratory Manual. 
Measurements may also include, but are not limited to, assessme nts of  SARS-CoV-2  serol ogic 
status. Serum will be collected at baseline and end of study fo r optional measurements of SARS-
CoV-2 serology (anti-SARS-CoV-2 IgM and/or IgG and/or IgA). Fur ther details of sample 
collection and processing for blood, serum, and skin biopsies wi ll be provided to the site in the 
Study Laboratory Manual.
Protocol Amendment No.: 01
Date: 30-Jun-2021 97
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutinib
Table 9.8-1: Biomarker Sampling Schedule All Participants (IM018 005)
Study Day of 
Sample CollectionSerum 
BiomarkersaWhole 
Blood for 
BTK 
OccupancyWhole 
Blood 
Total 
BTK 
pBTKWhole 
Blood 
DNAWhole 
Blood 
Epi[INVESTIGATOR_576879] 
(PAXgene)cFlow 
CytometrySkin 
Tape 
Strippi[INVESTIGATOR_576880] 
(optional)SARS-
CoV-2 
Serology
Day 1 X X X X X X X X X X
Day 8 X X X X
Day 29 X X X XXX X
Day 85 X X X X
Day 113 / EOTX X X XXX X X
Follow Up -Day 127X X X XXX
Follow Up -
Day 169X X X XXX X
Study WithdrawalX
Abbreviations: BTK = Bruton Tyrosine Kinase; DNA = deoxyribonuc leic acid; EOT = end of treatment: RNA = ribonucleic acid
aSerum analyses on Day 8 and Day 85 will be performed if deemed necessary based on efficacy and other biomarker results.
bEpi[INVESTIGATOR_576881].
cWhole blood for all RNAseq (RNA sequencing) time points will be  stored, and analyses will be performed if warranted based on efficacy and other biomarker 
results.
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756729] Engagement Assays
As one of the primary biological roles of S1P signaling is regu lation of tissue/blood leukocyte 
trafficking.132S1P target and pathway engagement will be assessed by [CONTACT_576981] 
(ALC) in blood and tissue assessments of lymphocyte infiltration in AD lesions. 
Blood and tissue analyses of other immune cell populations w ill be assessed in parallel to 
determine if any effects seen are global or specific to subsets of leukocytes.Branebrutinib target engagement will be assessed by a mass-spec trometric based BTK occupancy 
assay and measurement of total BTK in whole blood. 
9.8.[ADDRESS_756730] ce lls, neutrophils, myeloid cells, and 
innate lymphoid cells. A combination of techniques including ge ne expression analyses, ELISA 
or other protein measurements for serum IgE and cytokines, prot eomic/gene expression analyses 
of skin tape strippi[INVESTIGATOR_128876], autoantibodies, and clinical ch emistry tests such as RAST and 
serum surrogates of mast cell activation will be used to build a comprehensive pi[INVESTIGATOR_576882] S1P inhibition. Genetic analyses will include, but are not 
limited to mutations in the Filaggrin gene (FLG), with FLG potentially informing on disease 
mechanisms relevant to pediatric vs. adult AD in particular.
24,[ADDRESS_756731] via ble blood/serum surrogates and 
what can only be assessed accurately from biopsies. Immune cell  trafficking, expected to be one 
of the major phenomena affected by [CONTACT_20444]-986166, is expected to f all into the category of those 
requiring tissue assessment. Skin punch biopsies will be taken at baseline and at end of treatment, 
and either frozen, placed in formalin, or sent into an equivale nt process as appropriate for the 
experimental end use of the material (ie, separate processing f or RNA extraction). Details for the 
biopsy procedures will be provided in the Study Laboratory Manu al. 
Extra serum, plasma and whole blood for DNA and RNA will be tak en to explore pathways 
impacted by [CONTACT_576982]-[ADDRESS_756732] or directed 
profiling of gene expression.
Protocol Amendment No.: 01
Date: 30-Jun-2021 99
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Biomarker samples will be co llected in the appropriate collecti on tubes or devices at the times 
indicated in Table 9.8-1 .
Allowed windows of biomarker assessments will be detailed in th e lab manual. 
Biomarker samples will be shipped to a central and contracted laboratories for the analytical 
assessments for the measurement of the following exploratory bi omarkers: 
â€¢Target engagement assay, mass-spectrometric BTK occupancy assay  (branebrutinib), or ALC 
(BMS-986166) 
â€¢Pathway engagement: ALC / assessment of immune cell infiltrate in AD skin lesions 
(BMS-986166) 
â€¢Immune cell counts from whole blood
â€¢Leukocyte profili ng from whole blood
â€¢Eosinophil and basophil profiling from whole blood
â€¢Serum cytokines, inflammatory markers, and soluble proteins 
â€¢Clinical chemistry measures of mast cell activity in serum (eg, serum histamine) 
â€¢Extra serum (explore pathway, disease and drug effects) 
â€¢Extra plasma (explore pathway, disease and drug effects) 
â€¢RNA from whole blood
â€¢DNA from whole blood
â€¢RNA and cytokine analyses 
â€¢Skin tape strippi[INVESTIGATOR_576883] / gene expression ana lyses
â€¢Skin biopsy  (optional)
â€¢Pathologic analyses of skin and immune cell populations in punc h biopsies (optional) 
â€¢Gene expression and cytokine analyses in skin biopsies (optional)
Details for collection, pro cessing, storing, and shippi[INVESTIGATOR_576884].
9.8.3 Additional Research Collection
This protocol will include sample collection and/or residual sa mple storage for additional research 
(AR).
For All US sites:
Additional research is required for all study participants, exc ept where prohibited by [CONTACT_1202]/ethics 
committees , or academic/institutional requirements. Where one or more of the se exceptions 
occurs, participation in the additional research should be encouraged but will not be a condition of 
overall study participation.
Protocol Amendment No.: 01
Date: 30-Jun-2021 100
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
â€¢If the IRB/ethics committees and site agree to the mandatory ad ditional research retention 
and/or collection, then the study participant must agree to the  mandatory additional research 
as a requirement for inclusion in the study.
â€¢If optional participation is permitted and approved, then the s tudy participants may opt out of 
the additional research retention and/or collection.
For non-US Sites
Additional research is optional for all study participants, exc ept where retention and/or collection 
is prohibited by [CONTACT_44896], ethics committees, or institutional requirements. 
This collection for additional research is intended to expand t he translational R&D capability at 
Bristol-Myers Squibb, and will s upport as yet undefined research aims that will advance our 
understanding of disease and options for treatment. It may also be used to support health authority 
requests for analysis, and advancement of pharmacodiagnostic development to better target drugs 
to the right participants. This may also include genetic/genomi c exploration aimed at exploring 
disease pathways, progression and response to treatment etc. 
Sample Collection and Storage
All requests for access to samples or data for additional resea rch will be vetted through a diverse 
committee of the study sponsorâ€™s senior leaders in Research and  Development (or designee) to 
ensure the research supports appropriate and well-defined scien tific research activities.
â€¢Prospective samples of serum, whole blood, and plasma w ill be collected a t selected time 
points (see Table 9.8.3-1 )
â€¢Residual samples of all types from all test co llections (see Table 9.8.3-2 ) will also be retained 
for additional research purposes
Samples kept for future research will be stored at the BMS Bior epository in New Jersey, [LOCATION_003] or
an independent, BMS-approved storage vendor.
The manager of these samples will ensure they are properly used  throughout their usable life and 
will destroy the samples at the end of the scheduled storage pe riod, no longer than fifteen (15) 
years after the end of the st udy or the maximum allowed by [CONTACT_1289].
Transfers of samples by [CONTACT_193615][INVESTIGATOR_841]â€™s 
agreement to establish similar storage procedures.Samples will be stored in a coded fashion, and no researcher wi ll have access to the key. The key 
is securely held by [CONTACT_576983], so t here is no direct ability for a researcher 
to connect a sample to a specific individual.Further details of sample collection and processing w ill be provided to the site in the procedure 
manual.
Protocol Amendment No.: 01
Date: 30-Jun-2021 101
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Table 9.8.3-1: Prospective Additional Research Sampling Schedule
Study DayTime 
(Event)
HourTime 
(Relative To 
Dosing)
Hour: MinBlood SampleSerum 
SamplePlasma 
Sample
Day 1 0 (predose) 00:00 X X X
Day 8 0 (predose) 00:00 X X X
Day 15 0 (predose) 00:00 X X X
Day 29 0 (predose) 00:00 X X X
Day 57 0 (predose) 00:00 X X X
Day 85 0 (predose) 00:00 X X X
Day 113/EOT 0 (predose) X X X
Day 127/Final 
Follow-up Visit0X X X
Day 169 0 X X X
Abbreviations: EOT = end of treatment: min = minute
Table 9.8.3-2: Residual Sample Retention for Additional Research Schedule
Sample Type Timepoints for which residual samples will be retained
Plasma All
Whole Blood All
Serum All
Skin Biopsy All
9.9 Health Economics OR Medical Resource Utilization and Health 
Economics
Health Economics/Medical Resource Utilization and Health Econom ics parameters w ill not be 
evaluated in this study.
10 STATISTICAL CONSIDERATIONS
10.1 Sample Size Determination
The sample size calculation is driven by [CONTACT_576913] m ean percentage change from 
baseline in EASI score at Week 16 between BMS-986166 or branebr utinib versus placebo. 
Thirty participants per group will provide 84% power to detect a treatment difference (versus 
placebo) of 30 % at the type I error of Î± = 0.05 (1-sided), assu ming a common standard deviation 
of 43%. The assumed treatment difference of 30% is similar to the mean difference observed from 
historical data on approved drugs across different mechanism of  actions. No adjustment will be 
made for multiplicity.
Protocol Amendment No.: 01
Date: 30-Jun-2021 102
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Assuming a 15% dropout rate (ie, the  fraction of participants not completing Week 16 assessment), 
25 participants per group will still provide 78% power to detect  a treatment difference of 30%.
10.2 Populations for Analyses
For purposes of analysis, the following populations are defined :
Population Description
Enrolled All participants who sign informed consent
Randomized All participants who are randomized to a treatment
Treated All participants who take at least 1 dose of study treat ment
modified Intent-To-Treat 
(mITT)All participants who are randomized and received at least one d ose 
of study treatment
Safety All randomized participants who take at least 1 dose of d ouble-
blind study treatmen t. Participants will be included in the 
treatment group they were randomized to, except in the following  
cases:
â€¢If a participant received the same incorrect treatment 
throughout the study, then the participant w ill be analyzed 
based on the treatment received.
â€¢If a participant received study drug from more than one 
treatment group, and none of the administrations were 
consistent with the assigned randomized treatment group, then 
the participant will be analyzed based on the first non-placebo  
treatment received.
â€¢If a participant is rando mized to placebo treatment and 
receives non-placebo treatment, then the participant w ill be 
analyzed based on the first non-placebo treatment received.
Pharmacokinetic All participants who received any corresponding study drug and 
have any available concentration-time data
Biomarker All participants that received any study treatment and  have any 
available biomarker measurement
Safety analysis will be based on Safety population, participants will be analy zed as per actual 
treatment received. E fficacy analysis will be based on mITT pop ulation, participants will be 
analyzed as per randomized treatment.
10.[ADDRESS_756733] ical analyses described in this sectio n. This 
Protocol Amendment No.: 01
Date: 30-Jun-2021 103
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
section is a summary of planned statistical analyses of the mos t important endpoints including 
primary and secondary endpoints.
A description of the participant population will be included in  a statistical output report, including 
subgroups of age, gender and race.
10.3.1 Efficacy Analyses
[IP_ADDRESS] Primary EndpointThe primary efficacy endpoint is mean percent change  from baseline in EASI score at Week 16.
A mixed effect model will be fit with treatment, visit and trea tment-by [CONTACT_576984] d measurements. Adjusted mean 
% change (LSMEAN) and unadjusted mean % change with correspondi ng 95% CI per treatment 
group w ill be provided. The di fference in adjusted means and corresponding 95 % CIs will be 
provided for the difference between active treatment groups and  placebo group at different visits 
(week 16 for primary endpoints). P-value will be provided for d ifference at Week 16. 
[IP_ADDRESS] Secondary Endpoint
The secondary efficacy endpoints are: 
â€¢Proportion of participants exhibiting a vIGA-AD score of 0 (cle ared) or 1 (almost cleared) 
AND a â‰¥ 2 point reduction from Baseline at Week 16; 
â€¢Proportions of participants exhibiting a â‰¥ 50% (EASI-50) reduct ion from baseline in EASI 
score at Week 16
â€¢Proportion of participants exhibiting a â‰¥ 4 point improvement from baseline in Pruritus NRS 
at Week 16.
â€¢Mean percentage change from baseline in Pruritus NRS at Week 16
â€¢Mean change from baseline in percentage of affected BSA at Week  16
For categorical (proportion) e ndpoints, the estimate and its corresponding 95% CI of each 
treatment  group will be estimated using Cl opper-Pearson method. The difference of the proportion 
between active treatments and the placebo will be estimated and  their corresponding 95% CI will 
be calculated.
All participants discontinuing prematurely prior to Week 16, re gardless of reason, will be counted 
as non-responders at subsequent visits. 
For continuous (percent change from baseline and change from ba seline) endpoints, the similar 
mixed effect model (as used in Section [IP_ADDRESS]) will be fit with treatment, visit, and treatment-by 
[CONTACT_576985]. The baseline value will be added into the model a s a covariate if necessary, for 
change from baseline endpoints. Adjusted mean % change (LSMEAN) and unadjusted mean % 
change with corresponding 95% CI per treatment group w ill be provided. The difference in 
adjusted means and corresponding 95% CIs w ill be provided for the difference between active 
treatment groups and placebo group at specific visits (eg, week  16 for secondary endpoints).
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756734] results will be listed  and summarized by [CONTACT_3148]. Any 
significant clinical la boratory results will be listed. ECG readings will be evalu ated by [CONTACT_576986], if present, will be listed. 
10.3.3 Other Analyses
PK, PD/biomarker and additionally efficacy exploratory analyses  will be described in the statistical 
analysis plan finalized before database lock. The population PK  analysis and PD analyses will be 
presented separately from the main clinical study report. 
10.3.4 Interim Analyses
When approximately 50% of the participants reached Week 16 or d iscontinued, an interim analysis 
(IA) for safety and efficacy will be performed to accelerate in ternal decision making. The safety 
analysis will focus on incidence and severity of AE, and SAE. T he efficacy analysis will focus on 
percent change from baseline in EASI score and proportion of pa rticipants with â‰¥ [ADDRESS_756735] ical Analysis Plan w ill further describe the planned interim analyses.
Protocol Amendment No.: 01
Date: 30-Jun-2021 105
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
11 REFERENCES
1Sacotte R, Silverberg JI. Epi[INVESTIGATOR_576885]. Clin Dermatol. 
2018;36(5):595-605.
2Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR; In ternational Study of 
Asthma and Allergies in Childhood (ISAAC) Phase One and Three S tudy Groups. Is eczema 
really on the increase worldwid e? J Allergy Clin Immunol 2008;1 21(4):947â€“54.
3Kang K, Polster AM, Nedorost ST, et al. Atopic dermatitis. In: Dermatology, Bolognia JL, 
Jorizzo JL, Rapi[INVESTIGATOR_576886], et al (Eds), Mosby, [LOCATION_001] 2003. p.199 .
4Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic de rmatitis from 
adolescence to adulthood in the TOACS cohort: prevalence, persi stence and comorbidities. 
Allergy. 2015;70(7):836-45.
5SandstrÃ¶m MH, Faergemann J. Prognosis and prognostic factors in adult patients with atopic 
dermatitis: a long-term follow-up questionnaire study. Br J Dermatol. 2004;150(1):103-10.
6Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic Derma titis in America Study: A 
Cross-Sectional Study Examining the Prevalence and Disease Burd en of Atopic Dermatitis in 
the US Adult Population. J Invest Dermatol. 2019;139(3):583-[ADDRESS_756736]  of atopic dermatitis  on health-related quality of life 
and productivity in adults in the [LOCATION_002]: An analysis us ing the National Health and 
Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-279.
8Chandra RK, Lin D, Tan B, et al. Chronic rhinosinusitis in the se tting of other chronic 
inflammatory diseases. Am J Otolaryngol 2011; 32(5): 388â€“91.
9Mallol J, Crane J, Mutius E von, et. al. The International Study  of Asthma and Allergies in 
Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr) 
2013;41(2):73â€“85.
10Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: A practice parameter update 2012. J 
Allergy Clin Immunol. 2013;131(2):295-9.
11Adamson AS. The Economics Burden of Atopic Dermatitis. Adv Exp Med Biol. 
2017;1027:79-92.
12Kelleher M, Dunn-Galvin A, Hourihane J Oâ€™B, et. al. Skin barrier dysfunction measured by 
[CONTACT_170583][INVESTIGATOR_207965] 2 days and 2 months predates and p redicts atopic dermatitis at 1 
year. J Allergy Clin Immunol. 2015;135(4):930-5.
13Flohr C, England K, Radulovic S, et. al. Filaggrin loss-of-func tion mutations are associated 
with early-onset eczema, eczema severity and transepi[INVESTIGATOR_576887] 3 months of age. Br 
J Dermatol. 2010;163(6):1333-6.
Protocol Amendment No.: 01
Date: 30-Jun-2021 106
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
14Gupta J, Grube E, Ericksen MB, et. al. Intrinsically defective skin barrier function in children 
with atopic dermatitis correlates with disease severity. J Alle rgy Clin Immunol. 
2008;121(3):725-730.
15Boguniewicz M, Leung DYM. Atopic de rmatitis: a disease of alter ed skin barrier and immune 
dysregulation. Immunol Rev. 2011;242(1):233-46.
16Akdis C A, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children 
and adults: European Academy of Allergology and Clinical Immuno logy/ American Academy 
of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 
2006;118(1):152-169.
17Novak N, T. Bieber. Allergic and nonallergic forms of atopic dis eases. J Allergy Clin Immunol. 
2003; 112(2):252-262.
18Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis 
and psoriasis--part I: clinical and pathologic concepts. J Alle rgy Clin Immunol. 
2011;127(5):1110-8.
19Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic ther apeutics in atopic 
dermatitis. Expert O pin Biol The r. 2013;13(4):549-61.
20Kabashima K. New concept of the pathogenesis of atopic dermatit is: interplay among the 
barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 20 13;70(1):3-11.
21Holmes J, Fairclough LC, Todd I. Atopic dermatitis and autoimmun ity: the occurrence of 
autoantibodies and their association with disease severity. Arc h Dermatol Res. 2019; 
311(3):141-162; 2020;312(5):393.
22Alexander H, Patton T, Jabbar-Lopez ZK, et. al. Novel systemic therapi[INVESTIGATOR_576888]: 
what do we need to fulfil the promise of a treatment revolution ?. F1000Res. 2019;8:F1000 
Faculty Rev-132.
23Muraro A, Lemanske RF Jr, Hellings PW, et al. Precision medicine  in patients with allergic 
diseases: Airway diseases and atopic dermatitis-PRACTALL docume nt of the European 
Academy of Allergy and Clinical Immunology a nd the Amer ican Academy of Allergy, Asthma 
& Immunology. J Allergy Clin Immunol. 2016;137(5):1347-58.
24Czarnowicki T, He H, Krueger J, Guttman-Yassky E. Atopic dermat itis endotypes and 
implications for targeted therapeutics. J Allergy Clin Immunol.  2019;143(1):1-11.
25FDA. Medical Review, Dupi[INVESTIGATOR_576889] 761055Orig1s000. 2016.
26Simpson E, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trial s of Dupi[INVESTIGATOR_576890]. N Eng J Med 2016;375(24):2335-48.
27Guttman-Yassky E, Nograles K, Krueger J. Contrasting pathogenes is of atopic dermatitis and 
psoriasis--part II: immune cell subsets and therapeutic concept s. J Allergy Clin Imm unol. 
2011;127(6):1420-32.
28Weidinger S, Beck L, Bieber T, et. al. Atopic dermatitis. Nat Re v Dis Primers. 2018;4(1):1.
Protocol Amendment No.: 01
Date: 30-Jun-2021 107
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
29AriÃ«ns L, Bakker D, van der Schaft J, Garritsen FM, Thijs JL, d e Bruin-Weller MS. Dupi[INVESTIGATOR_576891]: rationale, latest evidence and place in t herapy. Ther Adv Chronic Dis. 
2018;9(9):159-170.
30Kabashima K, Matsumura T, Komazaki H, et. al. Trial of Nemo lizumab and Topi[INVESTIGATOR_576892]. N Engl J Med. 2020;383(2): 141-150.
31Ruzicka T, Hanifin JM, Furue M, et al. Anti-Interleukin-31 Recep tor A Antibody f or Atopic 
Dermatitis. N Engl J Med. 2017;376(9):826-835.
32Hla T. Physiological and pathological actions of sphingosine 1- phosphate Semin Cell Dev Biol 
2004;15(5):513-20.
33Stepanovska B, Huwiler A. Targeti ng the S1P receptor signaling pathways as a promising 
approach for treatment of autoimmune and inflammatory diseases.  Pharmacol Res. 
2020;154:104170.
34Herzinger T, Kleuser B, SchÃ¤fer-Korting M, et. al. Sphingosine- 1-phosphate signaling and the 
skin. Am J Clin Dermatol. 2007;8(6):329-36; 2008;9(4):277.
35Allende ML, Sipe LM, Tuymetova G, et. al. Sphingosine-1-phospha te phosphatase 1 regulates 
keratinocyte differentiation and epi[INVESTIGATOR_576893]. J Biol Chem. 2013;288(25):[ZIP_CODE]-91.
36Jeon S, Song J, Lee D, et al. Inhibition of sphingosine 1-phosp hate lyase activates human 
keratinocyte differentiation and attenuates psoriasis in mice. J Lipid Res. 2020;61(1):20-32.
37ADVISE. https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED] 
38S1P Receptor Modulator BMS-986166 Investigatorâ€™s Brochure, Versi on 03. Bristol-Myers 
Squibb Company, 2021. Document Control No. 930097755.
39Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and Saf ety of Oral Janus Kinase 1 
Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Ph ase 2 Randomized Clin ical 
Trial JAMA Dermatol. 2019;155(12):1371-1379.
40Simpson E et al. Poster presented at: 28th EADV Congress; Octob er 9-13, 2019; Madrid, 
Spain.
41Guttman-Yassky E, ThaÃ§i D, Pangan AL, et al. Upadacitinib in ad ults with moderate to severe 
atopic dermatitis: 16-week results from a randomized, placebo-c ontrolled trial. J Allergy Clin 
Immunol. 2020;145(3):877-884.
42Smith CI, Baskin B, Humire-Greiff P, et al. Expression of Bruton's agammaglobulinemia 
tyrosine kinase gene, BTK, is s electively down-re gulated in T l ymphocytes and plasma cells. 
J Immunol 1994;152(2):557-65.
43Middendorp S, Dingjan GM, Maas A, et al. Function of Bruton's tyrosine kinase during B cell development is partially indepe ndent of its cataly tic activity.  J Immunol 2003;171(11):5988-
96.
Protocol Amendment No.: 01
Date: 30-Jun-2021 108
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
44Chang BY, Huang MM, [LOCATION_009]sco M, et al. The Bruton tyrosine kin ase inhibitor PCI-[ZIP_CODE]
ameliorates auto immune arthritis by [CONTACT_576987]. Arthritis Res Ther 
2011;13(4):R115.
45Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell- and myeloid 
cell-mediated arthritis. Nat Chem Biol 2011;7(1):41-50.
46Xu D, Kim Y, Postelnek J, et al. RN486, a selective Bruton's ty rosine kinase inhibitor, 
abrogates immune hypersensitivity  responses and arthritis in ro dents. J Pharmacol Exp Ther 
2012;341(1):90-103.
47Branebrutinib BMS-986195 Investigator's Brochure, Version 06. B ristol-Myers Squibb 
Company, 2020. Docume nt Control No. 930097752.
48Szilveszter KP, NÃ©meth T, MÃ³csai A. Tyrosine Kinases in Autoimm une and Inflammatory 
Skin Diseases. Front Immunol. 2019;10:1862. 
49Rankovic Z, Brust TF, Bohn LM. Biased agonis m: An emerging para digm in GPCR drug 
discovery. Bi oorg Med Chem Lett. 2016;26(2):241- 250.
50Evaluation of S1PR1 Modulator BMS-986166 in an Animal Model of Atopic Dermatitis. 
Study IM00331. Bristol-Myers Squibb Company; 2021. Document Contr ol No. 930163082. 
51Wedman PA, Aladhami A, Chumanevich AP, et. al. Mast cells and s phingosine-1-phosphate 
underlie prelesional remodeling in a mouse model of eczema. Allergy. 2018;73(2):405-415.
52Yoon SB, Lee CH, Kim HY, et al. A  novel sphingosylphosphorylcho line and sphingosine-1-
phosphate receptor [ADDRESS_756737], KRO-105714, for alleviating at opic dermatitis. J Inflamm 
(Lond). 2020;17:20.
53BMS-986166: 6-Month Or al Gavage Toxicity Study in Rats, with an  8-week Recovery Period 
(Study DN17005). Bristol-Myers S quibb Company; 2018. Document C ontrol No. 930127381.
54BMS-986166: 9-Month Oral Toxicity Study in Beagle Dogs, with a 12-week Post-Dose 
Recovery Period (Study DN16259). Bristol-Myers Squibb Company; 2 018 Document Control 
No. 930131924.
55Nonclinical evaluation of the pharmacokinetics and metabolism o f BMS-986166. Bristol-
Myers Squibb Company; 2016. Document Control No. 930101208.
56In vitro characterization of abs orption, distribut ion, metaboli sm, and elimination properties of 
BMS-986166. Bristol-Myers Squi bb Company, 2015. Document Contro l No. 930086619.
57BMS-986195: Characterization of the irreversible BTK inhibitor BMS-986195 in biochemical 
and human immune cell assays (Study IM00086). Bristol-Myers Squ ibb Company; 2016. 
Document Control No. 930096590.
58BMS-986195: In vivo pre-clinical pharmacol ogy of the irreversib le BTK inhibitor 
BMS-986195 in mice (Study IM [ZIP_CODE]). Bristol-Myers Squibb Company; 2016. Document 
Control No. 930096587.
Protocol Amendment No.: 01
Date: 30-Jun-2021 109
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
59BMS-986195: 6-month oral toxicity study in rats, with a 5-week recovery period (Study 
DN16062). Bristol-Myers Squibb Company; 2017. Document Control No. 930116391.
60Erickson RI, Schutt LK, Tarrant JM, et al. Bruton's Tyrosine Kinase Small Molecule Inhibitors 
Induce a Distinct Pancreatic Toxicity in Rats. J Pharmacol Exp Ther 2017;360(1):226-238.
61BMT-136986: Two-week exploratory toxicity study in rats (Study DN15006). Bristol-Myers 
Squibb Company; 2015. Docum ent Control  No. 930096737.
62BMS-986195: One-month Oral Toxicity Study in Rats with a Two-we ek Post-dose Recovery 
(Study DM15036). Bristol-Myers Squibb Company; 2016. Document C ontrol No. 930097403.
63BMS-986195: One-month Oral Toxicity Study in Rats (Study DM1600 5). Bristol-Myers 
Squibb Company; 2016. Document Control No. 930103158.
64BMS-986195: 9-month oral tox icity study in beagle dogs with a 4-week recovery period (Study  
DN16030). Bristol-Myers Squibb Company; 2017. Document Control No. 930116257.
65Randomized, placebo-controlled, single and multiple ascending d ose study to evaluate the 
safety, tolerability, pharmacokinetics (PK) and pharmacodynamic s (PD), and nonrandomized, 
bioavailability (BA) study of  BMS-986195 in healthy subjects (C linical Protocol IM014001). 
Bristol-Myers Squibb Research and Development; 2016. Document C ontrol No. 930093934.
66Liu, FT, Goodar zi, H, Chen, H. IgE, mast cells, and eosinophils  in atopic dermatitis. Clin Rev 
Allerg Immunol 2011;41(3):298-310.
67Sidbury R, Davis DM, Cohen DE, et .al. Guidelines of care for the  management of atopic 
dermatitis: section 3. Management and treatment with photothera py and systemic agents. J Am 
Acad Dermatol. 2014: 71(2):327-49 .
68Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Effica cy and safety of systemic 
treatments for moderate-to-severe atopic dermatitis: a systemat ic review. J Allergy Clin 
Immunol. 2014;133(2):429â€“38.
69Gilenya (fingolimod) [prescribing information]. East Hanover, NJ: [COMPANY_001] Pharmaceu ticals 
Corporation; December 2019.
70BÃ¤umer W, Rossbach K, Mischke R, et. al. Decreased concentration and enhanced metabolism 
of sphingosine-1-phosphate in lesional skin of dogs with atopic  dermatitis: disturbed 
sphingosine-1-phosphate homeostasis in atopic dermatitis. J Invest Dermatol. 
2011;131(1):266â€“8.
71Cohen S, Tuckwell K, Katsumoto TR, et al. Fenebrutinib versus P lacebo or Adalimumab in 
Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study). Arthritis 
Rheumatol. 2020;10.1002/art.[ZIP_CODE].
72Effects of concomitant administration of BMS-986195 on the sing le-dose pharmacokinetics of 
methotrexate and probe substrates for cytochrome P450 1a2, 2c8,  2c9, 2cl9, 3a4, organic anion 
transporter polypeptide 1b1 and P-glycoprotein in healthy parti cipants (Study IM014013); 
Clinical Study Report. Bristol-Myers Squibb; 2018. Document Con trol No. 930126532.
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756738] of BMS-986195 on the pharmacokinetics of a combined oral contraceptive (Ethinyl 
Estradiol/Norethindrone) in healthy female subjects (Study IM01 4023). Bristol-Myers Squibb 
Company; 2018. Document Control No. 930 152299.
74Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrilla tion with ibrutinib use: a systematic 
review and meta-analysis. Blood. 2016; 128(1):138â€“140. 
75Imbruvica (ibrutinib) [product monograph]. Toronto, Ontario, Ca nada: Janssen Inc; December 
2020.
76Xiao L, Salem JE, Clauss S, et al. Ibrutinib-med iated atrial fibrillation a ttributable to Inhibition 
of C-Terminal Src Kinase. Circulation. 2020;142(25):2443-2455.
77McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the ri sk of atrial fibrillation, 
potentially through inhibition of cardiac PI3K-Akt signaling. B lood. 2014;124(25):3829-30.
78Shafaattalab S, Lin E, Christidi E, et al. Ibrutinib displays atr ial-specific toxicity in human 
stem cell-derived cardiomyocytes. Stem Cell Reports. 2019;12(5) :996-1006 .
79Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: re view and applications 
to Phase 3 vaccine candidates. Lancet 2020;396([ZIP_CODE]):1595-606.
80Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. NEJM 2020;383(25):2451-60.
81Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in  B-cell malignancy. Int Rev 
Immunol 2012;31(2):119-32.
82Roman-Garcia S, Merino-Cortes SV, Gardeta SR, et al. Distinct r oles for Brutonâ€™s tyrosine 
kinase in B cell immune synapse formation. Front Immunol 2018;9 :2027.
83El-Sayed ZA, Abramova I, Aldave JC, et al. X-linked agammaglobu linemia 
(XLA):Phenotype, diagnosis, and therapeutic challenges around t he world. World Allergy 
Organ J 2019;12(3):100018.
84Quinti I, Lougaris V, Milito C, et al. A possible role for B ce lls in COVID-19? Lesson from 
patients with agammaglobulinemia. J Allergy Clin Immunol 2020;1 46(1):211-3.e4.
85Buckland MS, Galloway JB, Fhogar taigh CN, et al. Treatment of C OVID-19 with remdesivir 
in the absence of humoral immunity: a case report. Nat Commun 2 020;11(1):6385.
86M i r a  E ,  Y a r c e  O A ,  O r t e g a  C ,  e t  a l .  R a p i d  r e c o v e r y  o f  a  S A R S - C o V -2-infected X-linked 
agammaglobulinemia patient after infusion of COVID-[ADDRESS_756739] 2020;8(8):2793-5.
87Soresina A, Moratto D, Chiarini M, et al. Two X-linked agammagl obulinemia patients develop 
pneumonia as COVID-19 manifestation but recover. Pediatr Allerg y Immunol 
2020;31(5):565-9.
88Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ib rutinib may protect against 
pulmonary injury in COVID-19-infected patients. Blood 2020;135(21):1912-5.
89Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bru ton tyrosine kinase in patients 
with severe COVID-19. S ci Immunol 2020; 5(48):eabd0110.
Protocol Amendment No.: 01
Date: 30-Jun-2021 111
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
90Mikuls TR, Johnson SR, Fraenkel L, et al. American Co llege of Rheumatology guidance for 
the management of rheumatic disease in adult patients during th e COVID-19 pandemic: 
Version 3. Arthritis Rheumatol 2021;73(2):e1-12.
91Schulze-Koops H, KrÃ¼ger K, Hoyer BF, et al. Updated recommendat ions of the German 
Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in 
times of SARS-CoV-2 methodology, key messages and justifying in formation. Rheumatology 
2021;60(5):2128-33.
92Au K, Reed G, Curtis JR, et al. High disease activity is associ ated with an increased risk of 
infection in patients with rheu matoid arthritis. Ann Rheum Dis 2011;70(5):785-91.
93Pi[INVESTIGATOR_138713]-Quiroz VR, Ugarte-Gil MF, Harvey GB, et al. Factors pr edictive of serious infections 
over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, 
Latin American lupus cohort. Lupus 2019;28(9):1101-10.
94Hyrich KL, Machado PM. Rheumatic disease and COVID-19: epi[INVESTIGATOR_576894]. 
Nat Rev Rheumatol 2021;17(2):71-2.
95Davies NG, Klepac P, Liu Y, et al. Age-dependent effects in the  transmission and control of 
COVID-19 epi[INVESTIGATOR_7509]. Nat Med. 2020;26(8):1205-1211. 
96Li H, Wang S, Zhong F, et al. Age-dependent risks of incidence and mortality of COVID-19 
in Hubei Province and other parts of China. Front Med (Lausanne). 2020;7:190. 
97Liu Y, Mao B, Liang S, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J. 2020;55(5):2001112. 
98Comirnaty. Summary of Product Characteristics. BioNTech Manufacturing GmbH; 2021.
99COVID-[ADDRESS_756740] Characteristics. M oderna Biotech Spain, 
S.L.; 2021.
100Vaxzevria. Summary of Product Characteristics. [COMPANY_008] AB; 2021.
101COVID-[ADDRESS_756741] Characteristics. J anssen-Cilag International 
NV; 2021.
102Pfaar O, Klimek L, Hamelmann E, et al. COVID-19 vaccination of p atients with allergies and 
type-2 inflammation wi th concurrent antibody therapy (biologica ls)- A Position Paper of the 
German Society of Allergology and Clinical Immunology (DGAKI) and the German Society 
for Applied Allergology (Ae DA). Allergol Select 2021 5 140-7.
103Hamilton JD, SuÃ¡rez-FariÃ±as M, Dhingra N. et al. Dupi[INVESTIGATOR_576895]-to-severe atopic de rmatitis. J Allergy Clin 
Immunol. 2014;134(6):1293-1300.
104Tofte SJ, Papp K., Sadick N, et al. Efficacy and safety of dupil umab for the treatment of 
moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase [ADDRESS_756742]. 2018;30(9):529-541.
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756743] Dermatol. 2019;139(5):1063-107 2.
106Beck LA, ThaÃ§i D, Hamilton JD, et al. Dupi[INVESTIGATOR_576896]-to-severe 
atopic dermatitis. N Engl J Med. 2014;371(2):130-9.
107Lee J-Y, Wang Y. Use of a biomarker in exposure-response analys is to support dose selection 
for fingolimod. CPT Pharmacometrics Syst Pharmacol. 2013;2(8):e 67.
108Kaufmann M, Haase R, Proschmann U, et. al. R eal World Lab D ata: Patterns of Lymphocyte 
Counts in Fingolimod Treated Patients. Front Immunol. 2018;9:26 69.
109Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic derma titis. J Am Acad Dermatol. 
2014;70(2):338-51.
110Levey AS, Stevens LA, Schmid CH, et al. A new equation to estim ate glomerular filtration 
rate. Ann Intern Med. 2009;150(9):604-12; 2011;155(6):408.
111Williams B, Mancia G, Spi[INVESTIGATOR_110971] W,  et al. 2018 Practice Guidelin es for the management of 
arterial hypertension of the European Society of Hypertension a nd the European Society of 
Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 
2018;36(12):2284-2309.
112Simpson E, Bissonnette R, Eichenfield LF, et al. â€œThe Validated  Investigator Global 
Assessment for Atopic Dermatitis (vIGA-AD): The development and  reliability testing of a 
novel clinical outcome measurement instrument for the severity of atopic dermatitis.â€ J. Am. 
Acad Dermol 2020; 83(3);839-846.
113Hanifin JM, Thurston M, Omoto M , et al. The eczema area and sev erity index (EASI): 
assessment of reliability in atopic dermatitis. Exp Dermatol 20 01; 10(1):11-8.
114Charman CR, Venn AJ, Williams HC. Measurement of body surface a rea involvement in 
atopic eczema: an impossible task?. Br J Dermatol. 1999;140(1): 109-11.
115Severity scoring of atopic dermatitis: the SCORAD Index. Consen sus report of the European 
Task Force on Atopic Dermatitis. Dermatology 1993;186(1):23-31.
116Martin S, Chandran A, Zografos L, et. al. Evaluation of the imp act of fibromyalgia on patientsâ€™ 
sleep and the content validity of two sleep scales. Health Qual L ife Outcomes 2009;7:64.
117Reich A, Heisig M, Phan NQ, et. al. Visual anal ogue s cale: evaluation of the instrument for 
the assessment of pruritus. Acta Derm Venereol 2012;92(5):497-5 01.
118Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a si mple practical measure 
for routine clinical use. Clin Exp Dermatol 1994;19(3):210â€“6.
119Kovarik JM, Slade A, Riviere GJ, et. al. The ability of atropi[INVESTIGATOR_576897] h ealthy sub jects. Br J Clin Pharmacol. 
2008;66(2):199-206. 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756744] induce ubiquitinylation and proteasomal degradation of the 
receptor. J Biol Chem 2007; 282(12):9082-9.
121Miron VE, Schubart A and Antel JP. Central nervous system-direc ted effects of FTY720 
(fingolimod). J Neuro Sci 2008;274(1-2):13-7.
122A Randomized, D ouble-blinded, P lacebo-controlled, Single Ascending Dose Study to 
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharma codynamics of BMS-986166 
in Healthy Subjects. Clin ical Study Report A ddendum to Study IM018001. Bristol-Myers 
Squibb; 2021. Document Control No. 930158432.
123A Randomized, Double Blind, P lacebo-controlled, Multiple Ascending Dose Study to 
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmac odynamics of BMS-986166 
in Healthy Subjects. Clin ical Study Re port Adde ndum to Study IM018003 . Bristol-Myers 
Squibb; 2021. Document Control No. 930158483. 
124Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the s ingle-breath determination of 
carbon monoxide uptake in the lung. Eur Respir J 2005;26(4):720- 35.
125Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur 
Respir J 2005;26(1):153-61.
126Miller MR, Hankinson J, Brusasco V, et al. Standardisation of s pi[INVESTIGATOR_038]. Eur Respir J 
2005;26(2):319-38.
127Mandal P, Gupta A, Fusi-Rubiano W et al. Fingolimod: therapeuti c mechanisms and ocular 
adverse effects. Eye (Lond) 2017; 31(2):232-240.
128Olesen CM, Pavel AB, Wu J, et. al. Tape-strips provide a minima lly invasive approach to track 
therapeutic response to topi[INVESTIGATOR_576898]. J A llergy Clin 
Immunol Pract. 2020; S2213-2198(20)[ZIP_CODE]-2.
129He H, Bissonnette R, Wu J, et. al. Tape strips detect distinct immune and barrier profiles in 
atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2020; S0091-6749(20)[ZIP_CODE]-1.
130Pavel AB, Renert-Yuval Y, Wu J, et. al. Tape strips from early-o nset pediatric atopic dermatitis 
highlight disease abnormalities in nonlesional skin. Allergy. [ADDRESS_756745] 9;155(12):1358-70.
132Matloubian M, Lo CG, Cinamon G, et. al. Lymphocyte egress from t hymus and peripheral
lymphoid organs is dependent on S1P receptor 1. Nature. 2004; 4 27(6972):355-60.
133Rasheed Z, Zedan K, Saif GB, et. al. Markers of atopic dermatiti s, allergic rhinitis and 
bronchial asthma in pediatric patients: correlation with filagg rin, eosinophil major basic 
protein and immunoglobulin E. Clin Mol Allergy 2018;16:23.
Protocol Amendment No.: 01
Date: 30-Jun-2021 114
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
12 APPENDICES
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756746] aspartate aminotransferase
AT aminotransferase
AUC area under the concentration-time curve
AUC(0-T) area under the concentration-time curve from time zero to the time of the 
last quantifiable concentration
AUC(TAU) area under the concentration-time curve in one dosing i nterval
AV atrioventricular
AZA azathioprine
BCR B-cell receptor
BCRP breast cancer resistance protein
BMS [COMPANY_016]
bpm beats per minute
BRA Branebrutinib
BSA body surface area
BTK Brutonâ€™s tyrosine kinase
BUN blood urea nitrogen
CBC complete blood count
CD cluster of differentiation
CFR Code of Federal Regulations 
CHO Chinese hamster ovary
CI confidence interval
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756747] X-ray
CYP cytochrome p-450
DC dendritic cell
DDI Drug-drug interaction
DILI Drug induced liver injury
DLCO Diffusion capacit y of carbon monoxide
DLQI Dermatology Life Quality Index
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
EASI Eczema Area and S everity Index
EC50 half maximal effective concentration
ECG electrocardiogram
eCRF electronic Case Report Form
eg exempli gratia (for example)
eGFR estimated glomerular filtration rate 
EGFR epi[INVESTIGATOR_576899].: 01
Date: 30-Jun-[ADDRESS_756748] in human
FITC fluorescein isothiocyanate
FLG filaggrin
FSH follicle stimulating hormone
FTY-720 fingolimod
FTY-P fingolimod phosphate
FVC forced vital capacity
GALT gut associated lymphoid tissue
GLP good laboratory practice
GTP guanosine triphosphate
H / hr hour
HBsAg hepatitis B surface antigen
HBcAb hepatitis B core antibody
HCG human chorionic gonadotrophin
HCV hepatitis C virus
HIV Human Immunodeficiency Virus
HR heart rate
HRT hormone replacement therapy
IB Investigatorâ€™s brochure
IC50 half maximal inhibitory concentration
IC Immune complexes
ICF Informed consent form
IDEC inflammatory dendritic epi[INVESTIGATOR_576900] (that is)
IEC Independent Ethics Committee
IFN interferon
IGA Investigatorsâ€™ Global Assessment
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756749]
IRT Interactive Response Technology
ITT Intent-To-Treat
IU/L International units per liter
IV intravenous
JAK Janus kinase
JCV John Cunningham virus
KLH keyhole limpet hemocyanin
LC Langerhans cell
LAM lactational amenorrhea method
LDH lactate dehydrogenase
LFT liver function test
LH luteinizing hormone
LTBI latent TB infection
MAD multiple ascending dose
mg milligram
min minute
mL milliliter
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756750]
PGI-C Patient Global Impression of Change
PGI-S Patient Global Impression of Severity
P-gp P-glycoprotein
PI [INVESTIGATOR_576901].: 01
Date: 30-Jun-[ADDRESS_756751]
RNA ribonucleic acid
RT-PCR reverse transcription polymerase chain reaction
SAD single ascending doses
SAE serious adverse event
SARS-CoV-2 severe acute res pi[INVESTIGATOR_92186] e coronavirus 2
SNP Single nucleotide polymorphisms
S[LOCATION_003]R Serious Adverse Reactions
S1P sphingosine-1-phosphate 
S1P-1R sphingosine-1-phosphate-1 receptor
TB tuberculosis
TDAR T-cell-dependent anti body response
TEAE treatment-emergent adverse events
Th helper T-cell
Th1 type 1 helper T-lymphocytes
Th2 type 2 helper T-lymphocytes
T-HALF mean half-life
TK toxicokinetics
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756752] upper limit of normal
UV ultraviolet
VA visual acuity testing
vIGA-AD Validated Investigator Global Assessment scale for Atopi c Dermatitis
VZV Varicella Zoster virus 
W week
WBC white blood cell
WNOCBP women notof childbearing potential
WOCBP women of childbearing potential
XLA X-linked agammaglobulinemia
Protocol Amendment No.: 01
Date: 30-Jun-2021 122
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS
The term â€˜participantâ€™ is used in the protocol to refer to a pe rson who has consented to participate 
in the clinical research study. Typi[INVESTIGATOR_897], the term â€œparticipantâ€ is used in the protocol and the term 
â€œsubjectâ€ is used in the Case Report Form (CRF).
REGULATORY AND ETHICAL CONSIDERATIONS
This study will be conducted in accordance with:
â€¢Consensus ethical principles derived from international guideli nes including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines, 
â€¢Applicable International Council on Harmonisation (ICH), Good Cl inical Practice (GCP)
â€¢Applicable laws, regulations and requirements.
The study will be c onducted in compliance with the protocol. The protocol and any 
revisions/amendments and the participant informed consent form (ICF) will r eceive 
approval/favorable opi[INVESTIGATOR_148662]/Indepe ndent Ethics Committee 
(IRB/IEC), and regulatory authorities according to applicable l ocal regulations prior to initiation 
of the study.
All potential serious breaches must be reported to the Sponsor or designee immediately. A 
potential serious breach is defined as a Quality Issue (eg, pro tocol deviation, etc) that is likely to 
affect, to a significant degree one or more of the following:  (1) the rights, physical safety or mental 
integrity of one or more participants; (2) the scientific value  of the clinical trial (eg, reliability and
robustness of generated data ). Items (1) or (2) can be associat ed with either GCP regulation(s) or 
trial protocol(s).
Personnel involved in conducting this study will be qualified by [CONTACT_8640], training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where s anctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medi cal licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and  dated approval/favorable opi[INVESTIGATOR_20291]/IEC for the protocol, Investigatorâ€™s Brochure, pro duct labeling information, ICF,
participant recruitment materials (eg, advertisements), and any other written information to be 
provided t o participants. 
The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safety reports, amendments, administ rative letters)  a nnually, or more 
frequently, in accordance with regulatory requirements or insti tution procedures.
The investigator is responsible for providing oversight of the conduct of the st udy at the site and 
adherence to requirements of the following where applicable:
â€¢ICH guidelines, 
Protocol Amendment No.: 01
Date: 30-Jun-2021 123
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
â€¢[LOCATION_002] Code of Federal Regulations, Title 21, Part 50 (21CFR50)
â€¢European Union Directive 2001/20/EC; or
â€¢European Regulation 536/2014 for clinical studies (if applicable), 
â€¢European Medical Device Regulation 2017/745 for clinical device  research (if applicable),
â€¢the IRB/IEC
â€¢and all other applicable local regulations.
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not imp lement any deviation or change t o the protocol without prior 
review and documented approval/favorable opi[INVESTIGATOR_102403]/IEC (and if 
applicable, also by [CONTACT_19407]) except where ne cessary to eliminate an immediate 
hazard(s) to study participants. 
If a deviation or change to a protocol is implemented to elimin ate an immediate hazard(s) prior to 
obtaining relevant approval/favorable opi[INVESTIGATOR_1649](s) the deviation or change will be submitted, as soon 
as possible to:
â€¢IRB/IEC
â€¢Regulatory authority(ies), if applicable by [CONTACT_427] ( per national requirements)
Documentation of approval/fa vorable opi[INVESTIGATOR_102404](s)/IEC(s) and if applicable, also by [CONTACT_576988]-Myers 
Squibb (BMS).
If an amendment substantially alters the study design or increa ses the potential risk to the 
participant: (1) the ICF must be revised and submitted to the IR B(s)/IEC(s) for review and 
approval/favorable opi[INVESTIGATOR_1649]; (2) the revised form must be used t o obtain consent from participants 
currently enrolled in the study if they are affected by [CONTACT_20508]; and (3) the new form must 
be used to obtain consent from new participants prior to enroll ment.
FINANCIAL DISCLOSURE
Investigators and su b-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with  regulations to allow the Sponso r to submit complete and accurate 
financial certification or disclosure statements to the appropriate h ealth aut horities. Investigators 
are responsible for providing information on financial interest s during the course of the study and 
for [ADDRESS_756753] ensure that participants are  clearly and ful ly informed about the purpose, 
potential risks, and other critical issues regarding clinical s tudies in which they volunteer to 
participate. 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756754] their origin in the Declaration of Helsinki.
The investigator or his/her representative must:
â€¢Obtain the IRB/IECâ€™s written approval/favorable opi[INVESTIGATOR_82705]/partic ipants, prior to the beginning of 
the study, and after any revisions are completed for new informa tion.
â€¢Provide a copy of the consent form and written information about the study in the language in 
which the participant is most proficient prior to clinical study participation. The language must 
be non-technical and easily understood. 
â€¢Explain the nature of the study to the participant and answer a ll questions regarding the study.
â€¢Inform par ticipant that his/her participation is voluntary. Participant wil l be required to sign a 
statement of informed consent that meets the requirements of [ADDRESS_756755] (HIPAA) requirements, 
where applicable, and the IRB/IEC or study center.
â€¢Allow time necessary for participant to inquire about the detai ls of the study.
â€¢Obtain an ICF signed and personally dated by [CONTACT_403579]. 
â€¢Include a statement in participan tâ€™s medical rec ord that written informed consent was obtained 
before participant was enrolled in the study and the date the w ritten consent was obtained. The 
authorized person obtaining the informed consent must also sign  the ICF.
â€¢Re-consent participant to the most current version of the ICF(s)  during his/her participation in 
the study, as applicable.
Revise the ICF whenever important new information becomes availa ble that is relevant to the 
participant's consent. The investigator, or a person designated by [CONTACT_093], should fully 
inform the participant of all pertinent aspects of the study and  of any new information relevant to 
the participantâ€™s willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify participants  must be protected, respecting the 
privacy and confidentiality rules applicable to regulatory requirements, the participantsâ€™ signed 
ICF and, in the US, the participantsâ€™ signed HIPAA Authorizatio n.
The ICF must also include a statement that BMS and regulatory au thorities have direct access to 
participant records. 
SOURCE DOCUMENTS
Source documents provide evidence for the existence of the part icipant and substantiate the 
integrity of the data collected. Source documents are filed at the investigatorâ€™s site.
Data reported on th e CRF or entered in the electronic CRF (eCRF ) that are transcribed from source 
documents must be consistent with the source documents or the d iscrepancies must be explained. 
Protocol Amendment No.: 01
Date: 30-Jun-2021 125
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
â€¢The investigator may need to request previous medical records or  transfer records, depending 
on the study. Also, current medical records must be available.
â€¢Definitions of what constitutes source data can be found in systems that may include, but are 
not limited to, electronic medical/healt h records (EMRs/EHTs), a dverse event (AE) 
tracking/reporting, protocol required assessments, and/or drug a ccountability records).
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data ar e handwritten on paper or entered 
electronically. If source  data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computer ized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such sy stems must be compliant with all 
applicable laws and regulations governing use of electronic rec ords and/or electronic signatures. 
Such systems may include, but are not limited to, electronic me dical records/e lectronic h ealth 
records , adverse event (AE) tracking/reporting, protocol requi red assessments, and/or drug 
accountability records).
When paper records from such systems are used in p lace of an electronic format to perform 
regulated activities, such paper records s hould be certified copi[INVESTIGATOR_014]. A certified copy consists of a 
copy of original i nformation that has been verified, as indicated by a d ated signature, as an exact 
copy having all of the same attributes and information as the o riginal. 
STUDY INTERVENTION RECORDS
Records for study treatments (whether supplied by [CONTACT_20444], its vend ors, or the site) must substantiate 
study intervention integrity  and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for revie w at the request of BMS/designee 
or a Health Authority.
Protocol Amendment No.: 01
Date: 30-Jun-2021 126
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
If Then
Supplied by [CONTACT_20444] (or its vendors): Records or logs must comply wi th applicable 
regulations and guidelines and should include:
â€¢amount received and placed in storage area
â€¢amount currently in storage area
â€¢label identification number or batch number
â€¢amount dispensed to and returned by [CONTACT_37117], including unique participant 
identifiers
â€¢amount transferred to another area/site for dispensing or storage
â€¢nonstudy disposition (eg, lost, wasted) 
â€¢amount destroyed at study site, if applicable
â€¢amount returned to BMS
â€¢retain samples for 
bioavailability/bioequivalence/biocomparability, 
if applicable 
â€¢dates and initials of person responsible for 
Investigational Product 
dispensing/accountability, as per the Delegation 
of Authority Form.
Sourced by [CONTACT_3725], and not supplied by 
[CONTACT_54024] (examples include IP 
sourced from the sites stock or 
commercial supply, or a specialty 
pharmacy)The investigator or desi gnee accepts r esponsibility 
for documenting traceability and study treatment 
integrity in accordance with requirements applicable 
under law and the standard operating procedures/standards of the sourcing pharmacy.
BMS or its designee will provide forms to fac ilitate invent ory control if the investigational site 
does not have an established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other d ata pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are der ived from source documents and 
reported on the CRF must be consistent with the source document s or the discrepancies must be 
explained. Additional clinical information may be collected and  analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture (EDC) tool, eCRFs will be prepared 
for all data collection fields except for fields sp ecific to SAEs and pregnancy, which will be 
reported on the electronic SAE form and Pregnancy Surveillance form, respectively. If electronic 
SAE form is not available, a paper SAE form can be used. 
Protocol Amendment No.: 01
Date: 30-Jun-2021 127
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
The confidentiality of records that could identify subjects/participants must be protected, 
respecting the privacy and confidentiality rules in accordance with the applicable regulatory 
requirement(s).
The investigator will maintain a signature [CONTACT_35899]/or corrections on CRFs. 
The completed CRF, SAE/pregnancy CRFs, must be promptly reviewe d, signed, and dated by [CONTACT_54025] a sub-investigator and who is delegated this task on the 
Delegation of Authority Form. Sub-investigators in Japan may not be delegated the CRF approval 
task. For eCRFs, review and approval/signature [CONTACT_576996]. The investigator must retain a copy of the CRFs including  records of the changes and 
corrections.
Each individual electronically signing eCRFs must meet Sponsor or designee training 
requirements and must only access the BMS EDC tool using the uniq ue user account provided by 
[CONTACT_16015]. User accounts are not to be shared or reassigned to other individuals.
MONITORING
Sponsor or designee representativ es will review data centrally to identify potential issues to 
determine a schedule of on-site visits for targeted review of s tudy records. Monitoring details 
describing strategy, including definition of study critical data items and processes (eg, risk-based 
initiatives in operations and quality such as risk management a nd mitigation strategies and 
analytical risk-based monitoring), methods, responsibilities, a nd requirements, including handling 
of noncompliance issues and monitoring techniques (central, remote, or on-site monitoring) are 
provided in the monitoring plan.
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity . On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with th e investigator, and verify that the 
facilities remain acceptable. Certain CRF pages and/or electronic files may serve as the source documents.
In addition, the study may be evaluated by [CONTACT_576989], sourc e documents, other study files, 
and study facilities. BMS audit reports will be kept confidenti al.
The investigator must notify BMS promptly of a ny inspections scheduled by [CONTACT_21755], 
and promptly forward copi[INVESTIGATOR_576902]. 
RECORDS RETENTION
The investigator (or head of the study site in Japan) must reta in all study records and source 
documents for the maximum period required by [CONTACT_35888], or 
institution procedures, or for the period specified by [CONTACT_576990] s designee, whichever is longer. 
The investigator (or head of the study site in Japan) must cont act BMS prior to destroying any 
records associated with the study.
Protocol Amendment No.: 01
Date: 30-Jun-2021 128
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
BMS or its designee will notify the investigator (or head of th e study site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (eg, relocation, r etirement), the records sh all be 
transferred to a mutually agreed upon designee (eg, another inv estigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or its designee.  
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by [CONTACT_20444], or a v endor or sourced by [CONTACT_1275]) such as partially used study treatment containers , vials and syringes may be dest royed 
on site. 
If.. Then
Study treatments supplied by [CONTACT_20444] (including 
its vendorsAny unused study interventions supplied by [CONTACT_576991], or to meet local regulations (eg, cytotoxics or biologics).
Partially used study interventions and/or 
empty containers may be destroyed after proper reconciliation a nd documentation. But 
unused IMP must be reconciled by [CONTACT_576992]/Clinical Research Associate prior to 
destruction. If study treatments will be returned, the return will be arranged by [CONTACT_20459].
Study treatments sourced by [CONTACT_3725], not supplied by [CONTACT_20444] (or its vendors); eg, study treatments sourced from the sites stock or commercial supply, or a specialty pharmacy)It is the investigatorâ€™s or designeeâ€™s responsibility to dispose of all containers according to the institutional guidelines and procedures.
It is the investigatorâ€™s or designeeâ€™s responsibility to arrang e for disposal of study interventions, 
provided that  procedures for proper disposal have been established according  to applicable federal, 
state, local, and institutional guidelines and procedures, and provided that appropriate records of 
disposal are kept. The following minimal standards must be met:
â€¢On-site disposal practices must not expose humans to risks from  the drug.
â€¢On-site disposal practices and procedures are in agr eement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
Protocol Amendment No.: 01
Date: 30-Jun-2021 129
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
â€¢Written procedures for on-site disposal are available and follo wed. The procedures must be 
filed with the siteâ€™s standard operating procedures and a copy p rovided to BMS  upon request.
â€¢Records are maintained that allow for traceability of each cont ainer, including the date 
disposed of, quantity disposed, and identif ication of the person disposing the containers. The 
method of disposal (eg, incinerator, licensed sanitary landfill , or licensed waste disposal 
vendor) must be documented.
â€¢Accountability and disposal records are complete, up-to-date, a nd available for the Monitor to 
review throughout the clinical trial period.
It is the investigatorâ€™s or designeeâ€™s responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Stu dy Monitor will make arrangements 
for return of study treatments provided by [CONTACT_20444] (or its vendors) . Destruction of non- study 
treatments s ourced by [CONTACT_779], not supplied by [CONTACT_20444], is solely the responsibility of the investigator 
or designee.STUDY AND SITE START AND CLOSURE
The Sponsor/designee reserves the right to close the study site  or to terminate th e study at any time 
for any reason at the sole discretion of the Sponsor. Study sit es will be clo sed upon study 
completion. A study site is considered closed when all required documents and study supplies have 
been collected and a study-site closure visit has been performe d.
The investigator may initiate study-site closure at any time, p rovided there is reasonable cause and 
sufficient notice is given in advance of the intended terminati on.
Reasons for the early closure of a study site by [CONTACT_148709], but are 
not limited to:
â€¢Failure of the investigator to comply with the protocol, the re quirements of the IRB/IEC or 
local Health Authorities, the Sponsorâ€™s procedures, or GCP guid elines
â€¢Inadequate recruitment of participants by [CONTACT_093]
â€¢Discontinuati on of fur ther study intervention development
If the study is prematurely terminated or suspended, the Sponso r shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and a ny contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The inve stigator shall promptly inform  the participant and should assure 
appropriate participant therapy and/or follow-up.
DISSEMINATION OF CLINICAL STUDY DATA
In order to benefit potential study participants, patients, hea lthcare providers and researchers, and 
to help BMS honor its co mmitments to study participants, BMS will make i nformation about 
clinical research studies and a summary of their results availab le to the public as per regulat ory 
and BMS requirements. BMS w ill post study  information on local, national or regional databases 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756756] be selected to sign the Clinical Study Report (CSR). 
For each CSR r elated to this protocol, the following criteria will be used to  select the signatory 
investigator:
â€¢External Principal Investigator [INVESTIGATOR_122349]
â€¢National Coordinating Investigator 
â€¢Study Steering Committee chair or their designee
â€¢Participant recruitment (eg, among the top quartile of enroller s)
â€¢Involvement in trial design
â€¢Regional representation (eg, amo ng top quar tile of enrollers from a specified region or country)
SCIENTIFIC PUBLICATIONS
The data collected during this study are confidential and proprietary to t he Sponsor or designee. 
Any publications or abst racts arising from this study must adhe re to the publication requirements 
set forth in the Clinical Trial Agreement (CTAg) governing [stu dy site or investigator] 
participation in the study. These requirements include, but are  not limited to, submitting proposed 
publications to the Sponsor or designee at the earliest practic able time prior to submission or 
presentation and otherwise within the time peri od set forth in the CTAg.
Scientific Publications (such as abstracts, congress podium presentations and posters, and 
manuscripts) of the study results will be a collaborative effor t between the study Sponsor and the 
external authors. No public  presentation or publication of any i nterim results may be made by [CONTACT_143966], sub-investigator or any other member of  the study staff without the prior 
written consent of the Sponsor.  
Authorship of publications at BMS is aligned with the criteria of the International Committee of 
Medical Journal Editors (ICMJE, www.icmje.org). Authorship sele ction is based upon significant 
contributions to the study (ie, ICMJE criterion #1). Authors mu st meet all 4 ICMJE criteria for 
authorship:1) Substantial intellectual contribution to the conception or de sign of the work; or the acquisition 
of data (ie, evaluable participants with quality data), analysis , or interpretati on of data for the 
work (eg, problem solving, advice, evaluation, insights and con clusion); AND
2) Drafting the work or revising it critically for important int ellectual content; AND
3) Final approval of the version to be published; AND
4) Agreement to be accountable for all asp ects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropria tely investigated and resolved.
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756757] significant contributions, as defined a bove, will be considered by [CONTACT_148712]. Sub-investigators wi ll generally not be considered for 
authorship in the primary publication. Geographic representatio n will also be considered.  
Authors will be lis ted by [CONTACT_148713] (highest to lowest), with the exception 
of the last author. Authors i n first a nd last position have provided the most signif icant contributions 
to the work. 
For secondary analyses and related publications, author list an d author order may vary from 
primary to reflect additional contributions.
Protocol Amendment No.: 01
Date: 30-Jun-2021 132
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW UP AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical oc currence or worsening of a 
pre-existing medical c ondition in a clin ical investigation participant administered s tudy 
treatment  that does not necessarily have a causal relationship  with this treatment. 
An AE can therefore be any unfavorable and unintended sign (suc h as an abnormal laboratory 
finding), symptom, or disease temporally associated with the us e of study treatment, whether or 
not considered related to the study treatment.
Events Meeting the AE Definition
â€¢Any abnormal laboratory test results (hematol ogy, clinical chem istry, or urinalysis) or 
results from other safety assessments (eg, electrocardiograms, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically significant 
in the medical and scie ntific judgment of the investigator. Note  that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not 
available. Once the final diagnosis is known, the reported term  should be updated to be the 
diagnosis.
â€¢Exacerbation of a chronic or intermittent pre-existing conditio n including either an increase 
in frequency and/or intensity of the condition.
â€¢New conditions detected or diagnosed after study intervention a dministration even though it 
may have been present before the start of the study.
â€¢Signs, symptoms, or the clinical sequelae of a suspected drug-d rug interaction.
â€¢Signs, symptoms, or the clinical sequelae of a s uspected overdo se of either study intervention 
or a concomitant medication. Overdose, as a verbatim term (as r eported by [CONTACT_093]), 
should not be reported as an AE/serious adverse event (SAE) unle ss it is an intentional 
overdose taken with possible suicidal/self-harming intent. Such  overdoses should be 
reported regardless of sequelae and should specif y "intentional  overdose" as the verbatim 
term.
Events NOT Meeting the AE Definition
â€¢Medical or surgical proce dure (eg, endoscopy, appendectomy): th e condition that leads to 
the procedure is the AE.
â€¢Situations in which an untoward medical occ urrence did not occur (so cial and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot b e an SAE even if serious conditions 
are met.
Protocol Amendment No.: 01
Date: 30-Jun-2021 133
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
SERIOUS ADVERSE EVENTS
A Serious Adverse Event (SAE) is defined as any untoward medica l occurrence that, at 
any dose:
Results in death.
Is life-threatening (defined as an event in which the participant was at risk of deat h at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe).
Requires inpatient hospi[INVESTIGATOR_576903] n (see NOTE 
below).
NOTE: 
The following hospi[INVESTIGATOR_576904]-Myers Squibb (BMS) clinical 
studies: 
â€¢A visit to the emergency room or other hospi[INVESTIGATOR_20347] < 24 hours, that does not result 
in admission (unless considered an important medical or life-th reatening event).
â€¢Elective surg ery, planned prior to signing consent.
â€¢Admissions as per protocol for a planned medical/surgical proce dure.
â€¢Routine health assessment requiring admission for baseline/tren ding of health status (e.g., 
routine colonoscopy).
â€¢Medical/surgical admission other than to remedy ill health and planned pri or to entry into 
the study. Appropriate documentation is required in these cases .
â€¢Admission encountered for another life circumstance that carrie s no bearing on health status 
and requires no medical/surgical intervention (e.g., lack of housi ng, economic inadequacy, 
caregiver respi[INVESTIGATOR_040], family circumstances, administrative reason) .
â€¢Admission for administration of anticancer therapy in the absen ce of any other SAEs (app lies 
to oncology protocols).
Results in persistent or significant disability/incapacity.
Is a congenital anomaly/birth defect.
Is an important medical event (defined as a medical event[s]) th at may not be immediately life-
threatening or result in death or hospi[INVESTIGATOR_313], based up on appropriate medical and 
scientific judgment, may jeopardize the participant or may requ ire intervention [e.g., medical, 
surgical] to prevent one of the other serious outcomes listed i n the definition above.) Examples 
of such events include, but are not limited to, intensive treat ment in an emergency room or at 
home for allergic bronchospasm and blood dyscrasias or convulsion s that do not result in 
hospi[INVESTIGATOR_059].) Potential  drug induced liver injury (DILI) is  also considered an important 
medical event. (See Section 9.2.7 for the definition of potential DILI.) 
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756758] follow the same transmission timing and  processes to BMS as used for 
SAEs (see Section 9.2.5 for reporting pregnancies).
Any component of a study endpoint that is considered related to  study therapy should be reported 
as an SAE (eg, death is an endpoint, if death occurred due to a naphylaxis, anaphylaxis must be 
reported).
EVALUATING AES AND SAES
Assessment of Causality
â€¢The investigator is obligated to assess the relationship betwee n study intervention and each 
occurrence of each AE/SAE.
â€¢A â€œreasonable possibilityâ€ of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relat ionship cannot be ruled out.
â€¢The investigator will use clinical judgment to determine the re lationship.
â€¢Alternative causes, such as underlying disease(s), concomitant t herapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated.
â€¢The investigator will also consult the Investigatorâ€™s Brochure  and/or product information 
for marketed products, in his/her assessment.
â€¢For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality .
â€¢There may be situations in which an SAE has occurred and the in vestigator has minimal 
information to i nclude in the initial report to the Sponsor. However, it is very important that 
the investigator always make an assessment of causality for eve ry event before the initial 
transmission of the SAE data to the Sponsor.
â€¢The investigator may change his/her opi[INVESTIGATOR_35816]-up information 
and send an SAE follow-up report with the updated causality asse ssment.
â€¢The causality assessment is one of the criteria used when deter mining regulatory reporting 
requirements.
â€¢Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign i t to 1 of the following categories: 
â€¢Mild: An event that is easily tolerated by [CONTACT_2299], cau sing minimal discomfort and 
not interfering with everyday activities.
â€¢Moderate: An event that causes sufficient discomfort and interf eres with normal everyday 
activities.
â€¢Severe: An event that prevents normal everyday activities. An A E that is assessed as severe 
should not be confused with an SAE. Severe is a category utiliz ed for rating the intensity of 
an event, and both AEs and SAEs can be assessed as severe.
Protocol Amendment No.: 01
Date: 30-Jun-2021 135
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
An event is defined as â€œseriousâ€ when it meets at least 1 of th e predefined outcomes as described 
in the definition of an SAE, NOT when it is rated as severe.
Follow-up of AEs and SAEs
If only limited information is i nitially available, follow- up reports are required. (Note: Follow-
up SAE reports must include the same investigator term(s) initi ally reported.) 
If an ongoing SAE changes in its intensity or relationship to s tudy treatment or if new 
information becomes available, the SAE report must be updated and submitted within 24 hours 
to BMS (or designee) using the same procedure used for transmit ting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
REPORTING OF SAES TO SPONSOR OR DESIGNEE
â€¢SAEs, whether related or not r elated to study treatment, and pre gnancies must be reported 
to BMS (or designee) immediately within 24 hours of awareness of the event.
â€¢SAEs must be recorded on the SAE Report Form.
âˆ’The required method for SAE data reporting is through the elect ronic case report form 
(eCRF).
âˆ’The paper SAE Report Form is  intended only as a back-up option  when the electronic 
data capture  system is unavailable/not functioning for transmi ssion of the eCRF) to BMS 
(or designee).
â™¦In this case, the paper form is transmitted via email or confirmed facs imile 
transmission
â™¦When paper forms are used, the original paper forms are to remain on site
â€¢Pregnancies must be recorded on  paper Pregnancy Surveillance F orms and transmitted via 
email or confirmed facsimile transmission 
SAE Email Address: [EMAIL_3041].
SAE Facsimile Number: Will be provided by [CONTACT_148714].
SAE Telephone Contact (required for SAE and pregnancy reporting): Will be provided by [CONTACT_148715].
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756759] clinical trials. For information 
specific to this study regarding acceptable contraception requi rements for f emale and male 
participants, refer to Section 6.1  of the protocol. Only the contraception methods as described i n 
Section 6.1 are acceptable for this study.
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until beco ming postmenopausal unless 
permanently sterile. Permanent sterilization methods include hy sterectomy, bilateral 
salpi[INVESTIGATOR_1656], and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
â€¢Premenarchal
â€¢Premenopausal female wi th 1 of the following:
âˆ’Documented hysterectomy
âˆ’Documented bilateral salpi[INVESTIGATOR_1656]
âˆ’Documented bilateral oophorectomy
Note: Documentation can come from the site personnelâ€™s review o f the participantâ€™s medical 
records, medical examinatio n, or medical history interview.
â€¢Postmenopausal female
âˆ’A postmenopausal state is defined as [ADDRESS_756760] a serum follicle stimulating hormone, (FSH) level 
> 40 mIU/mL to confirm menopause.
Note: Females treated with hormone replacement thera py, (HRT) are likely to have artificially 
suppressed FSH levels and may re quire a washout period in order to obtain a  physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. Suggested 
guidelines for the duration of the washout periods for HRT types  are presented below. Investigators 
should use their judgement in checking serum FSH levels. 
â€¢1-week minimum for vaginal hormonal products (rings, creams, ge ls)
â€¢4-week minimum for transdermal products
â€¢8-week minimum for oral products
Other parenteral products may require washout periods as long a s 6 months. If the serum FSH 
level is > 40 mIU/ml at any time during the washout period, the  woman can be considered 
postmenopausal.
Protocol Amendment No.: 01
Date: 30-Jun-[ADDRESS_756761] 
(IMP) or any active major metabolites have decreased to a concent ration that is no longer 
considered to be relevant for human teratogenicity or fetotoxic ity. This should be evaluated in 
context of safety margins from the no-observed adverse effect level  or the time required for 5 half-
lives of the IMP to pass.
METHODS OF CONTRACEPTION
Local laws and regulations may require use of alternative and/o r additional contraception methods.
Highly Effective Contraceptive Methods That Are User Dependent
Failure rate of <1% per year when used consistently and correctly.a
â€¢Combined (estrogen- and progestoge n-containing) hormonal contrac eption associated with 
inhibition of ovulation and/or implantation. (This method of contraception can  only be used 
by [CONTACT_551319] i s permitted by [CONTACT_17143])b 
âˆ’Oral (birth control pi[INVESTIGATOR_3353])
âˆ’Intravaginal (rings)
âˆ’Transdermal 
â€¢Combined (estrogen-and progest ogen-containing) hormonal contrac eption must begin at 
least 30 days prior to initiation of study therapy
â€¢Progestogen-only hormonal contraception associated with inhibit ion of ovulation. (This 
method of contraception can only be used by [CONTACT_143971].)b 
âˆ’Oral 
âˆ’Injectable 
â€¢Progestogen-only hormonal contraception must begin at least 30 days prior to initiation of 
study therapy
Highly Effective Methods That Are User Independent 
â€¢Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulation and/or implantation. (This method of contraception can  only be used by [CONTACT_551321].)b
â€¢Intrauterine device 
â€¢Intrauterine hormone -releasing system (IUS). (This method of contraception can only be 
used by [CONTACT_499862].)b,c
â€¢Bilateral tubal occlusion.
Protocol Amendment No.: 01
Date: 30-Jun-2021 138
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
â€¢Vasectomized partner 
Having a vasectomized partner is a highly effective contraception method provided that the partner is the 
sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an 
additional highly effective method of contraception should be used.
A vasectomy is a highly effective contraception method provided  that the participant is the sole male 
sexual partner of the WOCBP and the absence of sperm has been c onfirmed. If not, an additional highly 
effective method of contraception should be used.
â€¢Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the 
study and the preferred and usual lifestyle of the participant.
â€¢Continuous abstinence must begin at least 30 days prior to init iation of study therapy.
â€¢It is not necessary to use any other method of contraception wh en complete abstinence is 
elected. 
â€¢WOCBP participants who choose complete abstinence must continue  to have pregnancy 
tests, as specified in Section 2. 
â€¢Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participant chooses to forego complete abs tinence.
â€¢Periodic abstinence (including but not limited to calendar, sym ptothermal, postovulation 
methods), withdrawal (coitus interruptus), spermicides only, an d lactational amenorrhea
method (LAM) are not acceptable methods of contraception for this study.
NOTES: 
aTypi[INVESTIGATOR_576905] r ates when contraceptive methods are used consistently and 
correctly. Use should be consistent with local regulations rega rding the use of contraceptive methods for 
participants in clinical studies. 
bHormonal contraception may be susceptible to interaction with t he study tr eatment, which may reduce the 
efficacy of the contraceptive method. Hormonal contraception is  permissible only when there is sufficient 
evidence that the IMP and other study med ications will not alter hormonal exposures such that contracept ion 
would be ineffective or result in increased exposures that coul d be potentially hazardous.  In this case, alternative 
methods of contraception should be utilized. For information sp ecific to this study regarding permissibility of 
hormonal contraception, refer to Sections 6.1  INCLUSION CRITERIA and 7.7.1 PROHIBITED AND/OR 
RESTRICTED TREATMENTS of the protocol.
cIUSs are acceptable methods of contraception in the absence of d efinitive drug interaction studies when hormone 
exposures from intrauterine devices do not alter contraception effectiveness. For information specific to this 
study regarding permissibility of hormonal contraception, refer  to Sections 6.1 INCLUSION CRITERIA and 
7.7.1 PROHIBITED AND/OR RESTRICTED TREATMENTS of the protocol.
Protocol Amendment No.: 01
Date: 30-Jun-2021 139
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Less Than Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of >1% per year when used consistently and correctly.
â€¢Male or female condom with or wit hout spermicide.  Male and fem ale condoms cannot be 
used simultaneously.
â€¢Diaphragm with spermicide.
â€¢Cervical cap with spermicide.
â€¢Vaginal Sponge with spermicide.
â€¢Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action. (This method of contraception canno t be used by [CONTACT_576993]).
Unacceptable Methods of Contraception
â€¢Periodic abstinence (calendar, symptothermal, postovulation met hods).
â€¢Withdrawal (coitus interruptus).
â€¢Spermicide only.
â€¢LAM.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnanc y Information and outcome of  pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.2.5  and Appendix 3 .
Protocol Amendment No.: 01
Date: 30-Jun-2021 140
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 5 DIAGNOSTIC CRITERIA FOR ATOPIC DERMATITIS
Protocol Amendment No.: 01
Date: 30-Jun-2021 141
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 6 NEW YORK HEART ASSOCIATION (NYHA) CLASSIFICATION 
OF CARDIOVASCULAR DISABILITY
The Criteria Committee of the [LOCATION_001] Heart Association. Nomen clature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels, 9thed, Little, Brown & Co, [LOCATION_011] 1994. 
p.253.
Protocol Amendment No.: 01
Date: 30-Jun-2021 142
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 7 DSM-5 DIAGNOSTIC CRITERIA FOR SUBSTANCE USE 
DISORDER
DSM-5 diagnostic criteria for substance use disorder are descri bed below:
A problematic pattern of use leading to clinically significant impairment or distress is manifested 
by [CONTACT_576994] a 12-month period:
1. Often taken in larger amounts or over a longer period than wa s intended.
2. A persistent desire or unsuccessful efforts to cut down or control use.
3. A great deal of time is spent in activities necessary to obta in, use, or recover from the 
substanceâ€™s effects.
4. Craving or a strong desire or urge to use the substance.5. Recurrent use resulting in a failure to fulfill major role ob ligations at work, school, or home.
6. Continued use despi[INVESTIGATOR_576906] o r interpersonal problems caused 
or exacerbated by [CONTACT_576995].
7. Important social, occupati onal, or recreational a ctivities are given up or reduced because of 
use.
8. Recurrent use in situations in which it is physically hazardo us.
9. Continued use despi[INVESTIGATOR_147607] a persistent or rec urrent physical or psychological 
problem that is likely to have been caused or exacerbated by [CONTACT_3433] e substance.
10. Tolerance.11. Withdrawal.American Psychiatric Association. Diagnostic a nd Statis tical Manual of Mental Disorders, Fifth 
Edition (DSM-5), American Psychiatric Association, Arlington, V A 2013
Protocol Amendment No.: 01
Date: 30-Jun-2021 143
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 8 VALIDATED INVESTIGATOR GLOBAL ASSESSMENT SCALE 
FOR ATOPIC DERMATITIS (VIGA-ADTM)
Protocol Amendment No.: 01
Date: 30-Jun-2021 144
2.0 Approved 930158234 2.0v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
Body Surface Area Estimate Work Sheet (Continued)
Protocol Amendment No.: 01
Date: 30-Jun-2021 147
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 11 PRURITUS AND SLEEP QUALITY NUMERICAL RATING 
SCALES (NRS)
Protocol Amendment No.: 01
Date: 30-Jun-2021 148
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 12 DERMATOLOGY LIFE QUALITY INDEX (DLQI)
Protocol Amendment No.: 01
Date: 30-Jun-2021 149
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 13 PATIENT ORIENTED ECZEMA MEASURE (POEM)
Protocol Amendment No.: 01
Date: 30-Jun-2021 150
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 14 PATIENT GLOBAL IMPRESSION OF CHANGE (PGI-C)
Compared to the beginning of the study, before you started the study treatment, which of the 
following best describes the skin symptoms of your atopic derma titis today?
Â† 1Much improved 
Â† 2Moderately improved
Â† 3A little improved
Â† 4The same
Â† 5A little worse
Â† 6 Moderately worse
Â† 7 Much worse
Protocol Amendment No.: 01
Date: 30-Jun-2021 151
2.0 Approved 930158234 2.0v
Approved
1.0
v
Clinical Protocol IM018005
BMS-986166 and BMS-986195 S1P Receptor Modulator and Branebrutin ib
APPENDIX 15 PATIENT GLOBAL IMPRESSION OF SEVERITY (PGI-S)
Which of the following best describes the severity of the skin symptoms of your atopic dermatitis 
over the past 7 days?
Â† 1None 
Â† 2Mild
Â† 3Moderate 
Â† 4Severe
Â† 5Very Severe
Protocol Amendment No.: 01
Date: 30-Jun-2021 152
2.0 Approved 930158234 2.0v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v
Approved
1.0
v